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ABSTRACT 
 
 Asymmetric C–H functionalization could deliver a highly efficient transformation by 
installing both oxidized functionality and absolute stereochemistry simultaneously. In this 
context, palladium(II)-catalyzed asymmetric allylic C–H functionalization of terminal olefins 
through the intermediacy of π-allyl/Pd(II) complex represents a viable platform. Traditionally, 
the asymmetric functionalization of π-allyl/Pd(II) intermediate generally proceeded with 
phosphine-based ligands, under redox-neutral and basic conditions. Current efforts to develop 
the oxidative allylic C–H functionalization reaction have focused on the adaptation of phosphine-
based ligands, which are prone to oxidation. As such, these systems suffer from limited substrate 
scope (activated olefins, e.g. allylarenes) and modest enantioselectivity.  Alternatively, the 
oxidatively stable bis-sulfoxide ligand has shown to promote general reactivity with broad scope. 
However, its underlying mechanism, known as “serial ligand catalysis”, is challenging for 
asymmetric catalysis, due to the highly dynamic and fluxional binding environment of 
palladium. This work describes the development of oxidatively stable, chiral sulfoxide-oxazoline 
ligands for palladium(II)-catalyzed asymmetric allylic C–H oxidations and alkylations. The 
design principle is to combine the sulfoxide moiety, known to promote C–H cleavage, with a 
strongly coordinately oxazoline moiety that can anchor the ligand to the metal and thereby 
provide a stable chiral environment. Additionally, the σ-donation from oxazoline could promote 
the formation of a cationic π-allyl/Pd(II) intermediate, which becomes more reactive towards 
functionalization.  
 The first chapter of this dissertation describes the development of a general 
intermolecular allylic C–H alkylation with tertiary nucleophiles under palladium(II)/bis-
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sulfoxide catalysis. This work laid the foundation for asymmetric processes with the resultant 
quaternary stereogenic centers that would not be prone to racemization. This reaction 
incorporates a broad scope of terminal olefins (e.g. aromatic, aliphatic) and tertiary nucleophiles 
(e.g. nitroketones, β-ketoesters) with good yields and excellent selectivities (>20:1 
linear:branched, >20:1 E:Z). The use of tertiary nucleophiles allows for strategic incorporation of 
latent functionality into the alkylation partner, which can be exploited for further elaboration to 
generate molecular complexity. This concept is demonstrated in a tandem allylic C–H 
alkylation/Diels-Alder reaction sequence: a reactive diene is generated upon the alkylation of a 
terminal olefin and trapped by a dienophile contained within the tertiary nucleophile to afford a 
complex tricyclic core structure.  
 The second chapter describes the development of chiral sulfoxide-oxazoline (SOX) 
ligands for Pd(II)-catalyzed enantioselective allylic C–H oxidation. Chiral isochromans are 
formed by the intramolecular cyclization between alcohol and terminal olefin, leading to good 
yields and high enantioselectivities (>90% ee). Pd(II)/trans-SOX catalysts are found to be 
significantly more selective than Pd(II)/cis-SOX. Systematic ligand modification reveals bulky 
para-substituents (tert-butyl or trifluoromethyl) on the aryl sulfoxide moiety to be optimal. The 
synthetic utility of this reaction is demonstrated in the synthesis of a chiral amide-containing 
isochroman, which is a known pharmacophore found in selective 5HT1d agonist.  
 Finally, Pd(II)/SOX catalysis is applied to the development of asymmetric allylic C–H 
alkyation. A significant challenge is that the intermolecular alkylation of π-allyl/Pd(II) 
intermediate generally procceds with linear regioselectivity, where the approach of the prochiral 
nucleophile is relatively remote from the ligand environment. As a solution, the π-π interaction 
between the substituents on the sulfoxide and the oxazoline in the cis-SOX ligand is exploited to 
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achieve an orientation that projects the steric element towards the approach of the nucleophile. 
The modular SOX scaffold enables the successful alkylation of a diverse array of nucleophiles, 
including α-nitrotetralones and β-ketoesters, all in good yields and high enantioselectivies (>90% 
ee). The Pd(II)/cis-SOX catalysis has also demonstrated the ability to achieve catalyst-controlled 
diastereoselectivity in the alkylation of chiral aliphatic olefins.  
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CHAPTER 1: ALLYLIC C–H ALKYLATION WITH TERTIARY NUCLEOPHILES 
Acknowledgements 
This chapter has been adapted from the research article “General Allylic C–H Alkylation 
with Tertiary Nucleophiles” (Howell, J. M.; Liu, W.; Young, A. J.; White, M. C. J. Am. Chem. 
Soc., 2014, 136, 5750).  
This work was a collaborative effort. The reaction development, the scope of tertiary 
nucleophiles, the scope of allylarenes, and part of the synthetic applications was accomplished 
by Dr. Jennifer Howell and Dr. Andrew Young, and will not be discussed in this thesis.  
1.1 Introduction 
The direct alkylation of allylic C(sp3)–H bonds has emerged as a powerful strategy for 
constructing C(sp3)–C(sp3) bonds, as it obviates the need for prefunctionalized starting materials 
and enables novel disconnections in the retrosynthesis of carbon frameworks.1 Although 
Pd(II)/bis-sulfoxide catalysis has been demonstrated as a viable platform to effect allylic C–H 
alkylation of terminal olefins, the scope of nucleophiles has been limited to disubstituted 
methylene nucleophiles bearing two electron-withdrawing groups (Scheme 1A).2 Tertiary 
nucleophiles have been sporadically used in previous allylic C–H alkylation methods, but are 
limited in either olefin scope (i.e., only 1,4-dienes) or nucleophile scope (i.e., 2-acetyl 1-
tetralones) (Scheme 1B).3 We envisioned that a method that incorporates a general scope of 
terminal olefins and tertiary nucleophiles would greatly expand the synthetic utility of allylic C–
H alkylation (Scheme 1C). High level of flexibility of R3 and R4 group in both alkylation 
partners can allow the incorporation of useful functionalities, which will not only enrich the 
carbon skeleton but also serve as synthetic handle for further elaboration.  
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Scheme 1. Allylic C–H Alkylation
 
 
1.2 Results and Discussion 
1.2.1 Reaction Development 
Previous allylic C–H alkylation with tertiary nucleophiles, as well as undergoing 
investigation in our own lab, are limited to activated, allylarene or diene structures.3 The 
rationale for the difficulty to engage unactivated α-olefins is thought to be the diminished 
electrophilicity of the π-allyl/Pd(II) intermediate (Figure 1A). When R1 is aryl or alkenyl group, 
the sp2-hybridized substituents could result in an electron-withdrawing effect, making π-
allyl/Pd(II) more electrophilic. In contrast, when R1 is alkyl group, π-allyl/Pd(II) becomes more 
electron-rich, therefore less readily functionalized by tertiary nucleophiles. For example, for the 
alkylation of ((1-nitroethyl)sulfonyl)benzene nucleophile, allylbenzene (R1=Ph, 1a) gives 83% 
yield after 24 hours (Figure 1B). When allylcyclohexane (R1=C6H11, 1b) is used, a significantly 
lower, 52% yield is obtained.  
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The choice of preparative methods to synthesize tertiary nucleophile precursor 3 is also 
critical to achieve the desired reactivity for the C–H alkylation reaction (Figure 1C). Previously, 
nitro(phenylsulfonyl)methane 3 is synthesized from the reaction among nitromethane, sodium 
benzenesulfinate and iodine with sodium methoxide as the base (Figure 1C, equation 1).4 The 
main impurity is found to be 1,3-bis(phenylsulfonyl)-1,3-dinitropropane.4 When this batch is 
carried forward to afford the corresponding tertiary nucleophile, a significant decrease in 
reactivity is observed for the C–H alkylation reaction. Instead, an improved procedure involves 
the use of DBU (1,8-Diazabicyclo[5.4.0]undec-7-ene) as the base and extraction/recrystallization 
as the purification method,5 leading to 3 with higher purity that eventually affords the competent 
tertiary nucleophile.  
Pd(OAc)2
S S
OO
Bn Bn
+
DMBQ (1.5 equiv.)
Dioxane/DMSO (0.33M)
45 ºC, 24 h
R1
O2N
Me
SO2Ph SO2Ph
MeO2NR1
H (10 mol%)
R1
PdLn R1 = aryl or alkenyl group: more electrophilic
R1 = alkyl group: less electrophilic
R1 = Ph; 1a
R1 = C6H11; 1b
2a: 83% yield 
2b: 52% yield
A. Rationale
B. Reaction
C. Nucleophile synthesis
Figure 1. Allylic C–H Alkylation with Aliphatic Olefins
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CH3NO2 SO2PhO2N
PhSO2Na/I2
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impurity
purified via extraction 
and recrystalliation
3
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1.2.2 Reaction Scope: Aliphatic Terminal Olefins 
With the optimized reaction condition in hand, the scope of terminal olefins is examined. 
In contrast to previously reported methods, this reaction enables the alkylation between 
unactivated aliphatic terminal olefins with tertiary nucleophiles in good yields and excellent 
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selectivities (Table 1). A variety of oxygen and nitrogen functionalities are tolerated, including 
benzoate (5a), acetate (5b), phthalimide (5c) and ketal (5d).  Notably, a substrate containing an 
unprotected alcohol at the homoallylic position undergoes smooth alkylation in 60% yield. No 
alcohol oxidation is observed, albeit known to occur under Pd(II)-mediated conditions.6 This 
example highlights the remarkable chemoselectivity of Pd(II)/bis-sulfoxide catalyzed allylic C–
H alkylation method, as well as the orthogonality to traditional base-mediated alkylation 
condition.   
a Reaction conditions: α-olefin 1 (1 equiv.), 4 (2 equiv.), 1 (10 mol%), 2,6-
dimethylbenzoquinone (DMBQ) (1.5 equiv.), DMSO/Dioxane (4:1, 0.33 M), 45 ºC, 24 h. 
Products isolated as one regio- and stero- olefin isomer. Isolated yield, average yield of 
2 runs.
R
NO2
SO2Ph
Me
R
H
+
>20:1 L:B; >20:1 E/Z
O2N
SO2Ph
Me
BzO
5a; 56% yield
O2N
SO2Ph
Me
5d; 69% yield
OO
O2N
SO2Ph
Me
AcO
5b; 56% yield
Me
SO2Ph
NO2
5e; 60% yield
OH
Me
Me
O2N
SO2Ph
Me
PhthN
5c; 54% yield
DMBQ (1.5 equiv.)
DMSO/Dioxane (4:1, 0.33M)
45 ºC, 72h
1Pd(OAc)2
S S
OO
Bn Bn
(10 mol%)SO2PhO2N
Me
Table 1. Allylic C-H Alkylation with Aliphatic Terminal Olefinsa
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1.2.3 Synthetic Application: Generating Molecular Complexity 
With the broad scope of terminal olefins and the use of tertiary nucleophiles, this reaction 
stands to serve as a general coupling method between functionalized fragments (Scheme 2). 
Latent functionality could be incorporated into both alkylation partners, and further exploited 
post alkylation stage to rapidly generate molecular complexity. For example, we envision that a 
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complex bicyclic structure could be furnished from a intramolecular Diels-Alder reaction of a 
linear precursor, which would be resulted from an allylic C–H alkylation between a skipped 
diene and a dienophile-containing tertiary nucleophile.  
 
To realize this plan, a terminal olefin-containing chiral butenolide substrate 7 is prepared 
from the Aldol reaction between methyl 4-pentenoate and the aldehyde 6 (Scheme 3a).7 Acid-
mediated hydrolysis/lactonization, followed by trifluoroacetic anhydride-mediated dehydration 
afford the chiral substrate 7. For the synthesis of the tertiary nucleophile that contains a 
dienophile, nitro(phenylsulfonyl)methane is deprotonated by LDA and subsequently alkylated 
with 4-bromo-1-butene. Cross-metathesis catalyzed by Grubbs II catalyst with methyl acrylate 
affords the desired product 9. 
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The chiral butenolide α-olefin 7 and dienophile-containing tertiary nucleophile 9 is 
subjected to the standard alkylation condition catalyzed by Pd(II)/bis-sulfoxide 1. The linear 
alkylated product 10 is observed when reaction is run for 24 hours at 45oC. More importantly, 
continuing the reaction for additional 48 hours at 55oC prompted the intramolecular Diels-Alder 
reaction between the conjugated diene and the α,β-unsaturated ester, leading to the formation of 
tricycles 11 and 12 in high yield (75%) and excellent endo-selectivity (27:1). The structure of 
11b, a C7 epimer of the endo diastereomers, is confirmed by X-ray crystallography (see 1.4 
Experimental Section). Subsequently, the nitrosulfone group at C7 is converted to the ketone 13 
by the treatment of acidic TiCl3 solution, affording additional synthetic handle for further 
manipulation. Significantly, the carbocyclic structure of 13 represents the common tricyclic core 
of class I galbulimima alkaloids, which exhibit a range of biological activities.8  
(10 mol%)
SS
O O
Bn Bn
Pd(OAc)2
O
O
Me
SO2Ph
NO2
O OMe
O
O
Me
SO2PhO2N
O OMe
+
H
O
O
Me H
H
H
OMeO
NO2
SO2Ph
11 12
75% yield, 
27:1 endo/exob
7 9 10
O
O
Me H
H
H
OMeO
NO2
SO2Ph
Diels-
Alder
13
O
O
Me H
H
H
OMeO
O
a Reaction conditions: (1) α-olefin 7 (1 equiv.), 9 (1.8 equiv.), 1 (10 mol%), 2,6-dimethylbenzoquinone (DMBQ) (1.5 
equiv.), DMSO/Dioxane (4:1, 0.33 M), 45 ºC, 24 h followed by warming to 55 ºC, 48 h, (2) 20% TiCl3 in 3% HCl, 
THF, rt. b Endo/exo isomers 11 and 12 result from addition anti to the methyl group of the butenolide. The endo 
isomer resulting from syn addition was also observed (6:1 endo-anti/endo-syn). c 50% yield after one recycle. 
Isolated as a 5:1 mixture of diastereomers, major diastereomer shown.
(2) TiCl3
(1)
1
50% yieldc
C—H 
Alkyation
7
common tricyclic 
core
Scheme 4. Tandem Allylic C-H Alkylation/Diels-Alder Reaction Cascadea
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1.3 Conclusions 
We have developed a general method for allylic C–H alkylation catalyzed by Pd(II)/bis-
sulfoxide catalyst that incorporates a broad scope of terminal olefins with tertiary nucleophiles. 
Specifically, this dissertation details the development of reaction scope towards unactivated 
aliphatic olefins, which has not been demonstrated with previous alkylation methods. One of the 
key to achieve desired reactivity with this important class of olefins is the improved preparative 
method and purification procedure for the tertiary nucleophile. The flexibility to incorporate 
useful functionalities into both alkylation partners has enabled this C–H alkylation method to 
generate reactive intermediates that can be exploited and further functionalized to rapidly 
generate molecular complexity from relatively simple materials.  
 
1.4 Experimental Sections 
1.4.1 General Information 
All commercially obtained reagents for the allylic alkylation reaction were used as 
received: 2,6-dimethylbenzoquinone (DMBQ) (Sigma-Adrich), allylbenzene (Sigma-Aldrich), 
allylcyclohexane (Alfa Aesar). Pd[1,2-bis(benzylsulfinyl)ethane](OAc)2 “Catalyst 1” was 
prepared according to the published procedure.2b Catalysts 1 are stored at 4°C in a desiccator, 
prior to use catalysts were warmed to room temperature and weighed out in air. 1,4-Dioxane was 
purified prior to use by passage through a bed of activated alumina (Glass Contour, Laguna 
Beach, California). Dimethyl sulfoxide (DMSO) was obtained from Fisher Scientific and stored 
under argon.  
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All allylic alkylation reactions were run under air. Thin-layer chromatography (TLC) was 
conducted with E. Merck silica gel 60 F254 pre-coated plates (0.25 mm) and visualized with UV 
and potassium permanganate (KMnO4) stain. Flash chromatography was performed as described 
by Still using ZEOprep 60 ECO 43-60 micron silica gel (American International Chemical, Inc.). 
Medium pressure liquid chromatography was performed on a Teledyne Isco CombiFlash Rf 
machine using pre-packed RediSep columns (12g C18) at a rate of 30 mL/min. Chiral 
supercritical fluid chromatography (SFC) purification studies were performed on a Berger 
Instruments Inc. system (Waters Corp., Milford, MA, USA) equipped with a Varian PrepStar 
solvent delivery module (a liquid CO2 pump and a modifier pump), a sampler manager, a diode 
array detector, and SFC ProNtO as software. Methanol, isopropyl alcohol and acetonitrile 
(HPLC Grade) were purchased from Fisher Scientific (Fair Lawn, NJ, USA). Industrial grade 
CO2 was obtained from Air Gas (Radnor, Pennsylvania, USA). Columns packed with Chiralpak 
AS-H and Chiralcel OJ-H were purchased from Chiral Technologies (West Chester, PA, USA). 
Dimensions and particle size for both were 30 x 250 mm, 5µm columns. 
1H NMR spectra were recorded on a Varian Unity-400 (400 MHz), Varian Inova-500 
(500 MHz), Varian Unity-500 (500 MHz), Varian Unity-600 (600 MHz) and a Varian 750 (750 
MHz) spectrometer and are reported in ppm using solvent as an internal standard (CHCl3 at 7.26 
ppm). Data reported as: s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, m = multiplet, 
b = broad, ap = apparent; coupling constant(s) in Hz; integration. Proton-decoupled 13C NMR 
spectra were recorded on a Varian Unity-500 (125 MHz) spectrometer and are reported in ppm 
using solvent as an internal standard (CDCl3 at 77.16 ppm). Stereoselectivity of the allylic 
alkylation reaction was determined by 1H NMR analysis of the crude reaction mixture. IR 
spectra were recorded as thin films on NaCl plates on a Perkin-Elmer Spectrum BX FT-IR and 
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are reported in frequency of absorption (cm-1). High-resolution mass spectrometry (HRMS) 
performed by Dr. Furong Sun, Dr. Kevin Tucker, Dr. Haijun Yao and Dr. Elizabeth Eves at the 
University of Illinois Mass Spectrometry Laboratory. X-ray crystallographic analysis carried out 
by Dr. Jeffery Bertke and Dr. Danielle Gray at the University of Illinois George L. Clark X-Ray 
Facility.  
Preparation of Starting Materials 
 ((nitromethyl)sulfonyl)benzene (NSM) (3): NMS was prepared following the 
improved procedure of Prakash and coworkers.5 We observed lower reactivity for both benzyl 
and alkyl substrates when an older literature procedure by Wade and coworkers was employed.4 
Spectral data matched those reported. 1H NMR (500 MHz, CDCl3) δ 7.97 (d, J = 7.4 Hz, 1H), 
7.79 (t, J = 7.4 Hz, 2H), 7.65 (t, J = 7.8 Hz, 3H), 5.61 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 
135.78, 135.74, 129.89, 129.43, 90.36. 
 
 ((1-nitroethyl)sulfonyl)benzene (4): The known compound was prepared 
following a modified procedure.4 Spectral data matched those reported. To a flame 
dried round bottom flask equipped with a magnetic stir bar was added sodium methoxide (120 
mg, 2.22 mmol, 0.87 equiv.) and methanol (2.22 mL); sodium methoxide dissolved to form a 
colorless homogeneous solution. Separately, iodomethane (159 mL, 2.55 mmol, 1 equiv) and 
((nitromethyl)sulfonyl)benzene (513 mg, 2.55 mmol, 1 equiv) were dissolved in N,N-
dimethylacetamide (DMA) (9.8 mL) and added to the basic methanol solution dropwise via 
cannula. The resultant reaction solution was stirred overnight at room temperature. The reaction 
was quenched with H2O (30 mL) and extracted with EtOAc (3 x 20 mL). The combined organic 
layers were dried over anhydrous MgSO4, filtered and concentrated. Purification by MPLC 
NO2PhO2S
NO2PhO2S
Me
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(10→30% EtOAc/Hexanes) afforded ((1-nitroethyl)sulfonyl)benzene (50-60% yield) as a white 
solid. 1H NMR (500 MHz; CDCl3): δ 7.90 (d, J = 8.5 Hz, 2H), 7.78 (t, J = 7.5 Hz, 1H), 7.63 (t, J 
= 7.9 Hz, 2H), 5.62 (q, J = 6.9 Hz, 1H), 1.91 (d, J = 6.9 Hz, 4H); 13C NMR (126 MHz, CDCl3) δ 
135.65, 133.90, 130.14, 129.68, 97.53, 13.44. 
 
 (S)-3-allyl-5-methylfuran-2(5H)-one (7): was prepared according to the 
published procedure.7 Spectral data matched those reported. 1H NMR (499 MHz; 
CDCl3): δ 7.00 (d, J = 1.5 Hz, 1H), 5.78 (ddt, J = 17.0, 10.2, 6.8 Hz, 1H), 5.05 
(dd, J = 17.0, 1.5 Hz, 1H), 5.03 (dd, J = 10.0, 1.3 Hz, 1H), 4.93 (qd, J = 6.8, 1.7 Hz, 1H), 2.91 
(d, J = 6.7 Hz, 2H), 1.31 (d, J = 6.8 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 173.32, 150.07, 
133.14, 132.37, 117.60, 77.66, 29.45, 19.05; HRMS (ESI) m/z calculated for C8H11O2 [M+H]+: 
139.0759, found 139.0753; [a]D26 = 57.388 (3.6, CHCl3). 
 
 ((1-nitropent-4-en-1-yl)sulfonyl)benzene (8): To an oven-dried 200 mL round 
bottom flask equipped with a magnetic stir bar was added 
((nitromethyl)sulfonyl)benzene (3) (2.16 g, 10.7 mmol, 1.0 equiv.), the system was purged with a 
nitrogen atmosphere, THF (32 mL) and HMPA (6.5 mL) were added. The 
homogeneous/colorless solution was cooled to –94°C, via a hexane/N2 (liq) bath, n-butyllithium 
(1.6 M in hexane, 15 mL, 22.0 mmol, 2.2 equiv.) was added dropwise to afford an orange 
reaction solution. The reaction solution was slowly warmed to –40 ºC over 3 hours. The reaction 
solution was cooled to –94°C and 4-bromo-1-butene (1.6 mL, 15 mmol, 1.5 equiv.) was added 
dropwise. The reaction solution was allowed to stir overnight warming to room temperature 
slowly. The reaction was cooled to 0 ºC. Quenched with acetic acid and warmed to room 
O
O
Me
H
NO2
SO2Ph
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temperature. The reaction solution was diluted with EtOAc (50 mL). The organic layer was 
washed with saturated aqueous NH4Cl solution (100 mL), H2O (100 mL) and brine (100 mL). 
The organic layer was dried over anhydrous MgSO4, filtered and concentrated in vacuo. 
Purification by flash chromatography (SiO2, 5→10→15% EtOAc/hexane) provided the pure 
product as a colorless oil (1.82 g, 66% yield). 1H NMR (500 MHz, CDCl3) δ 7.89 (dd, J = 8.3, 
1.4 Hz, 2H), 7.77 (t, J = 7.5 Hz, 1H), 7.63 (dd, J = 8.4, 7.4 Hz, 2H), 5.70 (dddd, J = 17.4, 10.2, 
7.5, 5.9 Hz, 1H), 5.52 (dd, J = 8.8, 5.6 Hz, 1H), 5.09 (d, J = 11.3 Hz, 1H), 5.06 (d, J = 17.8 Hz, 
1H), 2.40 – 2.32 (m, 2H), 2.25 (dq, J = 13.0, 6.9, 6.3 Hz, 1H), 2.07 (dq, J = 15.6, 7.5 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ 135.74, 134.34, 134.25, 130.21, 129.77, 118.46, 101.65, 29.45, 
27.15; IR (film, cm-1): 3070, 2981, 2960, 1643, 1564, 1448, 1340, 1315, 1218, 1157, 1083, 997, 
923, 757; HRMS (ESI) m/z calculated for C11H13NO4S [M+H]+: 256.0644, found 256.0646. 
 
Methyl (E)-6-nitro-6-(phenylsulfonyl)hex-2-enoate (9): A 200 mL 
oven-dried round bottom flask equipped with a magnetic stir bar was 
fitted with a flame-dried condenser and purged with nitrogen. Methyl acrylate (1.27 mL, 14.08 
mmol, 4.0 equiv.) and ((1-nitropent-4-en-1-yl)sulfonyl)benzene (8) (0.9 g, 3.53 mmol, 1.0 
equiv.) were dissolved in dichloromethane (10 mL) and added to the reaction vessel via syringe. 
Grubbs 2nd generation catalyst (75 mg, 0.088 mmol, 0.025 equiv.) was added as a solution in 
dichloromethane. The reaction was refluxed for 24 hours. After cooling to room temperature the 
reaction was quenched with DMSO (several drops) and concentrated in vacuo. Purification by 
flash chromatography (SiO2, 10→15→20→25% EtOAc/hexane) provided the pure product as a 
white solid (0.88 g, 80% yield). 1H NMR (500 MHz, CDCl3) δ 7.89 (dd, J = 8.5, 1.3 Hz, 2H), 
7.79 (t, J = 7.5 Hz, 1H), 7.64 (dd, J = 8.4, 7.4 Hz, 2H), 6.82 (ddd, J = 15.6, 7.5, 6.2 Hz, 1H), 5.86 
NO2
SO2Ph
MeO
O
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(dt, J = 15.6, 1.5 Hz, 1H), 5.48 (dd, J = 9.9, 4.5 Hz, 1H), 3.73 (s, 3H), 2.48 – 2.40 (m, 2H), 2.40 
– 2.33 (m, 1H), 2.27 (dqd, J = 15.3, 7.7, 1.4 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 166.38, 
143.97, 135.92, 133.99, 130.24, 129.87, 124.08, 101.30, 51.94, 27.86, 26.49; IR (film, cm-1): 
3070, 2952, 1722, 1660, 1562, 1448, 1338, 1315, 1159, 1083, 850, 759, 688; HRMS (ESI) m/z 
calculated for C13H15NO6S [M+H]+: 314.0698, found 314.0695. 
 
Reaction Development (Figure 1) 
 (E)-(4-nitro-4-(phenylsulfonyl)pent-1-en-1-yl)benzene (2a): A ½ dram 
oven dried borosilicate vial equipped with a Teflon magnetic stir bar was 
charged with ((1-nitroethyl)sulfonyl)benzene (43.0 mg, 0.20 mmol, 2.0 equiv.), 
2,6-dimethylbenzoquinone (DMBQ) (20.4 mg, 0.15 mmol, 1.5 equiv) and catalyst 1 (5.3 mg, 
0.01 mmol, 0.10 equiv.). To the reaction vial was sequentially added dimethylsulfoxide (240 µL) 
and allylbenzene (11.8 mg, 0.10 mmol, 1.0 equiv.) as a solution in 1,4-dioxane (60 µL). No 
further precautions were taken to exclude air or moisture. The reaction vial was capped and 
stirred for 24 hours at 45°C in an aluminum block. The vial was cooled to room temperature. The 
reaction mixture was quenched with saturated aqueous NH4Cl solution (10 mL) and extracted 
with ethyl acetate (EtOAc) (3 x 10 mL). The combined organic extracts were dried over 
anhydrous MgSO4, filtered and concentrated in vacuo. The crude reaction mixture was purified 
by flash chromatography (75:1 SiO2/weight of total reagents used) with a gradient elution 
10→15% EtOAc/hexanes yielded pure linear product, (E)-(4-nitro-4-(phenylsulfonyl)pent-1-en-
1-yl)benzene (2a), as a white solid. Run 1 (82% yield); Run 2 (83% yield). Average yield: 83%. 
1H NMR (500 MHz, CDCl3) δ 7.90 (d, J = 7.6 Hz, 2H), 7.78 (t, J = 7.4 Hz, 1H), 7.63 (t, J = 7.8 
Hz, 2H), 7.33 – 7.28 (m, 4H), 7.28 – 7.24 (m, 1H), 6.54 (d, J = 15.7 Hz, 1H), 5.90 (dt, J = 15.3, 
SO2Ph
MeO2N
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7.4 Hz, 1H), 3.41 (dd, J = 14.4, 6.8 Hz, 1H), 3.05 (dd, J = 14.3, 8.0 Hz, 1H), 1.97 (s, 3H); 13C 
NMR (126 MHz, CDCl3) δ 137.7, 136.0, 135.5, 132.8, 131.1, 129.4, 128.8, 128.4, 126.5, 118.6, 
106.5, 37.2, 17.2; IR (film, cm-1): 3062, 3032, 2924, 1552, 1448, 1333, 1155, 1074, 972, 742, 
719, 688; HRMS (ESI) m/z calculated for C17H17SNO4Na [M+Na]+: 354.0776, found 354.0777. 
 
 (E)-((5-cyclohexyl-2-nitropent-4-en-2-yl)sulfonyl)benzene (2b): A ½ 
dram oven dried borosilicate vial equipped with a Teflon magnetic stir bar 
was charged with ((1-nitroethyl)sulfonyl)benzene (43.0 mg, 0.20 mmol, 2.0 equiv.), 
2,6-dimethylbenzoquinone (DMBQ) (20.4 mg, 0.15 mmol, 1.5 equiv) and catalyst 1 (5.3 mg, 
0.01 mmol, 0.10 equiv.). To the reaction vial was sequentially added dimethylsulfoxide (240 µL) 
and allylcyclohexane (12.4 mg, 0.10 mmol, 1.0 equiv.) as a solution in 1,4-dioxane (60 µL). No 
further precautions were taken to exclude air or moisture. The reaction vial was capped and 
stirred for 24 h at 45°C in an aluminum block. The vial was cooled to room temperature. 
Important note: The product (Rf = 0.42 in 15% EtOAc/Hex) overlaps with 2,6-
dimethylbenzoquinone (DMBQ) (Rf = 0.42 in 15% EtOAc/Hex). Quenching the reaction 
with aqueous sodium bisulfite affords a polar compound (Rf is baseline in 15% 
EtOAc/Hex) and allows for purification of the alkylation product by flash chromatography. 
The reaction mixture was quenched with saturated aqueous NaHSO3 solution (10 mL) and 
extracted with ethyl acetate (EtOAc) (3 x 10 mL). The combined organic extracts were dried 
over anhydrous MgSO4, filtered and concentrated in vacuo. The crude reaction mixture was 
purified by flash chromatography (75:1 SiO2/weight of total reagents used) elution with 
10→15% EtOAc/hexanes yielded pure linear product, (E)-((5-cyclohexyl-2-nitropent-4-en-2-
yl)sulfonyl)benzene (2b), as a white solid. Run 1 (50% yield); run 2 (53% yield). Average yield: 
SO2Ph
MeO2N
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52%. 1H-NMR (500 MHz; CDCl3): δ 7.85 (d, J = 7.3 Hz, 2H), 7.74 (t, J = 7.5 Hz, 1H), 7.59 (t, J 
= 7.8 Hz, 2H), 5.55 (dd, J = 15.3, 6.8 Hz, 1H), 5.07 (dt, J = 15.1, 7.5 Hz, 1H), 3.10 (dd, J = 14.1, 
6.7 Hz, 1H), 2.76 (dd, J = 14.1, 7.8 Hz, 1H), 1.89 (s, 4H), 1.68-1.59 (m, 6H), 1.21 (q, J = 12.7 
Hz, 2H), 1.11 (tt, J = 12.3, 3.0 Hz, 1H), 0.99 (dddt, J = 16.1, 12.1, 8.1, 4.0 Hz, 2H); 13C NMR 
(126 MHz; CDCl3): δ 145.5, 135.3, 133.0, 131.1, 129.3, 116.4, 106.8, 40.8, 37.2, 32.7, 26.06, 
25.88, 16.6; IR (film, cm-1): 3066, 2925, 2852, 2657, 1980, 1907, 1818, 1795, 1776, 1685, 1664, 
1583, 1552, 1477, 1448, 1382, 1332, 1313, 1155, 1047, 973, 846, 754, 721, 688, 605; HRMS 
(CI+) m/z calculated for C17H24O4NS [M+H]+: 338.14260, found 338.14196. 
 
Reaction Scope (Table 1) 
General Procedure for Allylic C–H Alkylation of Aliphatic Terminal Olefin Substrates: An 
oven dried one dram (4mL) borosilicate vial equipped with a magnetic stir bar was charged with 
((1-nitroethyl)sulfonyl)benzene (0.60 mmol, 2.0 equiv), 2,6-dimethylbenzoquinone (DMBQ) 
(0.45 mmol, 1.5 equiv) and Pd[1,2-bis(benzylsulfinyl)ethane](OAc)2 (1) (0.030 mmol, 0.10 
equiv). To the reaction vial was added α-olefin (0.30 mmol, 1.0 equiv) as a solution in 
dimethylsulfoxide (DMSO) (0.72 mL) followed by the addition of 1,4-dioxane (0.18 mL). 
Reaction setup is performed open to the atmosphere. The reaction vial was capped and stirred in 
an oil bath at 45°C for 72 hours. IMPORTANT NOTE: For alkyl a-olefin substrates 
alternative reaction workup procedures were employed to ease purification, see product for 
detailed workup procedure. Purification by flash chromatography (SiO2, EtOAc/hexanes 
mixtures) provided the pure linear product.  
 
 (E)-6-nitro-6-(phenylsulfonyl)hept-3-en-1-yl benzoate (5a): Pent-4-
O2N
SO2Ph
Me
BzO
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en-1-yl benzoate9 (57.1 mg, 0.3 mmol, 1.0 equiv) and ((1-nitroethyl)sulfonyl)benzene (129.0 mg, 
0.6 mmol, 2.0 equiv) were reacted following the general procedure. The reaction vial was capped 
and stirred at 45°C in an oil bath for 72 hours. The vial was cooled to room temperature. 
Reaction was diluted with diethyl ether (Et2O) (30 mL) followed by washing with 2M NaOH (3 
x 10 mL), H2O (1 x 10 mL) and brine (1 x 10 mL). The organic layer was dried over anhydrous 
MgSO4, filtered and concentrated in vacuo. Important note: The product (Rf = 0.41 in 30% 
EtOAc/Hex) overlaps with ((1-nitroethyl)sulfonyl)benzene (Rf = 0.35 in 30% EtOAc/Hex). 
Sodium ((1-nitroethyl)sulfonyl)benzene dissolves in aq. NaOH solution rather than in the 
Et2O. Washing with 2M NaOH removes all excess ((1-nitroethyl)sulfonyl)benzene. The 
crude material was purified by flash chromatography (100:1 SiO2/theoretical yield; gradient 
elution with one column volume (approximately 25 mL) of 10→20→30→40→50% 
EtOAc/hexanes) yielded pure linear product as a light yellow solid. Product was initially a light 
yellow oil and upon sitting solidified. Run 1 (66.8 mg, 0.165 mmol, 55% yield); run 2 (67.6 mg, 
0.168 mmol, 56% yield). Average yield: 56%. 1H NMR (500 MHz; CDCl3): δ 7.98 (d, J = 8.4 
Hz, 2H), 7.84 (d, J = 8.5 Hz, 2H), 7.74 (t, J = 7.5 Hz, 1H), 7.59 (t, J = 7.8 Hz, 2H), 7.55 (t, J = 
7.4 Hz, 1H), 7.43 (t, J = 7.7 Hz, 2H), 5.70 (dt, J = 14.9, 7.2 Hz, 1H), 5.33 (dt, J = 15.1, 7.4 Hz, 
1H), 4.34-4.27 (m, 2H), 3.19 (dd, J = 14.2, 6.7 Hz, 1H), 2.83 (dd, J = 14.2, 7.8 Hz, 1H), 2.47 (q, 
J = 6.5 Hz, 2H), 1.86 (s, 3H); 13C NMR (126 MHz; CDCl3): δ 166.5, 135.4, 134.8, 133.1, 132.7, 
131.0, 130.1, 129.6, 129.3, 128.5, 122.2, 106.4, 63.6, 36.9, 32.2, 16.8; IR (film, cm-1): 3066, 
2958, 2894, 2358, 2337, 1976, 1914, 1718, 1602, 1583, 1552, 1450, 1382, 1332, 1315, 1276, 
1176, 1155, 1114, 1074, 1025, 998, 971, 937, 908, 846, 806, 754, 715, 688, 653, 607; HRMS 
(CI+) m/z calculated for C20H22O6NS [M+H]+: 404.11678, found 404.11636. 
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 (E)-6-nitro-6-(phenylsulfonyl)hept-3-en-1-yl acetate (5b) : Pent-4-en-
1-yl acetate10 (38.5 mg, 0.3 mmol, 1.0 equiv) and ((1-
nitroethyl)sulfonyl)benzene (129.0 mg, 0.6 mmol, 2.0 equiv) were reacted following the general 
procedure. The reaction vial was capped and stirred at 45°C in an oil bath for 72 hours. The vial 
was cooled to room temperature. Reaction was diluted with diethyl ether (30 mL) followed by 
washing with 2M NaOH (3 x 10 mL), H2O (1 x 10 mL) and brine (1 x 10 mL). The organic layer 
was dried over anhydrous MgSO4, filtered and concentrated in vacuo. Important note: The 
product (Rf = 0.30 in 30% EtOAc/Hex) overlaps with ((1-nitroethyl)sulfonyl)benzene (Rf = 
0.35 in 30% EtOAc/Hex). Sodium ((1-nitroethyl)sulfonyl)benzene dissolves in aq. NaOH 
solution rather than in the Et2O. Washing with 2M NaOH removes all excess ((1-
nitroethyl)sulfonyl)benzene. The crude material was purified by flash chromatography (100:1 
SiO2/theoretical yield; gradient elution with one column volume (approximately 25 mL) of 
10→20→30→40→50% EtOAc/hexanes) yielded pure linear product as a colorless oil. Run 1 
(58.4 mg, 0.171 mmol, 57% yield); run 2 (55.0 mg, 0.161 mmol, 54% yield). Average yield: 
56%. 1H NMR (500 MHz; CDCl3): δ 7.84 (d, J = 8.3 Hz, 2H), 7.75 (t, J = 7.5 Hz, 1H), 7.59 (t, J 
= 7.8 Hz, 2H), 5.59 (dt, J = 14.9, 7.3 Hz, 1H), 5.25 (dt, J = 15.1, 7.5 Hz, 1H), 4.02 (t, J = 6.5 Hz, 
2H), 3.16 (dd, J = 14.2, 6.8 Hz, 1H), 2.81 (dd, J = 14.2, 7.7 Hz, 1H), 2.31 (q, J = 6.6 Hz, 2H), 
1.99 (s, 3H), 1.88 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 171.18, 135.57, 134.88, 132.90, 
131.20, 129.45, 122.20, 106.53, 63.24, 37.03, 32.14, 21.08, 16.96; IR (film, cm-1): 3066, 2958, 
2927, 1737, 1583, 1550, 1448, 1384, 1332, 1241, 1157, 1074, 1041, 974, 846, 754, 688; HRMS 
(ESI) m/z calculated for C15H19NO6S [M+H]+: 342.1011, found 342.1003. 
 
 (E)-2-(6-nitro-6-(phenylsulfonyl)hept-3-en-1-yl)isoindoline-1,3-
O2N
SO2Ph
Me
AcO
O2N
SO2Ph
Me
PhthN
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dione (5c) : 2-(pent-4-en-1-yl)isoindoline-1,3-dione11 (64.6 mg, 0.3 mmol, 1.0 equiv) and ((1-
nitroethyl)sulfonyl)benzene (129 mg, 0.6 mmol, 2.0 equiv) were reacted following the general 
procedure. The reaction vial was capped and stirred at 45°C in an oil bath for 72 hours. The vial 
was cooled to room temperature. Reaction was diluted with diethyl ether (30 mL) followed by 
washing with 2M NaOH (3 x 10 mL), H2O (1 x 10 mL) and brine (1 x 10 mL). The organic layer 
was dried over anhydrous MgSO4, filtered and concentrated in vacuo. Important note: The 
product (Rf = 0.43 in 40% EtOAc/Hex) overlaps with ((1-nitroethyl)sulfonyl)benzene (Rf = 
0.54 in 40% EtOAc/Hex). Sodium ((1-nitroethyl)sulfonyl)benzene dissolves in aq. NaOH 
solution rather than in the Et2O. Washing with 2M NaOH removes all excess ((1-
nitroethyl)sulfonyl)benzene. Crude material was purified by flash chromatography (100:1 
SiO2/theoretical yield; gradient elution with one column volume (approximately 25 mL) of 
20→30% EtOAc/hexanes) yielded pure linear product as a white solid. Run 1 (71.0 mg, 0.166 
mmol, 55% yield); run 2 (68.4 mg, 0.160 mmol, 53%). Average yield: 54%. 1H NMR (500 
MHz; CDCl3): δ 7.82-7.79 (m, 4H), 7.73 (t, J = 7.6 Hz, 1H), 7.70 (dd, J = 5.4, 3.1 Hz, 2H), 7.58 
(t, J = 7.9 Hz, 2H), 5.61 (dt, J = 14.9, 7.3 Hz, 1H), 5.21 (dt, J = 15.0, 7.4 Hz, 1H), 3.70 (t, J = 6.8 
Hz, 2H), 3.10 (dd, J = 14.3, 6.7 Hz, 1H), 2.75 (dd, J = 14.3, 7.7 Hz, 1H), 2.39 (q, J = 6.8 Hz, 
2H), 1.77 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 168.41, 135.49, 135.16, 134.24, 132.95, 
132.16, 131.18, 129.41, 123.48, 122.54, 106.44, 37.29, 36.92, 31.90, 16.90; IR (film, cm-1): 
3467, 3064, 2942, 2360, 2341, 1772, 1710, 1550, 1448, 1396, 1334, 1155, 1074, 985, 846, 721, 
607; HRMS (ESI) m/z calculated for C21H20N2O6S [M+H]+: 429.1120, found 429.1120. 
 
(E)-6-(4-nitro-4-(phenylsulfonyl)pent-1-en-1-yl)-1,4-
dioxaspiro[4.5]decane (5d): 6-allyl-1,4-dioxaspiro[4.5]decane12 (54.7 mg, O2N
SO2Ph
Me
OO
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0.3 mmol, 1.0 equiv) and ((1-nitroethyl)sulfonyl)benzene (129.0 mg, 0.6 mmol, 2.0 equiv) were 
reacted following the general procedure. The reaction vial was capped and stirred at 45°C in an 
oil bath for 72 hours. The vial was cooled to room temperature. Reaction was diluted with 
diethyl ether (30 mL) followed by washing with 2M NaOH (3 x 10 mL), H2O (1 x 10 mL) and 
brine (1 x 10 mL). The organic layer was dried over anhydrous MgSO4, filtered and concentrated 
in vacuo. Important note: The product (Rf = 0.27 in 30% EtOAc/Hex) overlaps with ((1-
nitroethyl)sulfonyl)benzene (Rf = 0.24 in 30% EtOAc/Hex). Sodium ((1-
nitroethyl)sulfonyl)benzene dissolves in aq. NaOH solution rather than in the Et2O. 
Washing with 2M NaOH removes all excess ((1-nitroethyl)sulfonyl)benzene. Crude material 
was purified by flash chromatography (10→20→30→40% EtOAc/hexanes) yielded pure linear 
product as a white solid. Product was isolated as a mixture of diastereomers. Run 1 (80.3 mg, 
0.203 mmol, 68% yield); run 2 (82.2 mg, 0.208 mmol, 69% yield). Average yield: 69%. 
Mixture of diastereomers 1H NMR (500 MHz; CDCl3): δ 7.83 (d, J = 7.6 Hz, 4H), 7.74 (t, J = 
7.5 Hz, 2H), 7.59 (t, J = 7.8 Hz, 4H), 5.67 (dd, J = 15.5, 7.5 Hz, 1H), 5.61 (dd, J = 15.4, 8.1 Hz, 
1H), 5.20 (dq, J = 15.7, 7.9 Hz, 2H), 3.92-3.81 (m, 5H), 3.79-3.74 (m, 3H), 3.14 (dt, J = 13.7, 6.7 
Hz, 2H), 2.80 (dt, J = 14.1, 8.5 Hz, 2H), 2.22 (dq, J = 14.0, 5.3 Hz, 2H), 1.89 (s, 6H), 1.70 (t, J = 
9.3 Hz, 2H), 1.60 (d, J = 6.0 Hz, 6H), 1.49-1.40 (m, 4H), 1.31 (tdd, J = 12.4, 8.4, 3.8 Hz, 2H), 
1.24-1.17 (m, 2H); 13C NMR (126 MHz, CDCl3) δ 139.17, 138.93, 135.48, 133.05, 133.01, 
131.20, 129.40, 120.42, 120.32, 109.90, 109.77, 106.82, 106.78, 65.31, 65.13, 64.94, 48.93, 
48.36, 37.39, 37.28, 35.21, 34.96, 30.58, 30.15, 24.62, 24.41, 23.90, 16.81, 16.73; IR (film, cm-
1): 3064, 2935, 2286, 2881, 2360, 1552, 1448, 1334, 1155, 1076, 925, 721, 688; HRMS (ESI) 
m/z calculated for C19H25NO6S [M+H]+: 396.1481, found 396.1479. 
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 (E)-2-methyl-7-nitro-7-(phenylsulfonyl)oct-4-en-3-ol (5e): 
Commercial available 2-methyl-5-hexen-3-ol (34.3 mg, 0.3 mmol, 1.0 
equiv) and ((1-nitroethyl)sulfonyl)benzene (129.0 mg, 0.6 mmol, 2.0 equiv) were reacted 
following the general procedure. The reaction vial was capped and stirred at 45°C in an oil bath 
for 72 hours. The vial was cooled to room temperature. Reaction mixture was diluted with 
saturated aqueous NH4Cl solution (40 mL) followed by extraction with ethyl acetate (3 x 30 
mL). Combined organics were dried over anhydrous MgSO4, filtered and concentrated in vacuo. 
Flash chromatography (10→20→30→40→50→60% EtOAc/hexanes) yielded pure linear 
product (Rf = 0.14 in 30% EtOAc/Hex) as a colorless oil. Product was isolated as a mixture of 
diastereomers. Run 1 (58.9 mg, 0.180 mmol, 60% yield); run 2 (58.5 mg, 0.179 mmol, 59% 
yield). Average yield: 60%. Mixture of diastereomers 1H NMR (500 MHz, CDCl3) δ 7.85 (d, J 
= 7.4 Hz, 2H), 7.76 (t, J = 7.5 Hz, 1H), 7.60 (t, J = 7.8 Hz, 2H), 5.66 (ddd, J = 15.6, 9.5, 6.4 Hz, 
1H), 5.41 (dt, J = 15.5, 7.4 Hz, 1H), 3.81 (dt, J = 12.6, 6.0 Hz, 1H), 3.20 (dt, J = 14.8, 7.8 Hz, 
1H), 2.87 (ddd, J = 14.3, 7.5, 4.0 Hz, 1H), 1.91 (s, 1H), 1.74 – 1.56 (m, 2H), 0.88 – 0.79 (m, 
6H); 13C NMR (126 MHz, CDCl3) δ 139.97, 135.48, 132.72, 131.07, 129.35, 120.57, 120.48, 
106.41, 106.38, 77.41, 77.16, 77.13, 76.90, 36.71, 33.80, 33.76, 18.14, 18.09, 17.87, 17.78, 
17.02, 16.94; IR (film, cm-1): 3625-3220 (br), 2962, 2929, 2360, 2341, 1554, 1448, 1382, 1332, 
1155, 1074, 977, 846, 756; HRMS (ESI) m/z calculated for C15H21NO5S [M+H]+: 328.1219, 
found 328.1223. 
 
Tandem C—H Alkylation/Diels-Alder Reaction Cascade Procedure (Scheme 4): An oven 
dried one dram (4 mL) borosilicate vial equipped with a magnetic stir bar was charged with 
Pd[1,2-bis(benzylsulfinyl)ethane](OAc)2 (1) (45.0 mg, 0.085 mmol, 0.1 equiv.), 
Me
SO2Ph
NO2
OH
Me
Me
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2,6-dimethylbenzoquinone (DMBQ) (174 mg, 1.28 mmol, 1.4 equiv.) and methyl (E)-6-nitro-6-
(phenylsulfonyl)hex-2-enoate (532.0 mg, 1.70 mmol, 1.8 equiv.). Followed by the addition of 
(S)-3-allyl-5-methylfuran-2(5H)-one (130 mg, 0.94 mmol, 1.0 equiv.) as a solution in 1,4-
dioxane (0.5 mL) and dimethylsulfoxide (2 mL), solution was added via pipet. No further 
precautions were taken to exclude air or moisture. The vial was capped and stirred for 24 hours 
at 45°C in an aluminum block. The reaction was subsequently transferred to a 55°C oil bath for 
48 hours. The vial was cooled to room temperature and the reaction mixture was quenched with 
saturated aqueous NH4Cl solution (80 mL). The aqueous layer was extracted with EtOAc (2 x 80 
mL) and combined. The combined organic extracts were dried over anhydrous MgSO4, filtered 
and concentrated in vacuo. The crude reaction mixture was purified by flash chromatography 
(100:1 SiO2/total reagents used), gradient elution with 10%→15%→20%→30%→40%→50% 
EtOAc/hexanes. Flash chromatography afforded a complex mixture of diastereomers (11, 12) 
(317 mg, 75% yield) that was purified by preparative chiral SFC. 
 
methyl (2E,8E)-9-((S)-5-methyl-2-oxo-2,5-dihydrofuran-3-yl)-6-
nitro-6-(phenylsulfonyl)nona-2,8-dienoate (10): After 24 h at 45 ºC the 
diene was isolated. mixture of diastereomers - 1H NMR (500 MHz; 
CDCl3): δ 7.85 (d, J = 7.4 Hz, 2H), 7.77 (t, J = 7.5 Hz, 1H), 7.62 (t, J = 
7.9 Hz, 2H), 7.18 (s, 1H), 6.86 (dt, J = 15.6, 6.7 Hz, 1H), 6.69 (dt, J = 15.5, 7.6 Hz, 1H), 6.29 (d, 
J = 15.7 Hz, 1H), 5.87 (d, J = 15.7 Hz, 1H), 5.05 (q, J = 6.5 Hz, 1H), 3.72 (s, 3H), 3.27 (dd, J = 
15.3, 7.1 Hz, 1H), 3.18 (dd, J = 15.3, 7.7 Hz, 1H), 2.67-2.60 (m, 1H), 2.54 (ddd, J = 14.8, 11.4, 
3.7 Hz, 1H), 2.43-2.37 (m, 1H), 2.36-2.30 (m, 1H), 1.43 (d, J = 6.8 Hz, 3H); 13C NMR (101 
MHz; CDCl3): δ 171.3, 166.6, 150.45, 150.38, 145.53, 145.50, 135.7, 132.9, 131.06, 131.02, 
O
O
Me
SO2Ph
NO2
O OMe
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131.00, 129.50, 129.47, 129.44, 128.1, 126.9, 125.38, 125.35, 122.75, 122.72, 122.66, 108.1, 
77.36, 77.27, 51.89, 51.79, 51.70, 51.60, 35.52, 35.41, 35.31, 29.8, 26.4, 19.07, 18.99; IR (film, 
cm-1): 3070, 2983, 2950, 2871, 2254, 1754, 1724, 1658, 1554, 1448, 1332, 1280, 1222, 1176, 
1151, 1081, 1029, 979, 914, 848, 757, 723, 688, 622; HRMS (ESI) m/z calculated for 
C21H24NO8S [M+H]+: 450.1223, found 450.1206. 
 
IR and HRMS were obtained on a the isolated mixture of 
diastereomers: IR (film, cm-1): 3525, 3068, 2981, 2952, 2871, 2661, 
2256, 1982, 1911, 1760, 1733, 1552, 1689, 1583, 1552, 1448, 1388, 1371, 
1330, 1251, 1230, 1191, 1155, 1116, 1081, 1054, 1043, 1027, 998, 985, 914, 871, 836, 800, 773, 
757, 730, 688, 649, 603; HRMS (EI+) m/z calculated for C21H23NO8S [M]+: 449.11442, found 
449.11507.  
 
 Methyl (3S,3aR,4R,4aS,7S,8aS)-3-methyl-7-nitro-1-oxo-7-
(phenylsulfonyl)-1,3,3a,4,4a,5,6,7,8,8a-decahydronaphtho[2,3-
c]furan-4-carboxylate (11a): Preparative chiral SFC afforded 33.0 mg 
of a-nitro sulfone 11a. 1H NMR (500 MHz; CDCl3): δ 7.80 (d, J = 8.2 Hz, 2H), 7.77 (d, J = 7.5 
Hz, 1H), 7.61 (t, J = 7.6 Hz, 2H), 6.60 (s, 1H), 4.31-4.25 (m, 1H), 3.71 (s, 3H), 3.00 (d, J = 14.1 
Hz, 1H), 2.81 (app q, J = 8.0 Hz, 1H), 2.76 (d, J = 14.5 Hz, 1H), 2.69 (t, J = 10.8 Hz, 1H), 2.27 
(td, J = 13.9, 4.0 Hz, 1H), 2.19 (t, J = 13.6 Hz, 1H), 1.90-1.83 (m, 2H), 1.54-1.47 (m, 1H), 1.32 
(d, J = 6.0 Hz, 3H); 13C NMR (126 MHz; CDCl3): δ 172.5, 167.7, 136.8, 135.8, 131.97, 131.94, 
130.9, 129.5, 106.7, 77.4, 52.3, 45.7, 43.9, 39.3, 35.3, 33.3, 28.4, 26.4, 20.1.  
 
O
O
Me H
H
H
OMeO
NO2
SO2Ph
O
O
Me H
H
H
OMeO
SO2Ph
NO2
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Methyl (3S,3aR,4R,4aS,7R,8aS)-3-methyl-7-nitro-1-oxo-7-
(phenylsulfonyl)-1,3,3a,4,4a,5,6,7,8,8a-decahydronaphtho[2,3-c]furan-
4-carboxylate (11b): Preparative chiral SFC afforded 23.0 mg of a-nitro 
sulfone 11b. 1H NMR (500 MHz; CDCl3): δ 7.82 (d, J = 8.0 Hz, 2H), 7.78 (t, J = 7.4 Hz, 1H), 
7.62 (t, J = 7.2 Hz, 2H), 6.66 (s, 1H), 4.30 (dt, J = 12.5, 6.1 Hz, 1H), 3.75 (s, 3H), 3.20 (d, J = 
15.0 Hz, 1H), 2.96-2.86 (m, 4H), 2.08 (td, J = 14.3, 4.3 Hz, 1H), 2.03-1.95 (m, 2H), 1.89 (dd, J = 
12.6, 2.9 Hz, 1H), 1.50-1.41 (m, 2H), 1.37 (d, J = 5.9 Hz, 3H); 13C NMR (126 MHz; CDCl3): δ 
172.8, 167.9, 137.5, 135.8, 132.5, 131.6, 130.7, 129.5, 104.0, 77.4, 52.3, 45.8, 44.2, 39.4, 35.30, 
35.12, 30.3, 26.7, 20.2.  
 
Scheme 5. Crystal Structure of endo-anti-(R) a-Nitrosulfone (11b) 
 
Table 2. Crystal Data and Structure Refinement for cc25aas (11b) 
Identification code  cc25aas 
Empirical formula  C21 H23 N O8 S 
Formula weight  449.46 
Temperature  183(2) K 
O
O
Me H
H
H
OMeO
SO2Ph
NO2
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Table 2. (cont.) 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P2(1) 
Unit cell dimensions a = 10.8507(3) Å a= 90°. 
 b = 16.7356(5) Å b= 111.0770(10)°. 
 c = 12.5660(4) Å g = 90°. 
Volume 2129.23(11) Å3 
Z 4 
Density (calculated) 1.402 Mg/m3 
Absorption coefficient 1.781 mm-1 
F(000) 944 
Crystal size 0.569 x 0.493 x 0.219 mm3 
Theta range for data collection 3.77 to 67.59°. 
Index ranges -12<=h<=10, -19<=k<=19, -13<=l<=14 
Reflections collected 26142 
Independent reflections 7347 [R(int) = 0.0420] 
Completeness to theta = 67.59° 97.8 %  
Absorption correction Integration 
Max. and min. transmission 0.7501 and 0.5054 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7347 / 394 / 687 
Goodness-of-fit on F2 1.065 
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Table 2. (cont.) 
Final R indices [I>2sigma(I)] R1 = 0.0291, wR2 = 0.0751 
R indices (all data) R1 = 0.0296, wR2 = 0.0756 
Absolute structure parameter 0.026(9) 
Largest diff. peak and hole 0.353 and -0.286 e.Å-3 
 
1.5 References 
1. (a) Lyons, T. W.; Sanford, M. S., Chem. Rev. 2010, 110, 1147; (b) Colby, D. A.; 
Bergman, R. G.; Ellman, J. A., Chem. Rev. 2010, 110, 624; (c) Chen, X.; Engle, K. M.; Wang, D. 
H.; Yu, J. Q., Angew. Chem. Int. Ed. 2009, 48, 5094; (d) Davies, H. M.; Manning, J. R., Nature 
2008, 451, 417. 
2. (a) Young, A. J.; White, M. C., J. Am. Chem. Soc. 2008, 130, 14090; (b) Young, A. J.; 
White, M. C., Angew. Chem. Int. Ed. 2011, 50, 6824; (c) Lin, S.; Song, C. X.; Cai, G. X.; Wang, 
W. H.; Shi, Z. J., J. Am. Chem. Soc. 2008, 130, 12901. 
3. (a) Trost, B. M.; Hansmann, M. M.; Thaisrivongs, D. A., Angew. Chem. Int. Ed. 2012, 
51, 4950; (b) Trost, B. M.; Thaisrivongs, D. A.; Donckele, E. J., Angew. Chem. Int. Ed. 2013, 52, 
1523. 
4. Wade, P. A.; Hinney, H. R.; Amin, N. V.; Vail, P. D.; Morrow, S. D.; Hardinger, S. A.; 
Saft, M. S., J. Org. Chem. 1981, 46, 765. 
5. Prakash, G. K.; Wang, F.; Zhang, Z.; Ni, C.; Haiges, R.; Olah, G. A., Org. Lett. 2012, 14, 
3260. 
6. (a) Nishimura, T.; Onoue, T.; Ohe, K.; Uemura, S., J. Org. Chem. 1999, 64, 6750; (b) 
Sigman, M. S.; Jensen, D. R., Acc. Chem. Res. 2006, 39, 221. 
25 
 
7. (a) Jiang, S.; Liu, Z.-H.; Sheng, G.; Zeng, B.-B.; Cheng, X.-G.; Wu, Y.-L.; Yao, Z.-J., J. 
Org. Chem. 2002, 67, 3404; (b) Jiang, S.; Li, Y.; Chen, X. G.; Hu, T. S.; Wu, Y. L.; Yao, Z. J., 
Angew. Chem. Int. Ed. 2004, 43, 329. 
8. (a) Rinner, U.; Lentsch, C.; Aichinger, C., Synthesis 2010, 2010, 3763; (b) 
Chackalamannil, S.; Wang, Y.; Greenlee, W. J.; Hu, Z.; Xia, Y.; Ahn, H. S.; Boykow, G.; Hsieh, 
Y.; Palamanda, J.; Agans-Fantuzzi, J.; Kurowski, S.; Graziano, M.; Chintala, M., J. Med. Chem. 
2008, 51, 3061. 
9. Clavier, H.; Nolan, S. P.; Mauduit, M., Organometallics 2008, 27, 2287. 
10. Vilaça, G.; Rubio, C.; Susperregui, J.; Latxague, L.; Déléris, G., Tetrahedron 2002, 58, 
9249. 
11. Stang, E. M.; White, M. C., J. Am. Chem. Soc. 2011, 133, 14892. 
12. Knust, H.; Hoffmann, R. W., Helv. Chim. Acta 2003, 86, 1871. 
 
 
 
 
 
 
 
 
 
 
26 
 
CHAPTER 2: ASYMMETRIC ALLYLIC C–H OXIDATION VIA 
PALLADIUM(II)/SULFOXIDE-OXAZOLINE CATALYSIS 
Acknowledgements 
This chapter has been adapted from the research article “Enantioselective Allylic C–H 
Oxidation of Terminal Olefins to Isochromans by Palladium(II)/Chiral Sulfoxide Catalysis” 
(Ammann, S. E.; Liu, W.; White, M. C. Angew. Chem., Int. Ed. 2016, 55, 9571).  
This work was a collaborative effort. Mechanistic studies, and part of the synthetic 
applications was accomplished by Dr. Stephen Ammann, and will not be discussed in this thesis.  
2.1 Introduction 
Asymmetric functionalization of an inert C(sp3)–H allows for the installation of valuable 
functionality with the concomitant establishment of absolute stereochemistry.13 In this context, 
asymmetric allylic C–H oxidation has been pursued since 1960s;14 however, limitations still exist 
that hamper the broad and efficient synthetic application of this useful transformation. Copper-
catalyzed Kharasch-Sosnovsky reaction achieved high enantioselectivity only with symmetrical, 
cyclic olefins (Scheme 6a).15 In addition, excess equivalents of substrates and extended reaction 
time (days/weeks) at cryogenic temperatures were also required to obtain useful yields. More 
recently, chiral palladium/phosphoramidite catalysts have been developed for allylic C–H 
oxidation (Scheme 6b);16 however, this reaction suffered from modest enantioselectivity (avg. 
85% ee), limited olefin scope (skipped diene substrates with doubly activated C–H bonds) and 
the instability of the phosphine-based ligands under oxidative conditions.  
Alternatively, oxidatively stable palladium(II)/bis-sulfoxide catalysts have shown 
generality in effecting a range of allylic C–H functionalizations;2a, c, 17 but limited success was 
achieved in adapting this catalytic system to asymmetric catalysis (Scheme 6c).18  Mechanistic 
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studies showed that Pd/bis-sulfoxide catalysis proceeds via a serial ligand mechanism, where 
association of the bis-sulfoxide ligand with the metal is highly fluxional. While bis-sulfoxide is 
critical for C–H cleavage, it does not promote functionalization, necessitating the requirement for 
a second π-acidic ligand (e.g. benzoquinone) at high concentrations to promote this step. Because 
rapid π-σ-π isomerization occurs prior to functionalization, scrambling any chiral information 
that might be imparted during C–H cleavage, a chiral sulfoxide would not effect asymmetric 
induction. Previous effort to introduce chirality during functionalization involved the use of a 
chiral chromium Lewis-acid cocatalyst that works with benzoquinone, however only leading to 
modest enantioselectivity (avg. 54% ee).18  
H
R benzoquinone,
(R,R)-Cr(salen)F
OAc
R
avg. 54% ee
c.)  Pd(II)/bis-sulfoxide catalysis (Serial ligand catalysis)
SS
O O
Ph Ph
Pd(OAc)2+ AcOH
achiral bis-sulfoxide R
Pd
chiral Cr Lewis acid
a.)  Kharasch-Sosnovsky reaction
Cu / bisoxazoline
symmetrical olefins
avg. 98% ee
H OR'
n n–20˚C, 8-17 days
5 equiv
O O
Scheme 6. Previous Asymmetric Allylic C-H Oxidation
b.)  Pd/Phosphoramidite catalysis
R2
R3
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R1 O
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R3
R2
*
Pd(dba)2 (5 mol%)
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O
O
P
R4
R4
N
R6
R5
R4 = 4-NO2C6H4
R5 = 3,5-(CF3)2C6H3
R6 = 4-MeOC6H4
L1
avg. 85% ee
2 examples at 90% ee
 
To address these limitations, I envision a stronger-coordinating chiral sulfoxide ligand for 
palladium that promotes both C–H cleavage and functionalization would provide a stable 
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coordination environment to achieve asymmetric allylic C–H functionalization.  I hypothesize 
that combining the demonstrated C–H cleavage reactivity of sulfoxide ligand with oxazoline as a 
strong σ-donor could anchor the ligand at Pd and promote functionalization by the formation of 
cationic π-allyl/Pd(II) complex (Figure 2).  Importantly, the sulfoxide-oxazoline (SOX) ligand 
would be highly modular, containing three distinct portions (oxazoline, sulfoxide and aryl 
backbone) that could be tuned electronically and/or sterically. SOX ligands would also possess 
two potentially chiral sites (oxazoline and sulfoxide) and allow the access to both stereochemical 
combinations (trans or cis) that might lead to unique reactivity and selectivity. 
Figure 2. Design of a Stronger Binding Sulfoxide-Oxazoline Ligand
R
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There are previous examples of sulfoxide-oxazoline ligands being investigated for 
transition metal catalysis. In 1994, the Williams group evaluated SOX ligand 2 in the Pd(0)-
catalyzed allylic substitution of 1,3-diphenylpropenyl acetate as the single substrate (Scheme 
7a).19 The main purpose of this study was to compare the electronic effect of the sulfur donor. 
More recently, the Itami group applied ligand 2 to the Pd-catalyzed C–H arylation of thiophene 
with arylboronic acids.20 One example of chiral biaryl formation was demonstrated in 61% ee 
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(Scheme 7b). Concurrent with our efforts, in 2014, SOX ligand 3 was shown by Liu and Itami to 
promote Pd-catalyzed branched allylic acetoxylations with 1,4-benzoquinone as the oxidant 
(Scheme 7c).21 Although a chiral ligand was used, no asymmetric induction in the product was 
obtained. The authors also showed the dependence of reactivity on benzoquinone: when 
sterically bulky benzoquinones were used, the reactivity was dramatically decreased. These 
results likely suggest the functionalization is mediated by benzoquinone but not the SOX ligand, 
explaining the observation of no asymmetric induction.  
 
 In 2014, we have reported an achiral allylic C–H oxidation to synthesize cyclic ethers 
(e.g. chromans) by Pd(II)/bis-sulfoxide catalysis (Figure 3).22 Mechanistic studies showed the 
functionalization step in chroman formation likely proceeded via the pre-coordination of the 
alcohol to palladium and was promoted by benzoquinone. We reason this highly organized 
transition state would be beneficial for asymmetric induction. By using a bulkier quinone, the 
racemic background reaction could be prevented, allowing SOX ligands to effect a static chiral 
environment for functionalization. We envision the Pd(II)/SOX catalysis could enable an 
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asymmetric allylic C–H oxidation to furnish chiral isochromans, which are well-represented in 
natural products and medicinal agents (Figure 3).23 This C–H oxidation method would also be 
orthogonal to current enantioselective organocatalytic or metal-catalyzed methods using pre-
oxidized starting materials.24  
 
 
2.2 Results and Discussion 
2.2.1 Reaction Development 
The alcohol substrate 14a is first evaluated for Pd(II)-catalyzed cyclization to form chiral 
isochroman 15a. SOX ligand L4 is found to promote the reaction in low yield but with good 
enantioselectivity (entry 1, Table 3). Bronsted acid cocatalyst has previously been shown to 
promote the reactivity of Pd(II)/bis-sulfoxide catalyzed allylic oxidation,25 which prompts us to 
survey a range of Bronsted acid additives (entry 2-5).  Diphenylphosphinic acid (10 mol%) is 
identified to be the optimal additive, improve the reactivity to 63% yield (entry 5). With the 
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S
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O
R1
O
Me
(S,R)
L4:  R1 = Ph
L6:  R1 = iPr
L7:  R1 = tBu
(S,R)
L9:  R2 = OMe
L10:  R2 = tBu
L11:  R2 = CF3
S
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O
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O
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(S,S)-L5
S
N
O
Ph
O
(S,R)-L8
S
O
S
O
Me Me
(R,R)-L12
S
N
O
O
R2
Entry Ligand Additive % Yielda % ee
2,6-DMBQ (1.1 equiv.)
additive (10 mol%)
toluene, 8h, 45˚C
Pd(OAc)2 (10 mol%)
Ligand (10 mol%)
a. Average of two isolated runs. b. reaction run for 72 hours. c. p-
benzoquinone used in place of 2,6-DMBQ. 2,6-DMBQ = 2,6-
dimethylbenzoquinone
O
OH
1
L4 63 87
2
L5 32 19
3
L6 31 76
4
L7 8 25
5
L8 24 88
6
L9 60 86
7
L10 70 92
8
L11 49 93
9
10
11
12
L4 none
L4 benzoic acid
L4
L4
Table 3. Reaction Development
8
13
54
47
83
84
87
82
13b
14c
L12
59 77L10
19 –6
H
14a 15a
(nBuO)2PO2H
(PhO)2PO2H
Ph2PO2H
Ph2PO2H
Ph2PO2H
Ph2PO2H
Ph2PO2H
Ph2PO2H
Ph2PO2H
Ph2PO2H
Ph2PO2H
Ph2PO2H
(S)
Bronsted acid cocatalyst, systematic ligand modification is conducted to further improve the 
enantioselectivity. Switching the relative stereochemistry of substituents on oxazoline and 
sulfoxide from trans-(S,R)-L4 to cis-(S,S)-L5 led to significantly lowered reactivity and 
asymmetric induction. This indicates the trans-diastereomer of SOX ligands is preferred for this 
reaction. Previously reported SOX ligands with alkyl substitution on the oxazoline (L6, L7) 
resulted in diminished reactivity and enantioselectivity (entry 7 and 8).20-21 Sulfoxide 
modification is also examined: for alkyl sulfoxide, an isopropyl group (L8) shows improved 
enantioselectivity, but decreased reactivity (entry 9); for aryl sulfoxide, although a para-methoxy 
substituent (L9) is not beneficial, both para-tert-butyl (L10) and para-trifluoromethyl group 
(L11) improve the enantioselectivity to be above 90% ee (entry 11, 12). Given the higher 
reactivity and relative ease of synthesis of L10, it is selected for further evaluation of reaction 
scope. However, in some cases where enantiomeric excess falls below 90%, L11 could be the 
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optimal ligand and improved yields could be obtained by extending the reaction time (vida 
infra). When a chiral bis-sulfoxide ligand L12 is examined, a minimal asymmetric induction is 
obtained, underscoring the importance of a stronger binding sulfoxide ligand. The use of a 
sterically bulky benzoquinone as the oxidant is also critical, as switching to 1,4-benzoquinone 
significantly lowered the enantioselectivity to 77% (entry 14). 
2,6-DMBQ (1.1 equiv.)
Ph2PO2H (10 mol%)
toluene, 45˚C, 8h14 15
Pd(OAc)2 (10 mol%)
SOX L10 (10 mol%)
O
OH
O O O
O O O
O O
O
Me
Me
MeO
MeO
Br
F
Cl
F
F3C
15b; 69% yield, 92% ee 15c; 68% yield, 93% ee 15d;  46% yield, 87% ee
      64% yield, 95% eea
15e; 76% yield, 93% eeb 15f; 61% yield, 91% eec 15g; 64% yield, 92% ee
15h; 55% yield, 92% eec 15i; 52% yield, 88% ee
    56% yield, 92% eea,d
15j; 75% yield, 93% ee
Yields reported are isolated, average of three runs at 0.2 mmol. aL11 used in place of 
L10. bReaction run for 9h.  cReaction run for 10h. dReaction run for 48h.
Table 4. Substrate Scope for the Formation of Chiral Isochromans
H
 
2.2.2 Reaction Scope 
 Having identified the optimal condition, the reaction scope to form vinyl isochroman 
motif is next examined (Table 4). Electronically varied aromatic substitutions are well tolerated, 
with electron-neutral methyl group (15b,c), electron-rich methoxy group (15d), as well as 
electron-deficient halides (15e-h) and trifluoromethyl group (15i), furnishing the desired product 
in good yields and enantioselectivities. Bromo and chloro substitution could serve as additional 
synthetic handle for further elaboration. A substrate containing extend π-surface also furnishes 
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the chiral oxygen heterocycle in 93% ee (15j). Notably, the optimal enantioselectivity for 
product 15d and 15i is achieved with SOX L11 in place of L10.  
Me
OH
Pd(OAc)2 (10%)
Ligand (10%)
2,6-DMBQ (1.1 eq)
Ph2PO2H (10%)
toluene, 45˚C
Me
O +
Me
O
19a 19b
Ligand % Yield d.r. (6a : 6b)Entry
4
5
6
meso - 1,2-bis(phenylsulfinyl)ethane (L13)
(S,R)-SOX L10
(R,S)-SOX L10
60
67
68
3.6 : 1
> 20 : 1
1 : 1.4
O + O
17a 17b
1
2
3
meso - 1,2-bis(phenylsulfinyl)ethane (L13)
(S,R)-SOX L10
(R,S)-SOX L10
16
62
49
1.5 : 1
> 20 : 1
1 : 2.8
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Ligand % Yield d.r. (17a : 17b)Entry
Scheme 8. Catalytic influence on diastereoselective cyclization
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3
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2.2.3 Diastereoselective Synthesis of Disubstituted Chiral Isochromans 
 Because 1,3- and 1,4-disubstituted chiral isochromans are commonly found in natural 
products,26 we become interested in applying Pd(II)/SOX catalysis to achieve a 
diastereoselective cyclization (Scheme 8). Previous syntheses typically involved Pictect-
Spenglar reaction under substrate control, whereas catalyst-controlled diastereoselectivity has not 
been demonstrated.26 When the chiral alcohol precursor 16 is examined under the achiral 
Pd(II)/bis-sulfoxide L13 catalysis, 1,3-disubstituted isochroman is obtained in 1.5:1 d.r., slightly 
favoring the cis-diastereomer 17a. Significantly, using Pd(II)/(S,R)-SOX L10 improves the 
diastereoselectivity to be greater than 20:1, furnishing 17a as a single diastereomer. The 
enantiomer, (R,S)-SOX L10 leads to a mismatched scenario, which overturns the innate 
selectivity to favor the trans-diastereomer 17b in 2.8:1 ratio. This ability to impart catalyst-
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controlled diastereoselectivity is also observed in the synthesis of 1,4-disubstituted isochromans 
(Scheme 8b). The achiral catalyst favors the formation of cis-diastereomer in 3.6:1 d.r. The use 
of matched Pd(II)/(S,R)-SOX L10 once again increases the d.r. to >20:1 favoring 19a, and 
mismatched Pd(II)/(R,S)-SOX L10 slightly overturns the d.r. to 1:1.4 favoring 19b. 
(S)-PNU-109291 (27)
O
N
N
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MeHN
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O
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O
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O
Boc
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O
Boc OH
2,6-DMBQ (1.1 equiv.)
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25; 70% yield, 
     93% ee
Overall yield 
This route: 19% Yield
Previously reported: 16% Yield
Scheme 9. Target-oriented Synthesis of Chiral Isochroamn in Medicinal Agents
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2.2.4 Synthetic Application of Pd(II)/SOX-Catalyzed Asymmetric Allylic C–H Oxidation 
Chiral isochroman is a common motif in medicinal agents, as exemplified by PNU-
109291 (27), a selective 5HT1D agonist for the treatment of migraine.27 Previous route to obtain 
the chiral product involved a racemic synthesis followed by chiral resolution. We decide to apply 
our catalytic asymmetric allylic C–H oxidation method to access this valuable motif (Scheme 9). 
Starting from commercial available 5-bromo-2-methoxyphenylacetic acid, reduction of the 
carboxylic acid followed by tetrahydropyran (THP) protection affords the aryl bromide 20, 
which subsequently adds to methyl isocyanate through Grignard formation to furnish the amide 
21 (Scheme 9A). Stille coupling through the aryl C–O bond is achieved by methoxy group 
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deprotection, triflate formation, and subsequent coupling with allyltributyltin under Pd(PPh3)4 
catalysis to obtain allylarene 23.  The precursor for allylic oxdation 24 is furnished by protection 
of the primary amide 23 and deprotection of the THP group.  Gratifyingly, when 24 is subject to 
Pd(II)/SOX L10 catalyzed asymmetric allylic oxidation,  chiral vinyl isochroman 25 is formed in 
good yield (70%) and high enantioselectivity (93% ee). Further manipulation of the vinyl group 
affords the targeted compound 27, which involves hydroboration/oxidation, mesylate formation 
of the alcohol and nucleophilic displacement by piperazine. Importantly, this C–H oxidation 
route based on asymmetric catalysis results in a higher overall yield. Moreover, the terminal 
olefin in 25 can serve as a synthetic handle for late stage functionalization of this important 
pharmacophore (not shown), whereas previous studies on structure-activity relationship largely 
focus on variations on the aryl backbone.27  
 
2.3 Conclusions 
We have developed a new class of sulfoxide-oxazoline ligands for Pd(II)-catalyzed 
asymmetric allylic C–H oxidation of terminal olefins to form chiral isochromans. The key ligand 
modifications are identified to be diarylated substituents on oxazoline and sulfoxide in trans 
configuration, as well as bulky para-substituents (tert-butyl or trifluoromethyl) on the aryl 
sulfoxide moiety. A broad scope of chiral vinyl isochromans are obtained in good yields and 
high enantioselectivities (>90% ee) in all cases. This method is also applicable to the synthesis of 
medicinally relevant isochroman to furnish pharmaceutical compounds with high efficiency. 
Encouragingly, the Pd(II)/SOX catalysis has also shown the ability to influence 
diastereoselectivity  for the cyclization of chiral alcohol substrate with catalyst control.  
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2.4 Experimental Sections 
2.4.1 General Information 
All commercially obtained reagents were used as received; Pd(OAc)2 (Johnson-Matthey 
Chemicals) was stored in a glove box, and weighed out in the air at room temperature prior to 
use. Toluene was purified prior to use by passage through a bed of activated alumina (Glass 
Contour, Laguna Beach, California). 2,6-dimethylbenzoquinone, 1,4-benzoquinone, 
dibutylphosphate, diphenylphosphate, and diphenylphosphinic acid were purchased from Sigma-
Aldrich and used as received. All allylic oxidation reactions were run under ambient air with no 
precautions taken to exclude moisture. All other reactions were run under an argon balloon 
unless otherwise stated. Thin-layer chromatography (TLC) was conducted with E. Merck silica 
gel 60 F254 precoated plates (0.25 mm) and visualized with UV and potassium permanganate 
stain. Flash chromatography was performed using ZEOprep 60 ECO 43-60 micron silica gel 
(American International Chemical, Inc.). 1H NMR spectra were recorded on a Varian Unity-
u400nb (500 MHz), Varian Inova-500 (500 MHz), or Varian Unity-500 (500 MHz) spectrometer 
and are reported in ppm using solvent as an internal standard (CDCl3 at 7.26 ppm). Data reported 
as: s = singlet, d = doublet, t = triplet, q = quartet, quin. = quintet, sext. = sextet, sept. = septet, o 
= octet, m = multiplet, b = broad, ap = apparent; coupling constant(s) in Hz; integration. Proton-
decoupled 13C NMR spectra were recorded on a Varian Unity-500 (125 MHz) spectrometer and 
are reported in ppm using solvent as an internal standard (CDCl3). 19F NMR spectra were 
recorded on a Varian Unity-500 (470 MHz) spectrometer and are reported in ppm using solvent 
as an internal standard (CDCl3). Chiral gas chromatographic (GC) analysis was performed on an 
Agilent 6890N Series instrument equipped with FID detectors using a J&W Cyclosil-B column. 
Chiral high pressure liquid chromatography (HPLC) analysis was performed on an Agilent 1100 
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Series instrument equipped with a UV detector, using a CHIRALPAK AD-RH or OJ-H column. 
Optical rotations were measured with a sodium lamp using a 1 mL cell with a 50 mm path length 
on a Jasco P-1020 polarimeter. High-resolution mass spectra were obtained at the University of 
Illinois Mass Spectrometry Laboratory. 
Preparation of SOX Ligands 
General procedure: To a dried flask under argon was added the phenyloxazoline (1 equiv), THF 
(0.1 M), and TMEDA (1.1 equiv). The reaction was cooled to –78˚C with stirring, and n-
butyllithium (1.6M in hexane, 1.1 equiv) was added via syringe dropwise. The reaction was 
stirred 20 minutes at –78˚C. Subsequently, the chiral sulfinate ester (1.1 equiv) was added as a 
solution in THF (0.5 M) dropwise via syringe. The reaction was stirred 1 hour at –78˚C, then 1 
hour at 0˚C, then 5 hours at room temperature. The reaction was subsequently cooled to 0˚C, and 
quenched with water. The mixture was diluted with CH2Cl2, and the layers were separated. The 
aqueous layer was extracted with CH2Cl2. The combined organic layers were dried over 
anhydrous MgSO4, filtered, and concentrated under reduced pressure. The crude residue was 
purified via column chromatography (20 à 30% EtOAc in hexanes) to afford the desired 
product. 
S
O
N
O
Me  
(S)-4-phenyl-2-(2-((R)-p-tolylsulfinyl)phenyl)-4,5-dihydrooxazole (L4): Phenyloxazoline28 
(302 mg, 1 mmol, 1 equiv) was reacted according to the general procedure with commercial 
sulfinate ester (324 mg, 1.1 mmol, 1.1 equiv). Purification by flash column chromatography (20 
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à 30% EtOAc in hexanes) provided the product as a clear, viscous oil. (198 mg, 0.55 mmol, 
55% Yield.) 1H NMR (500MHz, CDCl3) δ 8.44 (d, J = 7.9 Hz, 1H), 7.95 (d, J = 7.5 Hz, 1H), 
7.78 (t, J = 7.9 Hz, 1H), 7.60-7.52 (m, 3H), 7.40-7.29 (m, 3H), 7.26 (d, J = 7.1 Hz, 2H), 7.15 (d, 
J = 8.4 Hz, 2H), 5.38 (t, J = 9.6 Hz, 1H), 4.74 (dd, J = 9.9, 8.4 Hz, 1H), 4.13 (t, J = 8.4 Hz, 1H), 
2.33 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 162.3, 147.3, 143.9, 142.1, 141.3, 132.4, 130.5, 
130.1, 129.8, 129.1, 127.9, 127.2, 126.8, 125.3, 125.2, 74.9, 70.4, 21.6; [α]21D = +364.78 (c = 1, 
CH2Cl2); HRMS (TOF MS ES+) m/z calc’d for C22H20NO2S [M+H]: 362.1215; found 362.1212. 
S
O
N
O
Me  
(S)-4-phenyl-2-(2-((S)-p-tolylsulfinyl)phenyl)-4,5-dihydrooxazole (L5): Phenyloxazoline28 
(302 mg, 1 mmol, 1 equiv) was reacted according to the general procedure with commercial 
sulfinate ester (324 mg, 1.1 mmol, 1.1 equiv). Purification by flash column chromatography (20 
à 30% EtOAc in hexanes) provided the product as a white powder. (162 mg, 0.45 mmol, 45% 
Yield.) 1H NMR (500MHz, CDCl3) δ 8.47 (d, J = 8.1 Hz, 1H), 8.03 (d, J = 7.7 Hz, 1H), 7.80 (t, J 
= 7.5 Hz, 1H), 7.58 (t, J = 7.7 Hz, 1H), 7.45 (d, J = 7.9 Hz, 2H), 7.30-7.25 (m, 3H), 7.02 (d, J = 
7.5 Hz, 2H), 7.00 (d, J = 8.1 Hz, 2H), 5.43 (t, J = 9.6 Hz, 1H), 4.74 (ap. t, J = 9.6, Hz, 1H), 4.21 
(t, J = 8.3 Hz, 1H), 2.32 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 162.0, 147.0, 143.7, 141.8, 
141.0, 132.4, 130.5, 130.3, 129.7, 128.8, 127.8, 127.1, 127.1, 125.5, 125.1, 74.6, 71.0, 21.6; 
[α]22D = –195.79 (c = 0.5, CH2Cl2); HRMS (TOF MS ES+) m/z calc’d for C22H20NO2S [M+H]: 
362.1215; found 362.1213. 
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(S)-4-isopropyl-2-(2-((R)-p-tolylsulfinyl)phenyl)-4,5-dihydrooxazole (L6): Phenyloxazoline29 
(249 mg, 0.93 mmol, 1 equiv) was reacted according to the general procedure with commercial 
sulfinate ester (300 mg, 1.02 mmol, 1.1 equiv). Purification by flash column chromatography (20 
à 30% EtOAc in hexanes) provided the product as a clear, viscous oil. (146 mg, 0.45 mmol, 
48% yield.) 1H NMR (500MHz, CDCl3) δ 8.38 (dd, J = 7.9, 1.1 Hz, 1H), 7.85 (dd, J = 7.7, 1.3 
Hz, 1H), 7.72 (td, J = 7.7, 1.3 Hz, 1H), 7.62 (d, J = 8.3 Hz, 2H), 7.50 (td, J = 7.7, 1.3 Hz, 1H), 
7.16 (d, J = 7.9 Hz, 2H), 4.36-4.29 (m, 1H), 4.06-3.99 (m, 2H), 2.32 (s, 3H), 1.80-1.72 (m, 1H), 
1.06 (d, J = 6.6 Hz, 3H), 0.96 (d, J = 6.9 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 160.5, 147.4, 
144.3, 141.1, 132.1, 130.4, 129.8, 129.8, 127.0, 125.6, 125.3, 73.6, 70.8, 33.5, 21.7, 19.2, 19.2; 
[α]22D = +270.80 (c = 0.5, CH2Cl2); HRMS (TOF MS ES+) m/z calc’d for C19H22NO2S [M+H]: 
328.1368; found 328.1371. 
S
O
N
O
Me  
(S)-4-(tert-butyl)-2-(2-((R)-p-tolylsulfinyl)phenyl)-4,5-dihydrooxazole (L7): synthesized 
based on a reported procedure.21 
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(S)-2-(2-((R)-isopropylsulfinyl)phenyl)-4-phenyl-4,5-dihydrooxazole (L8): To a dried flask 
under argon was added phenyloxazoline28 (302 mg, 1 mmol, 1 equiv), THF (10 mL), and 
TMEDA (0.16 mL, 1.1 mmol, 1.1 equiv). The reaction was cooled to –78˚C with stirring, and n-
butyllithium (0.69 mL, 1.6M in hexane, 1.1 equiv) was added via syringe dropwise. The reaction 
was stirred 20 minutes at –78˚C. Subsequently, sulfinate ester30 (386 mg, 1.1 mmol, 1.1 equiv) 
was added as a solution in THF (2 mL) dropwise via syringe. The reaction was stirred 1 hour at –
78˚C, then 1 hour at 0˚C, then 2 hours at room temperature. The reaction was subsequently 
cooled to 0˚C, and quenched with water. The mixture was diluted with CH2Cl2, and the layers 
were separated. The aqueous layer was extracted with CH2Cl2. The combined organic layers 
were dried over anhydrous MgSO4, filtered, and concentrated under reduced pressure. The crude 
residue was purified via column chromatography (20 à 30% EtOAc in hexanes) to afford the 
desired product along with a diacetone glucose impurity. The mixture was dissolved in 3 mL 
MeOH, and PTSA was added (10 mg). The reaction was stirred 10 hours at room temperature. 
The mixture was diluted with CH2Cl2 and water. The layers were separated, and the aqueous 
layer was extracted with CH2Cl2. The combined organic layers were dried over anhydrous 
MgSO4, filtered, and concentrated under reduced pressure. The residue was purified via column 
chromatography (30% EtOAc in hexanes) to afford the product as a white powder. (73 mg, 0.23 
mmol, 23% yield.) 1H NMR (500MHz, CDCl3) δ 8.14 (dd, J = 7.8, 1.0 Hz, 1H), 7.99 (dd, J = 
7.8, 1.0 Hz, 1H), 7.74 (td, J = 7.8, 1.2 Hz, 1H), 7.56 (td, J = 7.6, 1.2 Hz, 1H), 7.42-7.37 (m, 4H), 
7.35-7.31 (m, 1H), 5.56 (dd, J = 10.0, 8.8 Hz, 1H), 4.85 (dd, J = 10.3, 8.3 Hz, 1H), 4.23 (t, J 
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8.3 Hz, 1H), 3.52 (sept., J = 6.8 Hz, 1H), 1.43 (d, J = 7.1 Hz, 3H), 0.98 (d, J = 6.8 Hz, 3H); 13C 
NMR (125 MHz, CDCl3) δ 162.3, 145.8, 142.2, 131.7, 130.0, 129.9, 129.0, 127.9, 126.6, 126.2, 
124.8, 74.8, 70.8, 52.2, 18.8, 11.6; [α]22D = +313.19 (c = 0.225, CH2Cl2); HRMS (TOF MS ES+) 
m/z calc’d for C18H20NO2S [M+H]: 314.1215; found 314.1213. 
S
O
N
O
OMe  
(S)-2-(2-((R)-(4-methoxyphenyl)sulfinyl)phenyl)-4-phenyl-4,5-dihydrooxazole (L9): 
Phenyloxazoline (309 mg, 1.02 mmol, 1 equiv) was reacted according to the general procedure 
with sulfinate ester31 (349 mg, 1.13 mmol, 1.1 equiv). Purification by flash column 
chromatography (20 à 30% EtOAc in hexanes) provided the product as a white powder. (182 
mg, 0.48 mmol, 47% yield.) 1H NMR (500MHz, CDCl3) δ 8.46 (d, J = 7.9 Hz, 1H), 7.95 (d, J = 
7.3 Hz, 1H), 7.79 (t, J = 7.3 Hz, 1H), 7.62-7.58 (m, 2H), 7.55 (t, J = 7.7 Hz, 1H), 7.38-7.28 (m, 
3H), 7.23 (d, J = 7.5 Hz, 2H), 6.85 (d, J = 8.6 Hz, 2H), 5.37 (ap. t, J = 9.9 Hz, 1H), 4.73 (dd, J = 
10.1, 8.4 Hz, 1H), 4.11 (t, J = 8.8 Hz, 1H), 3.78 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 162.3, 
161.7, 147.3, 142.1, 138.3, 132.3, 130.4, 130.2, 129.2, 129.0, 127.9, 126.7, 125.2, 125.1, 114.5, 
74.8, 70.3, 55.6; [α]21D = +357.55 (c = 0.25, CH2Cl2); HRMS (TOF MS ES+) m/z calc’d for 
C22H20NO3S [M+H]: 378.1164; found 378.1160. 
S
O
N
O
tBu  
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(S)-2-(2-((R)-(4-(tert-butyl)phenyl)sulfinyl)phenyl)-4-phenyl-4,5-dihydrooxazole (L10): 
Phenyloxazoline (700 mg, 2.32 mmol, 1 equiv) was reacted according to the general procedure 
with sulfinate ester31 (857 mg, 2.55 mmol, 1.1 equiv). Purification by flash column 
chromatography (20 à 30% EtOAc in hexanes) provided the product as a white powder (400 
mg, 1 mmol, 43% yield.) 1H NMR (500MHz, CDCl3) δ 8.45 (dd, J = 7.9, 1.1 Hz, 1H), 7.96 (dd, 
J = 7.7, 1.3 Hz, 1H), 7.78 (td, J = 7.7, 1.3 Hz, 1H), 7.65-7.61 (m, 2H), 7.55 (td, J = 7.5, 1.1 Hz, 
1H), 7.38-7.30 (m, 7H), 5.41 (ap. t, J = 9.6 Hz, 1H), 4.76 (dd, J = 10.3, 8.4 Hz, 1H), 4.15 (t, J = 
8.6 Hz, 1H), 1.26 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 162.3, 154.2, 147.4, 143.8, 142.1, 
132.4, 130.4, 130.0, 129.1, 127.9, 126.8, 126.8, 126.1, 125.3, 125.2, 74.9, 70.4, 35.1, 31.4; [α]22D 
= +371.11 (c = 0.25, CH2Cl2); HRMS (TOF MS ES+) m/z calc’d for C25H26NO2S [M+H]: 
404.1684; found: 404.1680. 
S
O
N
O
CF3  
(S)-4-phenyl-2-(2-((R)-(4-(trifluoromethyl)phenyl)sulfinyl)phenyl)-4,5-dihydrooxazole 
(L11): Phenyloxazoline (387 mg, 1.28 mmol, 1 equiv) was reacted according to the general 
procedure with sulfinate ester (638 mg, 1.41 mmol, 1.1 equiv). Purification by flash column 
chromatography (20 à 30% EtOAc in hexanes) provided the product as a clear, viscous oil. (132 
mg, 0.32 mmol, 25% yield.) 1H NMR (500MHz, CDCl3) δ 8.39 (d, J = 7.9 Hz, 1H), 7.96 (d, J = 
7.7 Hz, 1H), 7.92 (d, J = 8.4 Hz, 2H), 7.79 (t, J = 7.7 Hz, 1H), 7.62-7.57 (m, 3H), 7.42-7.32 (m, 
5H), 5.45 (ap. t, J = 9.6 Hz, 1H), 4.80 (dd, J = 10.3, 9.2 Hz, 1H), 4.21 (t, J = 8.6 Hz, 1H); 13C 
NMR (125 MHz, CDCl3) δ 162.1, 151.4, 147.0, 141.9, 132.7, 132.5 (q, J = 33.0 Hz), 131.0, 
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130.1, 129.2, 128.1, 127.2, 126.7, 126.0 (q, J = 3.8 Hz), 125.3, 125.3, 123.8 (q, J = 271.1 Hz), 
75.1, 70.5; 19F NMR (470 MHz, CDCl3) δ -63.3; [α]23D = +317.47 (c = 0.25, CH2Cl2); HRMS 
(TOF MS ES+) m/z calc’d for C22H17NO2SF3 [M+H]: 416.0932; found 416.0927. 
 
Reaction Development (Table 3) 
General procedure: To a ½ dram vial was added ligand (0.02 mmol, 0.1 equiv) and Pd(OAc)2 
(4.4 mg, 0.02 mmol, 0.1 equiv). Toluene (0.4 mL) was added, and the vial was capped and 
heated to 45˚C until all solids had dissolved. Separately, to a 1 dram vial with stir bar was added 
14a (32.4 mg, 0.20 mmol, 1 equiv), 2,6-dimethylbenzoquinone (30 mg, 0.22 mmol, 1.1 equiv). 
The catalyst solution was subsequently added to the reaction flask, and toluene was used to rinse 
up to 1.3 mL toluene. The 1 dram vial was sealed with a Teflon cap, and allowed to stir for 8 
hours at 45˚C.  Afterward, the vial was allowed to cool to room temperature. The majority of the 
toluene was removed under reduced pressure, and the remaining mixture was directly subjected 
to flash column chromatography (10% EtOAc/hexanes) to provide vinylisochroman 15a as a 
clear oil.  
Entry 1: Reaction proceeded according to the General procedure using ligand L4 (7.2 mg, 0.02 
mmol, 0.1 equiv). Product isolated as a clear oil. Run 1 (2.3 mg, 7% yield, 83% ee); Run 2 (3.0 
mg, 9% yield, 83% ee); Average: 8% yield, 83% ee. 
Entry 2: Reaction proceeded according to the General procedure using ligand L4 (7.2 mg, 0.02 
mmol, 0.1 equiv) and benzoic acid (2.5 mg, 0.02 mmol, 0.1 equiv). Product isolated as a clear 
oil. Run 1 (4.0 mg, 13% yield, 84% ee); Run 2 (4.0 mg, 13% yield, 84% ee); Average: 13% 
yield, 84% ee. 
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Entry 3: Reaction proceeded according to the General procedure using ligand L4 (7.2 mg, 0.02 
mmol, 0.1 equiv) and dibutyl phosphate (4 µL, 0.02 mmol, 0.1 equiv). Product isolated as a clear 
oil. Run 1 (15 mg, 47% yield, 87% ee); Run 2 (½ scale) (9.7 mg, 61% yield, 87% ee); Average: 
54% yield, 87% ee. 
Entry 4: Reaction proceeded according to the General procedure using ligand L4 (7.2 mg, 0.02 
mmol, 0.1 equiv) and diphenyl phosphate (5.0 mg, 0.02 mmol, 0.1 equiv). Product isolated as a 
clear oil. Run 1 (15.9 mg, 50% yield, 82% ee); Run 2 (½ scale) (6.9 mg, 43% yield, 82% ee); 
Average: 47% yield, 82% ee. 
Entry 5: Reaction proceeded according to the General procedure using ligand L4 (7.2 mg, 0.02 
mmol, 0.1 equiv) and diphenylphosphinic acid (4.4 mg, 0.02 mmol, 0.1 equiv). Product isolated 
as a clear oil. Run 1 (20.1 mg, 63% yield, 87% ee); Run 2 (20.2 mg, 63% yield, 87% ee); 
Average: 63% yield, 87% ee. 
Entry 6: Reaction proceeded according to the General procedure using ligand L5 (7.2 mg, 0.02 
mmol, 0.1 equiv) and diphenylphosphinic acid (4.4 mg, 0.02 mmol, 0.1 equiv). Product isolated 
as a clear oil. Run 1 (11.8 mg, 37% yield, 19% ee); Run 2 (8.6 mg, 27% yield, 19% ee); 
Average: 32% yield, 19% ee. 
Entry 7: Reaction proceeded according to the General procedure using ligand L6 (6.5 mg, 0.02 
mmol, 0.1 equiv) and diphenylphosphinic acid (4.4 mg, 0.02 mmol, 0.1 equiv). Product isolated 
as a clear oil. Run 1 (10.4 mg, 33% yield, 78% ee); Run 2 (9.1 mg, 28% yield, 76% ee); 
Average: 31% yield, 76% ee. 
Entry 8: Reaction proceeded according to the General procedure using ligand L7 (6.8 mg, 0.02 
mmol, 0.1 equiv) and diphenylphosphinic acid (4.4 mg, 0.02 mmol, 0.1 equiv). Product isolated 
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as a clear oil. Run 1 (3.1 mg, 10% yield, 29% ee); Run 2 (1.3 mg, 5% yield, 25% ee); Average: 
8% yield, 25% ee. 
Entry 9: Reaction proceeded according to the General procedure using ligand L8 (6.3 mg, 0.02 
mmol, 0.1 equiv) and diphenylphosphinic acid (4.4 mg, 0.02 mmol, 0.1 equiv). Product isolated 
as a clear oil. Run 1 (6.1 mg, 19% yield, 88% ee); Run 2 (½ scale) (4.4 mg, 28% yield, 88% ee); 
Average: 24% yield, 88% ee. 
Entry 10: Reaction proceeded according to the General procedure using ligand L9 (7.5 mg, 0.02 
mmol, 0.1 equiv) and diphenylphosphinic acid (4.4 mg, 0.02 mmol, 0.1 equiv). Product isolated 
as a clear oil. Run 1 (18.6 mg, 58% yield, 88% ee); Run 2 (19.1 mg, 61% yield, 86% ee); 
Average: 60% yield, 86% ee. 
Entry 11: Reaction proceeded according to the General procedure using ligand L10 (8.1 mg, 0.02 
mmol, 0.1 equiv) and diphenylphosphinic acid (4.4 mg, 0.02 mmol, 0.1 equiv). Product isolated 
as a clear oil. Run 1 (22.8 mg, 71% yield, 91% ee); Run 2 (22.5 mg, 70% yield, 92% ee); 
Average: 70% yield, 92% ee. 
Entry 12: Reaction proceeded according to the General procedure using ligand L11 (8.3 mg, 0.02 
mmol, 0.1 equiv) and diphenylphosphinic acid (4.4 mg, 0.02 mmol, 0.1 equiv). Product isolated 
as a clear oil. Run 1 (14.7 mg, 46% yield, 92% ee); Run 2 (16.5 mg, 52% yield, 93% ee); 
Average: 49% yield, 93% ee. 
Entry 13: Reaction proceeded according to the General procedure for 72 hours at 0.5 M using 
ligand L12 and diphenylphosphinic acid (4.4 mg, 0.02 mmol, 0.1 equiv): (4.9 mg, 31% yield, –
6% ee). Reaction was also examined at standard 0.15 M concentration, resulting in slightly 
diminished reactivity: Run 1 (6.2 mg, 19% yield, –7% ee); Run 2 (½ scale) (3.0 mg, 19% yield, –
6% ee); Average: 19% yield, –6% ee.  
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Entry 14: Reaction proceeded according to the General procedure using ligand L10 (8.1 mg, 0.02 
mmol, 0.1 equiv) and diphenylphosphinic acid (4.4 mg, 0.02 mmol, 0.1 equiv). Product isolated 
as a clear oil. Run 1 (18.5 mg, 58% yield, 77% ee); Run 2 (18.8 mg, 59% yield, 77% ee); 
Average: 59% Yield, 77% ee. 
 
Preparation of Starting Materials (Table 4) 
General method: To a dried round-bottom flask (RBF) was added the 2-bromophenylacetic acid 
starting material and anhydrous MeOH (0.3 M). Concentrated Sulfuric acid (5 mol%) was added, 
and the reaction was refluxed for three hours. After cooling to room temperature, the volatiles 
were evaporated under reduced pressure, and the remaining mixture was dissolved in EtOAc. 
The organics were washed with sat. aq. NaHCO3 (x 3), and the organic layer was dried over 
anhydrous MgSO4, filtered, and concentrated under reduced pressure. The mixture was purified 
by column chromatography to afford the desired methyl ester. 
 To a dried RBF in a glove box was added Pd(PPh3)4 (0.1 equiv), LiCl (5.0 equiv), and the 
flask was sealed and taken out of the glovebox. THF (0.1 M) was added followed by the 
corresponding methyl ester substrate (1.0 equiv) and allyltributylstannane (1.2 equiv) via 
syringe. The reaction was refluxed under argon overnight. After complete conversion of the 
starting material was observed by TLC, the flask was cooled to 0˚C and diluted slowly with 
water. The layers were separated, and the aqueous layer was extracted with EtOAc (x 2). The 
combined organic layers were dried over anhydrous MgSO4, filtered, and concentrated under 
reduced pressure. The mixture was purified by column chromatography to afford the desired 
allylated methyl ester. 
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 To a dried RBF was added LiAlH4 (95%, 1 equiv) under argon. THF (0.1 M) was added, 
and the flask was cooled to 0˚C. To the mixture was added the allylated methyl ester (1.4 equiv) 
dissolved in THF (1 M) dropwise, and the mixture was warmed to room temperature and stirred 
for 2 hours under argon. After complete conversion of the starting material was observed by 
TLC, the reaction flask was cooled to 0˚C, and the reaction was quenched by dropwise addition 
of sat. aq. Rochelle’s salt. The reaction was diluted with ether, and the biphasic mixture was 
stirred until both layers became homogeneous (typically 2 hours to overnight). The layers were 
separated, and the aqueous layer was extracted with ether (x 3). The combined organic layers 
were washed once with brine, and dried over anhydrous MgSO4, filtered, and concentrated under 
reduced pressure. The mixture was purified by column chromatography to afford the desired 
alcohol. 
OH
 
2-(2-allylphenyl)ethan-1-ol (14a): Product is a clear oil 1H NMR (500MHz, CDCl3) δ 7.20-7.18 
(m, 4H), 5.98 (ddt, J = 16.9, 10.1, 6.2 Hz, 1H), 5.07 (d, J = 10.1 Hz, 1H), 4.99 (d, J = 16.9 Hz, 
1H), 3.84 (app. q, J = 6.4 Hz, 2H), 3.44 (d, J = 6.2 Hz, 2H), 2.91 (t, J = 6.9 Hz, 2H), 1.46 (br. s, 
1H); 13C NMR (125 MHz, CDCl3) δ 138.6, 137.6, 136.7, 130.3, 130.3, 127.1, 126.9, 116.1, 63.5, 
37.4, 36.2; HRMS (EI) m/z calc’d for C11H13O [M]+: 161.0966; found 161.0969.  
OHMe
 
2-(2-allyl-5-methylphenyl)ethan-1-ol (14b): Product is a clear oil. 1H NMR (500 MHz, 
Chloroform-d) δ 7.07 (d, J = 7.5 Hz, 1H), 7.01 (d, J = 8.1 Hz, 2H), 5.95 (ddt, J = 17.1, 10.1, 6.3 
Hz, 1H), 5.05 (dq, J = 10.1, 1.4 Hz, 1H), 4.98 (ddd, J = 17.1, 2.3, 1.3 Hz, 1H), 3.83 (t, J = 6.9 
Hz, 2H), 3.39 (d, J = 6.3 Hz, 2H), 2.87 (t, J = 6.8 Hz, 2H), 2.31 (s, 3H); 13C NMR (126 MHz, 
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CDCl3) δ 137.79, 136.42, 136.24, 135.41, 130.99, 130.17, 127.76, 115.84, 63.48, 37.00, 36.11, 
21.24; HRMS (EI) m/z calc’d for C12H16O [M]+: 176.1201; found 176.1209. 
OH
Me  
2-(2-allyl-4-methylphenyl)ethan-1-ol (14c): Product is a clear oil. 1H NMR (500 MHz, 
Chloroform-d) δ 7.09 (d, J = 8.2 Hz, 1H), 7.04 – 6.98 (m, 2H), 5.96 (ddt, J = 17.2, 10.1, 6.3 Hz, 
1H), 5.06 (dq, J = 10.1, 1.6 Hz, 1H), 5.00 (dq, J = 17.1, 1.8 Hz, 1H), 3.82 (t, J = 6.9 Hz, 2H), 
3.40 (dt, J = 6.4, 1.6 Hz, 2H), 2.87 (t, J = 6.9 Hz, 2H), 2.31 (s, 3H), 1.45 (br, 1H); 13C NMR (126 
MHz, CDCl3) δ 138.31, 137.64, 136.54, 133.47, 130.94, 130.18, 127.50, 115.98, 63.53, 37.38, 
35.71, 21.25; HRMS (EI) m/z calc’d for C12H16O [M]+: 176.1201; found 176.1201.  
OH
MeO
MeO
 
2-(2-allyl-4,5-dimethoxyphenyl)ethan-1-ol (14d): Product is a clear oil 1H NMR (500MHz, 
CDCl3) δ 6.72 (s, 1H), 6.69 (s, 1H), 5.95 (ddt, J = 16.3, 10.1, 6.2 Hz, 1H), 5.06 (dq, J = 10.1, 1.7 
Hz, 1H), 4.98 (dq, J = 17.1, 1.7 Hz, 1H), 3.86 (s, 3H), 3.85 (s, 3H), 3.81 (app. q, J = 6.6 Hz, 2H), 
3.36 (d, J = 6.2 Hz, 2H), 2.84 (t, J = 6.9 Hz, 2H), 1.42 (t, J = 5.6 Hz, 1H); 13C NMR (125 MHz, 
CDCl3) δ 147.9, 147.7, 137.9, 130.6, 128.6, 116.0, 113.6, 113.5, 63.8, 56.3, 56.3, 37.1, 36.0; 
HRMS (EI) m/z calc’d for C13H18O3 [M]+: 222.1256; found 222.1259. 
OHBr
 
2-(2-allyl-5-bromophenyl)ethan-1-ol (14e): Product is a clear oil. 1H NMR (500 MHz, 
Chloroform-d) δ 7.38 – 7.28 (m, 2H), 7.04 (d, J = 8.2 Hz, 1H), 5.92 (ddt, J = 16.4, 9.9, 6.1 Hz, 
1H), 5.08 (dd, J = 9.9, 1.8 Hz, 1H), 4.96 (dd, J = 17.2, 1.9 Hz, 1H), 3.80 (t, J = 6.8 Hz, 2H), 3.37 
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(d, J = 5.7 Hz, 2H), 2.84 (t, J = 6.8 Hz, 2H), 1.91 (br, 1H); 13C NMR (126 MHz, CDCl3) δ 
139.22, 137.47, 136.83, 132.87, 131.84, 129.95, 120.38, 116.49, 63.07, 36.81, 35.80; HRMS (EI) 
m/z calc’d for C11H13OBr [M]+: 240.1050; found 240.1050. 
OH
F  
2-(2-allyl-4-fluorophenyl)ethan-1-ol (14f): Product is a clear oil 1H NMR (500MHz, CDCl3) δ 
7.18 (dd, J = 8.3, 5.9 Hz, 1H), 6.94-6.87 (m, 2H), 5.97 (ddt, J = 16.4, 10.0, 6.1 Hz, 1H), 5.14 (dq, 
J = 10.0, 1.5 Hz, 1H), 5.04 (dq, J = 17.1, 1.7 Hz, 1H), 3.84 (app. q, J = 6.6 Hz, 2H), 3.44 (d, J = 
6.1 Hz, 2H), 2.89 (t, J = 6.8 Hz, 2H), 1.51 (br. s, 1H); 13C NMR (125 MHz, CDCl3) δ 161.9 (d, J 
= 244.1 Hz), 140.8 (d, J = 6.8 Hz), 136.6, 132.3 (d, J = 2.8 Hz), 131.6, 131.5, 116.3 (d, J = 21.0 
Hz), 113.4 (d, J = 20.5 Hz), 63.4, 37.3, 35.4; 19F NMR (470 MHz, CDCl3) δ -117.1; HRMS (EI) 
m/z calc’d for C11H13OF [M]+: 180.0950; found 180.0948. 
OH
F
 
2-(2-allyl-6-fluorophenyl)ethan-1-ol (14g): Product is a clear oil 1H NMR (500MHz, CDCl3) δ 
7.15 (dt, J = 7.9, 5.8 Hz, 1H), 6.97 (d, J = 7.7 Hz, 1H), 6.92 (t, J = 9.6 Hz, 1H), 5.96 (ddt, J = 
16.5, 10.1, 6.2 Hz, 1H), 5.08 (dq, J = 10.1, 1.5 Hz, 1H), 4.98 (dq, J = 17.2, 1.7 Hz, 1H), 3.81 
(app. q, J = 7.1 Hz, 2H), 3.46 (dt, J = 6.2, 1.5 Hz, 2H), 2.96 (td, J = 7.1, 1.9 Hz, 2H), 1.44 (br. s, 
1H); 13C NMR (125 MHz, CDCl3) δ 162.2 (d, J = 244.0 Hz), 141.3, 137.2, 128.0 (d, J = 9.2 Hz), 
125.7 (d, J = 2.8 Hz), 124.2 (d, J = 14.7), 116.5, 113.6 (d, J = 23.0 Hz), 62.7, 37.3, 29.3; 19F 
NMR (470 MHz, CDCl3) δ -117.4; HRMS (EI) m/z calc’d for C11H13FO [M]+: 180.0950; found 
180.0955. 
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OHCl
 
2-(2-allyl-5-chlorophenyl)ethan-1-ol (14h): Product is a clear oil 1H NMR (500MHz, CDCl3) δ 
7.20 (d, J = 1.9 Hz, 1H), 7.16 (dd, J = 8.1, 1.9 Hz, 1H), 7.10 (d, J = 8.1 Hz, 1H), 5.93 (ddt, J = 
16.3, 10.1, 5.6 Hz, 1H), 5.08 (d, J = 10.3 Hz, 1H), 4.96 (d, J = 17.1 Hz, 1H), 3.84 (app. q, J = 6.4 
Hz, 2H), 3.38 (d, J = 6.2 Hz, 2H), 2.87 (t, J = 6.6 Hz, 2H), 1.46 (t, J = 5.6 Hz, 1H); 13C NMR 
(125 MHz, CDCl3) δ 138.8, 137.0, 132.4, 131.6, 130.1, 127.1, 127.1, 116.5, 63.2, 36.9, 35.9; 
HRMS (EI) m/z calc’d for C11H13OCl [M]+: 196.0655; found 196.0652. 
OH
F3C  
2-(2-allyl-4-(trifluoromethyl)phenyl)ethan-1-ol (14i): Product is a clear oil 1H NMR (500MHz, 
CDCl3) δ 7.48-7.45 (m, 2H), 7.36 (d, J = 8.3 Hz, 1H), 5.99 (ddt, J = 16.4, 10.0, 6.1 Hz, 1H), 5.16 
(dq, J = 10.3, 1.5 Hz, 1H), 5.03 (dq, J = 17.1, 1.7 Hz, 1H), 3.90 (t, J = 6.8 Hz, 2H), 3.52 (d, J = 
6.1 Hz, 2H), 2.99 (t, J = 6.6 Hz, 2H); 13C NMR (125 MHz, CDCl3) δ 141.1, 139.3, 136.4, 130.5, 
129.2 (q, J = 32.1 Hz), 126.8 (q, J = 3.6 Hz), 124.5 (q, J = 270.1 Hz), 123.5 (q, J = 3.6 Hz), 
117.0, 63.0, 37.2, 35.9; 19F NMR (470 MHz, CDCl3) δ -62.8; HRMS (EI) m/z calc’d for 
C12H13OF3 [M]+: 230.0918; found 230.0925. 
OH
 
2-(2-allylnaphthalen-1-yl)ethan-1-ol (14j): Product is a clear oil 1H NMR (500MHz, CDCl3) δ 
8.12 (d, J = 8.5 Hz, 1H), 7.85 (d, J = 8.1 Hz, 1H), 7.74 (d, J = 8.5 Hz, 1H), 7.55 (t, J = 6.8 Hz, 
1H), 7.48 (t, J = 7.8 Hz, 1H), 7.36 (d, J = 8.5 Hz, 1H), 6.07 (ddt, J = 16.1, 10.0, 6.1 Hz, 1H), 
5.12 (dq, J = 10.0, 1.7 Hz, 1H), 5.03 (dq, J = 17.1, 1.7 Hz, 1H), 3.97 (t, J = 7.1 Hz, 2H), 3.68 (dt, 
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J = 6.1, 1.7 Hz, 2H), 3.45 (t, J = 7.3 Hz, 2H), 1.48 (br. s, 1H); 13C NMR (125 MHz, CDCl3) δ 
137.6, 136.2, 133.0, 132.9, 131.5, 128.9, 128.8, 127.4, 126.4, 125.3, 124.1, 116.0, 63.2, 38.2, 
31.8; HRMS (EI) m/z calc’d for C15H16O [M]+: 212.1201; found 212.1207. 
 
Substrate Scope for Isochromans (Table 4) 
Absolute stereochemistry for compound 15a is assigned by matching the rotation to the reported 
literature value.24d The stereochemistry of all other compounds was assigned by analogy. 
O
 
(S)-1-vinylisochromane (15a): General Procedure:  To a ½ dram vial was added ligand L10 (8.1 
mg, 0.02 mmol) and Pd(OAc)2 (4.4 mg, 0.02 mmol). Toluene (0.4 mL) was added, and the vial 
was capped and heated to 45˚C until all solids had dissolved. Separately, to a 1 dram vial with 
stir bar was added 14a (32.4 mg, 0.20 mmol), 2,6-dimethylbenzoquinone (30 mg, 0.22 mmol), 
and diphenylphosphinic acid (4.4 mg, 0.02 mmol) with no precautions to exclude air or moisture. 
The catalyst solution was subsequently added to the reaction flask, and toluene was used to rinse 
up to 1.3 mL toluene. The 1 dram vial was sealed with a Teflon cap, and allowed to stir for 8 
hours at 45˚C, until complete conversion of the starting material was observed by TLC.  
Afterward, the vial was allowed to cool to room temperature. The majority of the toluene was 
removed under reduced pressure, and the remaining mixture was directly subjected to flash 
column chromatography (10% EtOAc in hexanes) to provide the vinylisochroman as a clear oil. 
Run 1 (22.8 mg, 71% yield); Run 2 (22.5 mg, 70% yield); Run 3 (22.2 mg, 70% yield). 
Average: 70% yield. The enantiomeric excess was determined to be 92% by chiral GC analysis 
(Cyclosil-B, 100˚C isothermal, tR(major) = 32.78 min, tR(minor) = 35.08 min.) [α]21D = +9.66 (c 
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= 1, CHCl3).  1H NMR (500MHz, CDCl3) δ 7.22-7.18 (m, 2H), 7.16-7.13 (m, 1H), 7.09-7.06 (m, 
1H), 5.99 (ddd, J = 17.2, 10.1, 7.3 Hz, 1H), 5.40 (d, J = 17.2 Hz, 1H), 5.37 (d, J = 10.1 Hz, 1H), 
5.18 (d, J = 7.5 Hz, 1H), 4.19 (dt, J = 11.3, 4.9 Hz, 1H), 3.89 (ddd, J = 11.4, 9.0, 4.1 Hz, 1H), 
3.00 (ddd, J = 16.5, 8.8, 5.1 Hz, 1H), 2.78 (dt, J = 16.1, 4.1 Hz, 1H); 13C NMR (125 MHz, 
CDCl3) δ 138.3, 136.4, 133.8, 129.2, 126.9, 126.3, 126.2, 118.8, 78.4, 63.4, 29.0; HRMS (EI) 
m/z calc’d for C11H12O [M]+: 160.0888; found 160.0879.  
O
Me
 
(S)-6-methyl-1-vinylisochromane (15b): 2-(2-allyl-5-methylphenyl)ethan-1-ol (14b) (35.2 mg, 
0.20 mmol) was reacted according to the general procedure. Purification by flash column 
chromatography (2% EtOAc in hexanes) provided the vinylisochroman as a clear oil. Run 1 
(25.1 mg, 72% yield); Run 2 (23.6 mg, 68% yield); Run 3 (23.6 mg, 68% yield).  Average: 69% 
yield. The enantiomeric excess was determined to be 92% by chiral HPLC analysis 
(CHIRALPAK AD-RH column, 0.5 mL/min, 50% MeCN in H2O, λ = 214.4 nm): tR(major) = 
18.263 min, tR(minor) = 25.081 min. [α]24D = +20.7 (c = 1, CHCl3); 1H NMR (500 MHz, 
Chloroform-d) δ 7.02 – 6.92 (m, 3H), 5.96 (ddd, J = 17.3, 10.2, 7.4 Hz, 1H), 5.38 (d, J = 17.3 
Hz, 1H), 5.34 (d, J = 10.5 Hz, 1H), 5.13 (d, J = 7.3 Hz, 1H), 4.16 (dt, J = 11.5, 4.9 Hz, 1H), 3.86 
(ddd, J = 11.3, 9.0, 4.1 Hz, 1H), 2.95 (ddd, J = 15.0, 8.9, 5.3 Hz, 1H), 2.72 (dt, J = 16.5, 4.2 Hz, 
1H), 2.32 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 138.44, 136.48, 133.64, 133.39, 129.67, 
127.08, 126.24, 118.55, 78.36, 63.48, 28.99, 21.27; HRMS (EI) m/z calc’d for C12H14O [M]+: 
174.1045; found 174.1044. 
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OMe
 
(S)-7-methyl-1-vinylisochromane (15c): 2-(2-allyl-4-methylphenyl)ethan-1-ol (14c) (35.2 mg, 
0.20 mmol) was reacted according to the general procedure. Purification by flash column 
chromatography (2% EtOAc in hexanes) provided the vinylisochroman as a clear oil. Run 1 
(24.1 mg, 69% yield); Run 2 (23.5 mg, 68% yield); Run 3 (23.9 mg, 68% yield).  Average: 68% 
yield. The enantiomeric excess was determined to be 93% by chiral HPLC analysis 
(CHIRALPAK AD-RH column, 0.5 mL/min, 50% MeCN in H2O, λ = 214.4 nm): tR(major) = 
16.639 min, tR(minor) = 19.879 min. [α]26D = -6.4 (c = 1, CHCl3); 1H NMR (500 MHz, 
Chloroform-d) δ 7.07 – 6.98 (m, 2H), 6.87 (s, 1H), 5.97 (ddd, J = 17.3, 10.1, 7.4 Hz, 1H), 5.40 
(dt, J = 17.1, 1.3 Hz, 1H), 5.35 (ddd, J = 10.3, 1.8, 0.9 Hz, 1H), 5.12 (d, J = 7.3 Hz, 1H), 4.16 
(ddd, J = 11.4, 5.3, 4.3 Hz, 1H), 3.85 (ddd, J = 11.3, 8.9, 4.0 Hz, 1H), 2.94 (ddd, J = 15.1, 9.0, 
5.3 Hz, 1H), 2.72 (dt, J = 16.2, 4.3 Hz, 1H), 2.31 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 138.35, 
136.15, 135.75, 130.69, 129.03, 127.77, 126.76, 118.71, 78.49, 63.62, 28.64, 21.41; HRMS (EI) 
m/z calc’d for C12H14O [M]+: 174.1045; found 174.1044. 
 
OMeO
MeO
 
(S)-6,7-dimethoxy-1-vinylisochromane (15d): Reaction proceeded according to a modified 
procedure:  To a ½ dram vial was added ligand L11 (8.3 mg, 0.02 mmol) and Pd(OAc)2 (4.4 mg, 
0.02 mmol). Toluene (0.4 mL) was added, and the vial was capped and heated to 45˚C until all 
solids had dissolved. Separately, to a 1 dram vial with stir bar was added 14d (44.4 mg, 0.20 
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mmol), 2,6-dimethylbenzoquinone (30 mg, 0.22 mmol), and diphenylphosphinic acid (4.4 mg, 
0.02 mmol). The catalyst solution was subsequently added to the reaction flask, and toluene was 
used to rinse up to 1.3 mL toluene. The 1 dram vial was sealed with a Teflon cap, and allowed 
to stir for 8 hours at 45˚C. Afterward, the vial was allowed to cool to room temperature. The 
majority of the toluene was removed under reduced pressure, and the remaining mixture was 
directly subjected to flash column chromatography (10% EtOAc in hexanes) to provide the 
vinylisochroman as a clear oil. Run 1 (26.2 mg, 59% yield); Run 2 (29.3 mg, 67% yield); Run 3 
(29.0 mg, 66% yield). Average: 64% yield. The enantiomeric excess was determined to be 95% 
by chiral GC analysis (Cyclosil-B, 160˚C isothermal, tR(major) = 23.47 min, tR(minor) = 24.24 
min.) [α]22D = +31.37 (c = 0.26, CH2Cl2).  1H NMR (500MHz, CDCl3) δ 6.64 (s, 1H), 6.55 (s, 
1H), 5.98 (ddd, J = 17.1, 10.0, 7.6 Hz, 1H), 5.41 (d, J = 17.1 Hz, 1H), 5.37 (d, J = 10.1 Hz, 1H), 
5.11 (d, J = 7.3 Hz, 1H), 4.17 (dt, J = 11.2, 4.4 Hz, 1H), 3.89 (s, 3H), 3.89-3.85 (m, 1H), 3.85 (s, 
3H), 2.97-2.89 (m, 1H), 2.70 (dt, J = 16.1, 3.7 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 148.1, 
147.6, 138.5, 128.1, 125.9, 118.8, 111.7, 109.2, 78.2, 63.5, 56.2, 56.1, 28.5; HRMS (EI) m/z 
calc’d for C13H16O3 [M]+: 220.1099; found 220.1105. 
 
O
Br
 
(S)-6-bromo-1-vinylisochromane (15e): 2-(2-allyl-5-bromophenyl)ethan-1-ol (14e) (48.2 mg, 
0.20 mmol) was reacted according to the general procedure for 9 hours. Purification by flash 
column chromatography (2% EtOAc in hexanes) provided the vinylisochroman as a clear oil. 
Run 1 (36.1 mg, 75% yield); Run 2 (36.9 mg, 76% yield); Run 3 (37.5 mg, 78% yield).  
Average: 76% yield. The enantiomeric excess was determined to be 93% by chiral HPLC 
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analysis (CHIRALPAK OJ-H column, 1 mL/min, 0.5% isopropanol in hexane, λ = 230.4 nm): 
tR(major) = 6.739 min, tR(minor) = 7.702 min. [α]22D = +19.6 (c = 1, CHCl3); 1H NMR (500 
MHz, Chloroform-d) δ 7.31 – 7.27 (m, 2H), 6.92 (d, J = 8.8 Hz, 1H), 5.93 (ddd, J = 16.8, 10.2, 
7.3 Hz, 1H), 5.40 – 5.34 (m, 2H), 5.08 (d, J = 7.3 Hz, 1H), 4.13 (dt, J = 11.4, 4.9 Hz, 1H), 3.83 
(ddd, J = 11.4, 8.8, 4.1 Hz, 1H), 2.95 (ddd, J = 16.7, 8.8, 5.4 Hz, 1H), 2.73 (dt, J = 16.5, 4.3 Hz, 
1H); 13C NMR (126 MHz, CDCl3) δ 137.71, 136.15, 135.31, 131.86, 129.33, 128.13, 120.68, 
119.28, 78.05, 63.01, 28.74; HRMS (EI) m/z calc’d for C11H11OBr [M]+: 237.9993; found 
237.9990. 
 
OF
 
(S)-7-fluoro-1-vinylisochromane (15f): 2-(2-allyl-4-fluorophenyl)ethan-1-ol (14f) (36.0 mg, 
0.20 mmol) was reacted according to the general procedure for 10 hours at 45˚C. Purification by 
flash column chromatography (10% EtOAc in hexanes) provided the vinylisochroman as a clear 
oil. Run 1 (24.0 mg, 67% yield); Run 2 (21.6 mg, 61% yield); Run 3 (20.4 mg, 57% yield). 
Average: 61% yield. The enantiomeric excess was determined to be 91% by chiral GC analysis 
(Cyclosil-B, 100˚C isothermal, tR(major) = 38.54 min, tR(minor) = 42.72 min.) [α]22D = +10.28 (c 
= 0.25, CH2Cl2). 1H NMR (500MHz, CDCl3) δ 7.12 (dd, J = 8.3, 6.5 Hz, 1H), 6.93 (dt, J = 8.5, 
2.3 Hz, 1H), 6.81 (dd, J = 9.5, 2.4 Hz, 1H), 5.98 (ddd, J = 17.6, 10.3, 7.6 Hz, 1H), 5.44 (dt, J = 
17.1, 1.5 Hz, 1H), 5.42 (d, J = 10.3 Hz, 1H), 5.14 (d, J = 7.3 Hz, 1H), 4.20 (ddd, J = 11.5, 5.4, 
4.4 Hz, 1H), 3.88 (ddd, J = 11.5, 9.0, 4.2 Hz, 1H), 2.98 (ddd, J = 15.9, 9.0, 5.4 Hz, 1H), 2.76 (dt, 
J = 16.1, 3.9 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 161.3 (d, J = 242.8 Hz), 138.2 (d, J = 6.5 
Hz), 137.6, 130.5 (d, J = 7.3 Hz) 129.3 (d, J = 2.8 Hz), 119.4, 114.1 (d, J = 22.0 Hz), 112.9 (d, J 
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= 22.0 Hz), 78.3, 63.5, 28.2; 19F NMR (470 MHz, CDCl3) δ -116.6; HRMS (EI) m/z calc’d for 
C11H11OF [M]+: 178.0794; found 178.0790. 
 
O
F
 
(S)-5-fluoro-1-vinylisochromane (15g): 2-(2-allyl-6-fluorophenyl)ethan-1-ol (14g) (36.0 mg, 
0.20 mmol) was reacted according to the general procedure. Purification by flash column 
chromatography (10% EtOAc in hexanes) provided the vinylisochroman as a clear oil. Run 1 
(22.1 mg, 62% yield); Run 2 (23.9 mg, 67% yield); Run 3 (22.9 mg, 64% yield). Average: 64% 
yield. The enantiomeric excess was determined to be 92% by chiral GC analysis (Cyclosil-B, 
100˚C isothermal, tR(major) = 34.44 min, tR(minor) = 37.65 min.) [α]23D = +2.37 (c = 0.25, 
CH2Cl2). 1H NMR (500MHz, CDCl3) δ 7.20-7.14 (m, 1H), 6.94 (t, J = 9.0 Hz, 1H), 6.88 (d, J = 
7.8 Hz, 1H), 5.99 (ddd, J = 17.1, 10.3, 7.1 Hz, 1H), 5.41 (d, J = 18.3 Hz, 1H), 5.40 (d, J = 10.3 
Hz, 1H), 5.17 (d, J = 7.1 Hz, 1H), 4.21 (dt, J = 11.5, 5.4 Hz, 1H), 3.89 (ddd, J = 11.5, 8.3, 4.4 
Hz, 1H), 2.89 (ddd, J = 13.7, 8.3, 5.6 Hz, 1H), 2.82 (dt, J = 17.3, 4.4 Hz, 1H); 13C NMR (125 
MHz, CDCl3) δ 160.7 (d, J = 243.6 Hz), 138.6 (d, J = 5.5 Hz), 137.7, 126.9 (d, J = 8.3 Hz), 
121.7 (d, J = 3.6 Hz), 121.5 (d, J = 19.1 Hz), 119.3, 113.2 (d, J = 21.1 Hz), 77.9, 62.6, 22.2; 19F 
NMR (470 MHz, CDCl3) δ -120.1; HRMS (EI) m/z calc’d for C11H11OF [M]+: 178.0794; found 
178.0787. 
 
O
Cl
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(S)-6-chloro-1-vinylisochromane (15h): 2-(2-allyl-5-chlorophenyl)ethan-1-ol (14h) (39.3 mg, 
0.20 mmol) was reacted according to the general procedure for 10 hours at 45˚C. Purification by 
flash column chromatography (10% EtOAc in hexanes) provided the vinylisochroman as a clear 
oil. Run 1 (20.2 mg, 52% yield); Run 2 (22.2 mg, 57% yield) Run 3 (22.1 mg, 57% yield). 
Average: 55% yield. The enantiomeric excess was determined to be 92% by chiral GC analysis 
(Cyclosil-B, 120˚C isothermal, tR(major) = 49.51 min, tR(minor) = 54.03 min.) [α]22D = +16.95 (c 
= 0.25, CH2Cl2).1H NMR (500MHz, CDCl3) δ 7.20-7.15 (m, 2H), 7.01 (d, J = 8.1 Hz, 1H), 5.98 
(ddd, J = 17.6, 9.8, 7.3 Hz, 1H), 5.41 (d, J = 17.1 Hz, 1H), 5.40 (d, J = 10.7 Hz, 1H), 5.15 (d, J = 
7.1 Hz, 1H), 4.18 (dt, J = 11.5, 4.9 Hz, 1H), 3.80 (ddd, J = 11.5, 8.8, 4.1 Hz, 1H), 2.99 (ddd, J = 
16.6, 8.5, 5.1 Hz, 1H), 2.78 (dt, J = 16.3, 4.2 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 137.8, 
135.8, 134.8, 132.6, 128.9, 127.8, 126.4, 119.2, 78.0, 63.0, 28.8; HRMS (EI) m/z calc’d for 
C11H11OCl [M]+: 194.0498; found 194.0499. 
 
OF3C
 
(S)-7-(trifluoromethyl)-1-vinylisochromane (15i):  Reaction proceeded according to a 
modified procedure:  To a ½ dram vial was added ligand L11 (8.3 mg, 0.02 mmol) and 
Pd(OAc)2 (4.4 mg, 0.02 mmol). Toluene (0.4 mL) was added, and the vial was capped and 
heated to 45˚C until all solids had dissolved. Separately, to a 1 dram vial with stir bar was added 
14i (46.0 mg, 0.20 mmol), 2,6-dimethylbenzoquinone (30 mg, 0.22 mmol), and 
diphenylphosphinic acid (4.4 mg, 0.02 mmol). The catalyst solution was subsequently added to 
the reaction flask, and toluene was used to rinse up to 1.3 mL toluene. The 1 dram vial was 
sealed with a Teflon cap, and allowed to stir for 48 hours at 45˚C. Afterward, the vial was 
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allowed to cool to room temperature. The majority of the toluene was removed under reduced 
pressure, and the remaining mixture was directly subjected to flash column chromatography 
(10% EtOAc in hexanes) to provide the vinylisochroman as a clear oil.  Run 1 (½ scale) (14.3 
mg, 62% yield); Run 2 (24.9 mg, 55% yield); Run 3 (23.6 mg, 52% yield). Average: 56% yield. 
The enantiomeric excess was determined to be 92% by chiral GC analysis (Cyclosil-B, 120˚C 
isothermal, tR(major) = 15.19 min, tR(minor) = 16.62 min.) [α]22D = +7.32 (c = 0.25, CH2Cl2). 1H 
NMR (500MHz, CDCl3) δ 7.43 (d, J = 7.7 Hz, 1H), 7.31-7.22 (m, 2H), 5.96 (ddd, J = 17.4, 9.9, 
7.5 Hz, 1H), 5.42 (d, J = 15.0 Hz, 1H), 5.41 (d, J = 10.7 Hz, 1H), 5.16 (d, J = 7.5 Hz, 1H), 4.19 
(dt, J = 11.4, 5.4 Hz, 1H), 3.87 (ddd, J = 11.4, 8.8, 3.9 Hz, 1H), 3.06-2.98 (m, 1H), 2.82 (d, J = 
16.7 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 138.0, 137.3, 137.1, 129.6, 128.6 (q, J = 32.9 Hz), 
124.4 (q, J = 271.0 Hz), 123.6 (q, J = 3.6 Hz), 123.3 (q, J = 3.6 Hz), 119.9, 78.3, 63.1, 28.9; 19F 
NMR (470 MHz, CDCl3) δ -62.8; HRMS (EI) m/z calc’d for C12H10OF3 [M]+: 227.0684; found 
227.0685. 
 
O
 
(S)-4-vinyl-1,4-dihydro-2H-benzo[f]isochromene (15j): 2-(2-allylnaphthalen-1-yl)ethan-1-ol 
(14j) (42.5 mg, 0.20 mmol) was reacted according to the general procedure. Purification by flash 
column chromatography (10% EtOAc in hexanes) provided the vinylisochroman as a clear oil. 
Run 1 (34.5 mg, 80% yield); Run 2 (30.7 mg, 73% yield); Run 3 (29.9 mg, 71% yield). 
Average: 75% yield. The enantiomeric excess was determined to be 93% by chiral GC analysis 
(Cyclosil-B, 160˚C isothermal, tR(major) = 45.98 min, tR(minor) = 48.09 min.) [α]23D = +74.03 (c 
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= 0.25, CH2Cl2). 1H NMR (500MHz, CDCl3) δ 7.99 (d, J = 8.5 Hz, 1H), 7.87 (d, J = 8.1 Hz, 1H), 
7.73 (d, J = 8.5 Hz, 1H), 7.59 (td, J = 8.3, 1.2 Hz, 1H), 7.54 (td, J = 8.1, 1.0 Hz, 1H), 7.24 (d, J = 
8.5 Hz, 1H), 6.08 (ddd, J = 17.3, 10.3, 7.3 Hz, 1H), 5.47 (d, J = 17.3 Hz, 1H), 5.44 (d, J = 11.7 
Hz, 1H), 5.36 (d, J = 7.3 Hz, 1H), 4.37 (dt, J = 11.5, 5.1 Hz, 1H), 4.07 (ddd, J = 11.5, 7.8, 4.6 
Hz, 1H), 3.00 (dt, J = 16.6, 6.3 Hz, 1H), 3.19 (dt, J = 16.6, 4.6 Hz, 1H); 13C NMR (125 MHz, 
CDCl3) δ 138.2, 133.1, 132.5, 132.2, 129.3, 128.8, 126.5, 126.4, 125.8, 124.5, 123.1, 119.2, 78.3, 
62.8, 25.6; HRMS (EI) m/z calc’d for C15H14O [M]+: 210.1045; found 210.1042. 
 
Diastereoselective cyclization for disubstituted isochroman synthesis (Scheme 8) 
OH
 
(R)-1-(2-allylphenyl)propan-2-ol (16): To a flamed-dried 50 mL RBF fitted with oven-dried 
condenser was added magnesium turnings (130 mg, 5.34 mmol, 1.2 equiv.). 0.5 mL of dry THF 
was added followed by the addition of a small portion of 2-bromoallylbenzene (877 mg, 4.45 
mmol, 1.0 equiv.) dissolved in 3 mL of dry THF. A few crystals of iodine were added, and the 
deep purple solution was heated by a heat gun. Upon disappearance of the color, the rest of THF 
solution  was added slowly, after which the reaction was heated at 70oC for 45 min. Then the 
reaction was cooled in ice bath, followed by the addition of a solution of R-(+)-propylene oxide 
(570 mg, 9.8 mmol, 2.0 equiv.) in 3 mL of dry THF. The reaction was allowed to stir at r. t. for 
90 min, followed by quenching with sat. NH4Cl solution (10 mL). The layers were separated and 
the aqueous layer was further extracted with ethyl acetate (2 x 10 mL). All the organic layers 
were combined and dried over anhydrous MgSO4. The solution was filtered and the solvent was 
removed under reduced pressure. The crude was purified twice via silica column 
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chromatography (5% acetone/hexane). A colorless oil (240 mg, 1.4 mmol, 31% yield) was 
obtained as the final product. 1H NMR (500 MHz, Chloroform-d) δ 7.20 (s, 4H), 5.98 (ddt, J = 
16.6, 10.0, 6.2 Hz, 1H), 5.09 (dt, J = 10.0, 1.4 Hz, 1H), 5.00 (dt, J = 17.1, 1.7 Hz, 1H), 4.08 – 
3.96 (m, 1H), 3.45 (ddd, J = 6.1, 4.0, 2.1 Hz, 2H), 2.86 – 2.71 (m, 2H), 1.98 – 1.75 (br, 1H), 1.27 
(d, J = 6.1 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 138.59, 137.52, 137.04, 130.73, 130.23, 
127.03, 126.71, 116.10, 68.64, 42.69, 37.40, 23.30; [α]26D = -41.8 (c = 1.00, CHCl3) HRMS (EI) 
m/z calc’d for C12H16O [M]+: 176.1201; found 176.1204. 
OH
 
(R)-2-(2-allylphenyl)propan-1-ol (18): Under the conditions of Yu,32 to a dried RBF was added 
PhI(OAc)2 (0.75 equiv) and I2 (0.75 equiv). The flask was wrapped in aluminum foil to protect it 
from light, and DMF (0.16 M) was added. The reaction was capped and stirred for 5 minutes, 
and then Pd(OAc)2 (0.05 equiv) and (-)-(R)-2-phenylpropionic acid (1.0 equiv) were added 
quickly. The flask was sealed with a glass stopper and the seal was wrapped in Teflon tape and 
parafilm and subsequently covered in aluminum foil. The reaction was stirred at 60˚C for 12 
hours. The solvent was subsequently evaporated under reduced pressure with the assistance of a 
high-vacuum, and the residue was dissolved in ether. The organic layer was extracted with sat. 
aq. NaHCO3 (x 3), and the combined aqueous layers were acidified with HCl. CH2Cl2 was 
added, and the aqueous layer was extracted with CH2Cl2 (x 2) and EtOAc (x 1). The combined 
organic layers were dried over anhydrous MgSO4, filtered, and concentrated under reduced 
pressure to afford the iodinated product that was taken on directly to the next step.  
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To a dried RBF was added the iodinated starting material and anhydrous MeOH (0.3 M). 
Concentrated Sulfuric acid (5 mol%) was added, and the reaction was refluxed for three hours. 
After cooling to room temperature, the volatiles were evaporated under reduced pressure, and the 
remaining mixture was dissolved in EtOAc. The organics were washed with sat. aq. NaHCO3 (x 
3), and the organic layer was dried over anhydrous MgSO4, filtered, and concentrated under 
reduced pressure. The mixture was purified by column chromatography to afford the desired 
methyl ester (54% over two steps). 
 To a dried RBF in a glove box was added Pd(PPh3)4 (0.05 equiv), CsF (2.0 equiv), CuI 
(0.1 equiv), and the flask was sealed and taken out of the glovebox. DMF (0.33 M) was added 
followed by the corresponding methyl ester substrate (1.0 equiv) and allyltributylstannane (1.2 
equiv) via syringe. The reaction was stirred at 45˚C for 6 hours under argon. After complete 
conversion of the starting material was observed by TLC, the flask was cooled to 0˚C and diluted 
slowly with water. The mixture was diluted with ether, and the layers were separated. The 
organic layer was washed with water (x 2). The organic layer was dried over anhydrous MgSO4, 
filtered, and concentrated under reduced pressure. The mixture was purified by column 
chromatography to afford the desired allylated methyl ester (81% yield). 
 To a dried RBF was added LiAlH4 (95%, 1 equiv) under argon. THF (0.1 M) was added, 
and the flask was cooled to 0˚C. To the mixture was added the allylated methyl ester dissolved in 
THF (1 M) dropwise, and the mixture was warmed to room temperature and stirred for 2 hours 
under argon. After complete conversion of the starting material was observed by TLC, the 
reaction flask was cooled to 0˚C, and the reaction was quenched by dropwise addition of sat. aq. 
Rochelle’s salt. The reaction was diluted with ether, and the biphasic mixture was stirred until 
both layers became homogeneous (typically 2 hours to overnight). The layers were separated, 
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and the aqueous layer was extracted with ether (x 3). The combined organic layers were washed 
once with brine, and dried over anhydrous MgSO4, filtered, and concentrated under reduced 
pressure. The mixture was purified by column chromatography to afford the desired alcohol 
(77% yield). 1H NMR (500MHz, CDCl3) δ 7.26-7.24 (m, 2H), 7.19-7.16 (m, 2H), 5.99 (ddt, J = 
16.3, 10.3, 6.2 Hz, 1H), 5.06 (d, J = 10.1 Hz, 1H), 5.96 (d, J = 17.2 Hz, 1H), 3.71 (m, 2H), 3.52 
(dd, J = 16.1, 6.4 Hz, 1H), 3.42 (dd, J = 15.9, 6.0 Hz, 1H), 3.27 (sex, J = 6.6 Hz, 1H), 1.31 (app. 
t, J = 6.4 Hz, 1H), 1.23 (d, J = 7.1 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 142.2, 138.4, 138.0, 
130.5, 127.2, 126.8, 126.2, 116.0, 68.8, 37.6, 37.1, 18.4; [α]23D = +4.52 (c = 0.25, CH2Cl2); 
HRMS (TOF MS AP+) m/z calc’d for C12H17O [M+H]: 177.1279; found 177.1281.   
 
O
 
(1S,3R)-3-methyl-1-vinylisochromane (17a): 1H NMR (500MHz, CDCl3) δ 7.23-7.20 (m, 2H), 
7.15-7.10 (m, 2H), 5.95 (ddd, J = 17.1, 10.3, 8.3 Hz, 1H), 5.52 (dd, J = 17.1, 1.7 Hz, 1H), 5.42 
(dd, J = 10.0, 1.7 Hz, 1H), 5.20 (d, J = 8.1 Hz, 1H), 3.95 (m, 1H), 2.81 (dd, J = 16.1, 10.7 Hz, 
1H), 2.74 (dd, J = 16.1, 2.9 Hz, 1H), 1.43 (d, J = 6.1 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 
138.2, 136.5, 134.1, 128.9, 126.9, 126.3, 125.9, 119.2, 80.2, 70.8, 36.6, 22.1; [α]23D = –34.28 (c 
= 0.25, CH2Cl2); HRMS (EI) m/z calc’d for C12H14O [M]+: 174.1045; found 174.1045.  cis-ring 
geometry was established by 1D 1HNOE spectral data. 
 
Scheme 8 Entry 1: General procedure: To a 1 dram vial with stir bar was added (R)-1-(2-
allylphenyl)propan-2-ol 16 (35.3 mg, 0.20 mmol, 1 equiv), 2,6-dimethylbenzoquinone (30 mg, 
0.22 mmol, 1.1 equiv), diphenylphosphinic acid (4.4 mg, 0.02 mmol, 0.1 equiv), meso-1,2-
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bis(phenylsulfinyl)ethane (L13) (5.6 mg, 0.02 mmol, 0.1 equiv) and Pd(OAc)2 (4.4 mg, 0.02 
mmol, 0.1 equiv). Toluene (0.4 mL) was added, and the vial was sealed with a Teflon cap and 
allowed to stir for 72 hours at 45˚C.  Afterward, the vial was allowed to cool to room 
temperature, and the solvent was removed under reduced pressure. A crude HNMR was used for 
determination of the diastereomer ratio, and crude mixture was subjected directly to flash column 
chromatography (10% EtOAc in hexanes) to provide a mixture of cis/trans isomers as a clear oil. 
Run 1 (7.4 mg, 21% yield); Run 2 (4.5 mg, 13% yield) Run 3 (5.4 mg, 15% yield). Average: 
16% yield, 1.5:1 cis:trans d.r. 
 
Scheme 8 Entry 2: General procedure is followed with L10 (8.1 mg, 0.02 mmol, 0.1 equiv) and 
reaction time of 15 hours at 45˚C. Run 1 (21.0 mg, 60% yield); Run 2 (23.0 mg, 66% yield) Run 
3 (21.4 mg, 61% yield). Average: 62% yield, >20:1 cis:trans d.r. 
 
Scheme 8 Entry 3: General procedure is followed with ent-L10 (8.1 mg, 0.02 mmol, 0.1 equiv) 
and reaction time of 48 hours at 45˚C. Run 1 (½ scale) (9.0 mg, 52% yield); Run 2 (17.0 mg, 
48% yield) Run 3 (16.5 mg, 47% yield). Average: 49% Yield, 1:2.8 cis:trans d.r. 
 
O
 
(1S,4R)-4-methyl-1-vinylisochromane (19a): 1H NMR (500MHz, CDCl3) δ 7.25-7.17 (m, 3H), 
7.07 (d, J = 7.5 Hz, 1H), 6.00 (ddd, J = 17.6, 9.9, 7.9 Hz, 1H), 5.44 (d, J = 17.2 Hz, 1H), 5.38 (d, 
J = 10.3 Hz, 1H), 5.15 (d, J = 7.5 Hz, 1H), 3.95-3.89 (ABq d, JAB = 11.4 Hz, Jd = 3.6 Hz, 2H), 
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2.90-2.84 (m, 1H), 1.38 (d, J = 7.1 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 139.4, 138.4, 135.8, 
128.5, 127.1, 126.2, 126.1, 118.9, 78.9, 69.4, 32.8, 21.0; [α]23D = +37.49 (c = 0.25, CH2Cl2); 
HRMS (EI) m/z calc’d for C12H14O [M]+: 174.1045; found 174.1043.  Cis-ring geometry was 
established by comparison with similar structures in the literature, and by 1D NOE spectral data 
of the trans-diastereomer: 
 
Scheme 8 Entry 4: General procedure: To a 1 dram vial with stir bar was added (R)-2-(2-
allylphenyl)propan-1-ol (18) (35.3 mg, 0.20 mmol, 1 equiv), 2,6-dimethylbenzoquinone (30 mg, 
0.22 mmol, 1.1 equiv), diphenylphosphinic acid (4.4 mg, 0.02 mmol, 0.1 equiv), meso-1,2-
bis(phenylsulfinyl)ethane (L13) (5.6 mg, 0.02 mmol, 0.1 equiv) and Pd(OAc)2 (4.4 mg, 0.02 
mmol, 0.1 equiv). Toluene (1.3 mL) was added, and the vial was sealed with a Teflon cap and 
allowed to stir for 72 hours at 45˚C.  Afterward, the vial was allowed to cool to room 
temperature, and the solvent was removed under reduced pressure. The crude mixture was 
subjected directly to flash column chromatography (10% EtOAc in hexanes) to provide a 
mixture of cis/trans isomers as a clear oil. Run 1 (21.7 mg, 62% yield); Run 2 (21.6 mg, 62% 
yield) Run 3 (19.9 mg, 57% yield). Average: 60% yield, 3.6:1 cis:trans d.r. 
 
Scheme 8 Entry 5: General procedure is followed with L10 (8.1 mg, 0.02 mmol, 0.1 equiv) and 
reaction time of 3 hours. Run 1 (23.7 mg, 68% yield); Run 2 (22.8 mg, 65% yield) Run 3 (23.5 
mg, 67% yield). Average: 67% yield, >20:1 cis:trans d.r. 
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Scheme 8 Entry 6: General procedure is followed with ent-L10 (8.1 mg, 0.02 mmol, 0.1 equiv) 
and reaction time of 8 hours. Run 1 (23.0 mg, 66% yield); Run 2 (22.9 mg, 66% yield) Run 3 
(24.7 mg, 71% yield). Average: 68% yield, 1:1.4 cis:trans d.r. 
 
Synthetic Application of Asymmetric Allylic C–H Oxidation (Scheme 9) 
Br
OMe
OTHP
 
2-(5-bromo-2-methoxyphenethoxy)tetrahydro-2H-pyran (20) 
To a 200 mL flamed-dried RBF, fitted with an oven-dried condenser, was added 2-(5-bromo-2-
methoxyphenyl)acetic acid (5 g, 20.4 mmol, 1 equiv) and 50 mL dry Et2O under N2. The solution 
was stirred at 0℃ and LiAlH4 (0.78 g, 20.4 mmol, 1 equiv) was added in 5 portions over 5 
minutes (CAUTION: gas evolution!). Then, the reaction was heated at 45℃ to reflux for 1 hour. 
After the solution was cooled to 0℃, 0.78 mL of water was added, followed by 0.78 mL of 15% 
NaOH aqueous solution and at last 2.4 mL of H2O. After the slurry was stirred for 30 minutes at 
RT, several spatulas of anhydrous MgSO4 were added and stirred for 30 minutes. The solid was 
filtered off and the solvent was removed under reduced pressure. The crude was continued to 
next step without purification. 
To a 100 mL flame-dried RBF was added the above crude starting material, a few crystals of p-
toluenesulfonic acid monohydrate, and 20 mL dry THF. After cooling to 0℃, 3,4-Dihydro-2H-
pyran (1.95 mL, 21.4 mmol, 1.05 equiv) was added dropwise. After the reaction was stirred at 
RT overnight, all the volatiles were removed under reduced pressure and the crude was applied 
directly to silica column chromatography (10% EtOAc in hexanes). A colorless oil (5.91 g, 18.7 
mmol, 94% yield) was obtained. 1H NMR (500 MHz, Chloroform-d) δ 7.32 (d, J = 2.5 Hz, 1H), 
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7.29 – 7.24 (m, 1H), 6.70 (d, J = 8.7 Hz, 1H), 4.60 (t, J = 3.7 Hz, 1H), 3.88 (dt, J = 9.7, 7.2 Hz, 
1H), 3.83 – 3.72 (m, 4H), 3.59 (dt, J = 9.7, 7.0 Hz, 1H), 3.46 (ddd, J = 12.7, 7.1, 3.4 Hz, 1H), 
2.89 (t, J = 7.1 Hz, 2H), 1.82 (dtd, J = 15.7, 8.1, 7.4, 3.6 Hz, 1H), 1.70 (ddt, J = 13.0, 9.7, 3.4 Hz, 
1H), 1.63 – 1.44 (m, 4H); 13C NMR (126 MHz, CDCl3) δ 156.94, 133.55, 130.19, 129.93, 
112.67, 112.07, 98.78, 66.66, 62.31, 55.73, 30.90, 30.69, 25.73, 19.70; HRMS (ESI) m/z calc’d 
for C14H19O3BrNa [M+Na]+: 337.0415; found 337.0414.  
OMe
OTHP
N
O
Me
H
 
4-methoxy-N-methyl-3-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl)benzamide (21) 
To a 100 mL RBF fitted with a condenser was added magnesium turnings (0.28 g, 11.57 mmol, 
1.2 equiv). The apparatus was flamed-dried under vacuum with vigorous stirring for 20 minutes. 
After cooling to RT, 2 mL of dry THF was added followed by the addition of a small portion of 
20 (3.04 g, 9.64 mmol, 1 equiv) dissolved in 8 mL of dry THF under N2. A few crystals of iodine 
were added, and the deep purple solution was heated by a heat gun. Upon disappearance of the 
color, the rest of the THF solution was added slowly, after which the reaction was heated to 
70℃ with vigorous stirring for 2 hours. The color of the solution was changed from light yellow 
to dark brown. Then, the reaction was cooled to 0℃, after which methyl isocyanate (500 mg, 
8.76 mmol, 0.91 equiv) dissolved in 24 mL of dry Et2O was added dropwise. (NOTE: A fresh 
new bottle of methyl isocyanate was opened and used immediately.) After the reaction was 
stirred at RT for 30 mins, 30 mL of saturated NH4Cl solution was added to quench the reaction 
and the resulting solution was partitioned in a 150 mL separatory funnel. The aqueous layer was 
extracted with EtOAc (50 mL x 3). The organic layers were combined and dried over anhydrous 
Na2SO4. The solid was filtered off and the solvent was removed under reduced pressure. The 
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crude was purified via silica column chromatography (40%→50% EtOAc in hexanes). A 
colorless oil (2.46 g, 8.39 mmol, 87% yield) was obtained. 1H NMR (500 MHz, Chloroform-d) δ 
7.66 – 7.61 (m, 2H), 6.81 (d, J = 8.5 Hz, 1H), 6.33 (d, J = 4.6 Hz, 1H), 4.57 (dd, J = 4.6, 2.7 Hz, 
1H), 3.89 (dt, J = 9.5, 7.4 Hz, 1H), 3.82 (s, 3H), 3.76 (ddd, J = 11.1, 8.0, 3.3 Hz, 1H), 3.60 (dt, J 
= 9.5, 7.1 Hz, 1H), 3.47 – 3.40 (m, 1H), 2.96 (d, J = 4.8 Hz, 3H), 2.91 (t, J = 7.2 Hz, 2H), 1.84 – 
1.73 (m, 1H), 1.67 (ddt, J = 12.3, 8.8, 3.2 Hz, 1H), 1.58 – 1.42 (m, 4H); 13C NMR (126 MHz, 
CDCl3) δ 168.16, 160.33, 129.47, 127.49, 127.12, 126.66, 109.96, 99.09, 66.78, 62.68, 55.70, 
30.98, 30.83, 27.02, 25.70, 19.92; HRMS (ESI) m/z calc’d for C16H23NO4Na [M+Na]+: 
316.1525; found 316.1522. 
OTf
OTHP
N
O
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4-(methylcarbamoyl)-2-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl)phenyl 
trifluoromethanesulfonate (22) 
To a 200 ml flamed-dried RBF was added NaH (200 mg, 8.36 mmol, 1.1 equiv) and 9 mL dry 
DMF under N2. After the solution was cooled to 0℃, ethanethiol (0.66 mL, 9.12 mmol, 1.2 
equiv) in 9 mL dry DMF was added dropwise. The reaction was stirred at RT for 20 mins to 
result in a homogeneous solution. Then 21 (2.23 g, 7.60 mmol, 1 equiv) dissolved in 19 mL dry 
DMF was added to the above solution. The flask was fitted with an oven-dried condenser and 
heated in 110℃ oil bath for 6 hours under N2. After cooling down to RT, the reaction was 
quenched with 20 mL of saturated NH4Cl solution and transferred to a 150 mL separatory funnel. 
The aqueous layer was extracted with EtOAc (80 mL x 4), and all the organic layers were 
combined and dried over Na2SO4. The solid was filtered off and the volatiles were removed 
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under reduced pressure including most of the residual DMF. A sticky yellow oil (2 g) was 
obtained and carried forward to next step without further purification. 
To a 100 mL flamed-dried RBF was added the above crude, 22 mL dry DCM, triethylamine (3 
mL, 21.5 mmol) and 4-dimethylaminopyridine (87.5 mg, 0.72 mmol). The solution was stirred at 
RT and then N-phenyl-bis(trifluoromethanesulfonimide) (3.8 g, 10.7 mmol) was added in one 
portion. The reaction was stirred at RT for 80 mins under N2, after which all the solution was 
directly loaded onto a silica column flushed with acetone/hexane (10%→15%→20%). The 
product (2.8 g, 6.81 mmol, 90% yield) was isolated as a pale yellow oil. 1H NMR (500 MHz, 
Chloroform-d) δ 7.90 (d, J = 2.3 Hz, 1H), 7.69 (dd, J = 8.6, 2.3 Hz, 1H), 7.28 (d, J = 8.6 Hz, 
1H), 6.58 (d, J = 7.7 Hz, 1H), 4.55 (dd, J = 4.6, 2.5 Hz, 1H), 3.97 (dt, J = 9.7, 6.8 Hz, 1H), 3.69 
(ddt, J = 22.3, 12.6, 5.0 Hz, 2H), 3.45 (ddd, J = 9.6, 5.2, 2.9 Hz, 1H), 3.07 – 2.92 (m, 5H), 1.76 
(dq, J = 10.8, 4.6, 3.4 Hz, 1H), 1.70 – 1.62 (m, 1H), 1.58 – 1.41 (m, 4H); 13C NMR (126 MHz, 
CDCl3) δ 166.95, 150.06, 134.71, 132.83, 130.88, 127.11, 121.57, 118.74 (q, J = 320.1 Hz), 
99.36, 66.19, 62.84, 30.83, 30.27, 27.17, 25.60, 19.82; 19F NMR (470 MHz, CDCl3) δ -74.18; 
HRMS (ESI) m/z calc’d for C16H20F3NO6S [M+H]+: 412.1042; found 412.1036. 
OTHP
N
O
Me
H
 
4-allyl-N-methyl-3-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl)benzamide (23) 
To a 300 mL flamed-dried RBF was added 22 (2.8 g, 6.81 mmol, 1 equiv), lithium chloride (1.44 
g, 34 mmol, 5 equiv), 70 mL of dry THF and finally allyltributylstannane (2.3 mL, 7.49 mmol, 
1.1 equiv). The solution was stirred and degassed under dry argon for 15 mins. Then, Pd(PPh3)4  
(0.79 g, 0.68 mmol, 0.1 equiv) was added as a solid and the reaction flask was fitted with an 
oven-dried condenser. The reaction was heated in 80℃ oil bath for 22 hours under argon. After 
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cooled down to RT, the reaction was diluted with 50 mL of water, which was then partition into 
a 150 mL separatory funnel. The aqueous layer was extracted with EtOAc (3 x 50 mL). The 
organic layers were combined and dried over anhydrous Na2SO4. The solid was filtered off and 
the solvent was removed under reduced pressure. The crude was purified via silica column 
chromatography (10%→15%→20% acetone/hexane). A colorless oil (1.90 g, 6.25 mmol, 92% 
yield) was obtained. 1H NMR (500 MHz, Chloroform-d) δ 7.65 (d, J = 2.1 Hz, 1H), 7.54 (dd, J = 
7.9, 2.0 Hz, 1H), 7.15 (d, J = 7.9 Hz, 1H), 6.54 (s, 1H), 5.91 (ddt, J = 16.6, 10.1, 6.2 Hz, 1H), 
5.04 (dd, J = 10.1, 1.7 Hz, 1H), 4.94 (dd, J = 17.1, 1.8 Hz, 1H), 4.53 (dd, J = 4.5, 2.7 Hz, 1H), 
3.90 (dt, J = 9.7, 7.3 Hz, 1H), 3.71 (ddd, J = 11.3, 8.1, 3.2 Hz, 1H), 3.57 (dt, J = 9.7, 7.2 Hz, 1H), 
3.47 – 3.38 (m, 3H), 2.95 (d, J = 4.8 Hz, 3H), 2.91 (t, J = 7.3 Hz, 2H), 1.76 (dddd, J = 15.7, 12.1, 
7.2, 3.4 Hz, 1H), 1.66 (ddt, J = 12.1, 8.7, 3.2 Hz, 1H), 1.59 – 1.38 (m, 4H); 13C NMR (126 MHz, 
CDCl3) δ 168.44, 142.05, 137.75, 136.69, 132.82, 129.96, 128.67, 125.14, 116.46, 99.19, 67.81, 
62.64, 37.21, 33.06, 30.90, 27.01, 25.64, 19.85; HRMS (ESI) m/z calc’d for C18H25NO3Na 
[M+Na]+: 326.1732; found 326.17302. 
OH
N
O
Me
Boc
 
Tert-butyl (4-allyl-3-(2-hydroxyethyl)benzoyl)(methyl)carbamate (24) 
To a 25 mL flame-dried RBF was added 23 (1.90 g, 6.25 mmol, 1 equiv), 6.3 mL of dry DCM, 
Et3N (0.88 mL, 6.25 mmol, 1 equiv) and (Boc)2O (4.3 mL, 18.8 mmol, 3 equiv) under N2. Then, 
DMAP (1.53 g, 12.5 mmol, 2 equiv) was added as a solid in one portion. After the reaction was 
stirred at RT for 6 h, another portion of (Boc)2O (2.2 mL, 9.58 mmol) was added. After stirring 
for 8 more hours, another portion of (Boc)2O (2.2 mL, 9.58 mmol) was further added and the 
reaction was allowed to stir for 6 more hours. The volatiles were removed under reduced 
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pressure and the resulting crude was flushed through a silica gel plug with 10% EtOAc/Hexane. 
After removal of the solvents under reduced pressure, the oil obtained was diluted with 35 mL of 
EtOH, followed by the addition of pyridinium p-toluenesulfonate (150 mg, 0.6 mmol, 0.1 equiv). 
The solution was stirred in a 45℃ oil bath for 24 hours. All the volatiles were removed by 
reduced pressure and the crude was applied directly to silica column chromatography 
(10%→15%→20%→25%→30% EtOAc in hexanes). A colorless oil (1.89 g, 5.92 mmol, 95% 
yield) was obtained as pure product. 1H NMR (500 MHz, Chloroform-d) δ 7.34 (d, J = 1.9 Hz, 
1H), 7.31 (dd, J = 7.9, 1.9 Hz, 1H), 7.18 (d, J = 7.9 Hz, 1H), 5.91 (ddt, J = 16.5, 10.0, 6.2 Hz, 
1H), 5.06 (dd, J = 10.3, 1.7 Hz, 1H), 4.97 (dd, J = 17.1, 1.8 Hz, 1H), 3.78 (t, J = 6.9 Hz, 2H), 
3.44 (d, J = 6.1 Hz, 2H), 3.27 (s, 3H), 2.88 (t, J = 6.9 Hz, 2H), 2.00 (br, 1H), 1.18 (s, 9H); 13C 
NMR (126 MHz, CDCl3) δ 173.84, 153.90, 141.88, 136.79, 136.74, 135.99, 129.82, 129.32, 
126.14, 116.49, 83.17, 63.11, 37.27, 35.91, 32.89, 27.72; HRMS (ESI) m/z calc’d for 
C18H25NO4Na [M+Na]+: 342.1681; found 342.1678. 
O
O
NBoc
Me
 
(S)-tert-butyl methyl(1-vinylisochromane-6-carbonyl)carbamate (25): tert-butyl (4-allyl-3-(2-
hydroxyethyl)benzoyl)(methyl)carbamate (24) (640 mg, 2.0 mmol) was reacted according to the 
general procedure for 7 hours. Purification by flash column chromatography (5%→8% EtOAc in 
hexanes) provided the vinylisochroman as a clear oil. Run 1 (440 mg, 70% yield); Run 2 (0.4 
mmol scale, 85.7 mg, 68% yield); Run 3 (0.73 mmol scale, 165.6 mg, 71% yield). Average: 70% 
yield. The enantiomeric excess was determined to be 93% by chiral HPLC analysis 
(CHIRALPAK AD-RH column, 0.5 mL/min, 50% MeCN in H2O, λ = 254.4 nm): tR
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10.882 min, tR(minor) = 14.043 min. [α]26D = +13.2 (c = 0.84, CHCl3); 1H NMR (500 MHz, 
Chloroform-d) δ 7.32 – 7.27 (m, 2H), 7.06 (d, J = 8.0 Hz, 1H), 5.92 (ddd, J = 17.3, 10.2, 7.3 Hz, 
1H), 5.40 – 5.33 (m, 2H), 5.16 (dd, J = 7.2, 1.5 Hz, 1H), 4.14 (dt, J = 11.4, 4.9 Hz, 1H), 3.84 
(ddd, J = 11.4, 8.7, 4.1 Hz, 1H), 3.28 (s, 3H), 2.95 (dddd, J = 15.3, 9.1, 5.5, 1.3 Hz, 1H), 2.76 
(dt, J = 16.4, 4.3 Hz, 1H), 1.17 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 173.53, 153.82, 139.36, 
137.67, 136.39, 133.68, 128.22, 126.10, 125.34, 119.32, 83.17, 78.23, 63.15, 32.81, 28.84, 
27.69; HRMS (ESI) m/z calc’d for C18H23NO4Na [M+Na]+: 340.1525; found 340.1522. 
N
O
Me
Boc O
OH  
Tert-butyl (1-(2-hydroxyethyl)isochromane-6-carbonyl)(methyl)carbamate (26) 
To an oven-dried 2 dram vial, fitted with PTFE/silicone septum and screw cap, was added 9-
BBN (1.44 mL, 0.72 mmol, 0.5 M in THF, fresh new bottle, 1.2 equiv) under argon. The solution 
was cooled to 0℃, after which 25 (190 mg, 0.6 mmol, 1 equiv) dissolved in 0.85 mL of dry THF 
was added dropwise. The reaction was stirred at 0℃ under argon for 12 hours. Then, 1.44 mL of 
H2O was added, followed by the addition of sodium perborate tetrahydrate (462 mg, 3 mmol, 5 
equiv). The reaction was warmed to RT and stirred overnight. The white suspension was 
transferred to a 60 mL separatory funnel by 10 mL of H2O and 20 mL of EtOAc. The aqueous 
layer was separated and extracted carefully with EtOAc (10 mL x 4). The organic layers were 
combined together and dried over anhydrous Na2SO4. The solid was filtered off and the solvent 
was removed under reduced pressure. The crude was purified via silica column chromatography 
(30% EtOAc in hexanes). A sticky colorless oil (162 mg, 0.48 mmol, 80% yield) was obtained. 
[α]26D = -50.6 (c = 1.00, CHCl3)  1H NMR (500 MHz, Chloroform-d) δ 7.31 (dd, J = 8.1, 1.8 Hz, 
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1H), 7.26 (s, 1H), 7.07 (d, J = 8.0 Hz, 1H), 5.00 – 4.95 (m, 1H), 4.16 (ddd, J = 11.4, 5.5, 3.2 Hz, 
1H), 3.82 (td, J = 5.1, 4.3, 1.4 Hz, 2H), 3.74 (ddd, J = 11.3, 10.1, 3.6 Hz, 1H), 3.27 (s, 3H), 3.06 
– 2.96 (m, 1H), 2.80 (br. s, 1H), 2.69 (dt, J = 16.5, 3.5 Hz, 1H), 2.21 (dddd, J = 14.7, 6.8, 5.1, 3.3 
Hz, 1H), 2.07 – 1.94 (m, 1H), 1.17 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 173.45, 153.79, 
140.87, 136.20, 133.83, 128.29, 125.66, 124.56, 83.21, 76.17, 63.72, 60.89, 37.94, 32.81, 29.16, 
27.68. HRMS (ESI) m/z calc’d for C18H25NO5Na [M+Na]+: 358.1630; found 358.1628. 
O
N
H
Me
O
N
N
OMe
 
(S)-1-(2-(4-(4-methoxyphenyl)piperazin-1-yl)ethyl)-N-methylisochromane-6-carboxamide (27) 
(NOTE: MsCl was distilled over P2O5 under high vacuum prior to use) 
To an oven-dried ½ dram vial, fitted with PTFE/silicone septum and screw cap, was added 26 
(68 mg, 0.2 mmol, 1 equiv), DMAP (1.2 mg, 0.01 mmol, 0.05 equiv), DIPEA (88 µL, 0.51 
mmol, 2.5 equiv) and 0.23 mL of dry THF under N2. After the reaction was cooled to 0℃, MsCl 
(17 µL, 0.21 mmol, 1.05 equiv) was added slowly under N2. The reaction was stirred at 0oC for 
35 minutes, after which 1-(4-methoxyphenyl)piperazine (55 mg, 0.29 mmol, 1.5 equiv) and 0.23 
mL of ethylene glycol was added. The reaction was heated in 110 oC oil bath and the residual 
THF was distilled off under N2. After 12 h reaction, 0.5 mL of water was added to the reaction. 
By using 2 mL of water and 4 mL of DCM, the solution was transferred to a 10 mL test tube, 
where extraction of the layers was performed. The mixing of layers was carefully performed by 
Pasteur pipette with bulb and the aqueous layer was extracted with DCM (4 mL x 5). The 
organic layers were combined and dried over anhydrous Na2SO4. The solid was filtered off and 
the solvent was removed under reduced pressure. The crude was purified via silica column 
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chromatography (1%%→2%→5% MeOH in DCM). A sticky colorless oil (45 mg, 0.11 mmol, 
54% yield) was obtained initially. Upon trituration with Et2O, a white solid was obtained as pure 
product. [α]23D = -44.7 (c = 0.93, MeOH/CHCl3 = 1:1). The enantiomeric excess was determined 
to be 93% by correlating optical rotation to the literature reported value of [α]D = -48 (c = 0.93, 
MeOH:CHCl3 = 1:1) for enantiopure product. 1H NMR (500 MHz, Chloroform-d) δ 7.57 – 7.51 
(m, 2H), 7.13 (d, J = 8.4 Hz, 1H), 6.88 (d, J = 9.1 Hz, 2H), 6.82 (d, J = 9.1 Hz, 2H), 6.36 (d, J = 
5.3 Hz, 1H), 4.84 (dd, J = 8.5, 3.2 Hz, 1H), 4.11 (ddd, J = 11.5, 5.3, 3.7 Hz, 1H), 3.74 (s, 3H), 
3.74 (dd, J = 20.7, 3.8 Hz, 1H), 3.09 (t, J = 5.0 Hz, 4H), 2.98 (d, J = 4.9 Hz, 3H), 3.02 - 2.92 (m, 
1H), 2.75 – 2.59 (m, 6H), 2.54 (ddd, J = 12.4, 10.3, 4.9 Hz, 1H), 2.23 – 2.11 (m, 1H), 2.02 (tq, J 
= 13.9, 4.8 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 168.24, 154.01, 145.87, 141.73, 134.64, 
132.89, 127.93, 125.20, 124.70, 118.40, 114.65, 74.73, 63.19, 55.80, 54.89, 53.70, 50.78, 33.30, 
29.27, 27.08. HRMS (EI) m/z calc’d for C24H32N3O3 [M]+: 410.2444; found 410.2437. The 
spectral data is consistent with the literature.27 
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CHAPTER 3: ASYMMETRIC ALLYLIC C–H ALKYLATION VIA 
PALLADIUM(II)/SULFOXIDE-OXAZOLINE CATALYSIS 
Acknowledgements 
This chapter has been adapted from the research article “Asymmetric Allylic C–H 
Alkylation via Palladium(II)/cis-ArSOX Catalysis” (Liu, W.; Ali, S. Z.; Ammann, S. E.; White, 
M. C. J. Am. Chem. Soc. 2018, doi: 10.1021/jacs.8b05668).  
 
3.1 Introduction 
The enantioselective formation of quaternary stereocenters through C(sp3)–C(sp3) bond 
represents a major challenge in synthesis.33 An attractive route to these motifs would involve an 
asymmetric allylic C–H alkylation of terminal olefins with carbon pronucleophiles. Such an 
approach would take advantage of the ease to install terminal olefin moiety in complex molecule 
settings as well as the abundance of terminal olefins in bulk commodity chemicals.  
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While Pd(0)-catalyzed asymmetric allylic substitution has been established with great 
success,34 Pd(II)-catalyzed directly alkylation of allylic C–H bonds remains to be explored 
(Scheme 10).3b, 35 Existing asymmetric allylic C–H alkylation methods only demonstrate limited 
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reactivity towards a focused set of olefins (e.g. electron deficient/neutral allylarenes3b or 2 equiv. 
of olefins35b, c). The nucleophiles being employed are also highly specialized, such as 1,3-
diketones3b and pyrazol-5-ones,35b that are not readily amenable to diversification. One possible 
reason for such limitations is the use of chiral phosphoramidite ligands, which are not stable 
under oxidative conditions. As such, iterative addition of the catalyst is required,3b or the 
oxidized ligand is observed during the reaction.36   
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Alternatively, sulfoxide-oxazoline (SOX) ligands are oxidatively stable,37 and have 
demonstrated static ligand binding to Pd37b and the ability to effect intramolecular asymmetric 
allylic C–H oxidation with high levels of enantioselectivity and good reactivity.37a 
Intermolecular allylic C–H alkylation generally proceeds with linear regioselectivity and 
therefore entails the use of a prochiral nucleophile to achieve asymmetric induction, which 
occurs relatively remote from the ligand environment (Scheme 11).34a We hypothesize that the 
highly modular SOX scaffold could allow for extensive exploration of electronic, steric and 
stereochemical combination of sulfoxide and oxazoline moiety, to access a ligand that can extend 
its chiral environment to impact remote enantioinduction. Particularly, inspirations are drawn 
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from previous studies of phosphinooxazoline (PHOX) ligands that have shown the placement of 
large groups on the unsymmetrically substituted phosphines cis to substituents on the oxazoline 
could significantly impact the remote chiral environment in asymmetric allylic substitutions.34b 
We envision that the stereogenic sulfoxide moiety would allow us to access the Pd(II)/cis-SOX 
complex that may be able to extend its chiral environment to influence nucleophile enantiofacial 
selection.  
 
3.2 Results and Discussion 
3.2.1 Reaction Development 
Working on the model reaction between allylbenzene and 2-nitrotetralone 28, previously 
optimized ligand (S,R)-SOX L10 for oxidation37a affords the alkylated product in 65% yield and 
-20% ee (Table 5, entry 1). Switching to the cis-diastereomer (S,S)-SOX L14 results in 
significant improvements in enantioselectivity (64% ee, entry 2), corroborating our hypothesis. A 
para-tolyl group on the sulfoxide (L15) performs comparably (entry 3) and is preferred for its 
relative ease of synthesis. Because no external base is added in this alkylation method, the acidic 
pro-nucleophile is thought to undergo in situ deprotonation by the acetate anion from palladium. 
We decide to introduce an alternate source of acetate with different cations to examine the effect 
of ion pair, which has been shown to influence the facial bias and significantly impact the 
stereoselectivity.34a, 38 Upon surveying a variety of acetate salts, that are known to form enolate 
complexes with nitroketones, Zn(OAc)2 is identified to be the optimal additive with 
benzene/dioxane as the solvent, improving the selectivity to 79% ee (entry 4).39 
Enantioselectivity is further improved by lowering the temperature to 5oC (entry 5). Next, 
systematic ligand modification is conducted on the oxazoline moiety: for para-substituents on 
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the aryl group, a trifluoromethyl group was not beneficial (entry 6), whereas a bulky tert-butyl 
group (L17) or electron-rich methoxy group (L18) led to slight increases in enantioselectivity 
(entry 7, 8). A combinatorial effect between sterics and electronics was found in the tert-butoxy 
(L19) substituent, which improves the enantioselectivity to be 92% ee (entry 9). Sub-
stoichiometric amount of Zn(OAc)2 additive is found to be equally effective (entry 10, 11), with 
50 mol% being the most broadly applicable (vide infra). Lowering to one equivalent of 
nucleophile results in synthetically useful yields (60%) without diminished enantioselectivity 
(91% ee, entry 12).  
Entry Ligand T (oC) ee (%)c
1d
2d
3d
4
5
6
8
9
45
45
5
Zn(OAc)2 2H2O (x mol%)
0%
0%
0%
L10
L14
L15
L15
L15
L16
L18
L19
45
45
S
N
O
O
CH3
R2
L16: R2 = CF3
L17: R2 = tBu
L18: R2 = OMe
L19: R2 = OtBu
S
N
O
O
tBu
S
N
O
O
R1
L10
L14 
R1 = tBu
L15 
R1 = Me
10 550%L19
11 525%L19
92
66
7 L17
Yield (%)b
83
80
65 -20
78 64
92
92
12e 525%L19 9160
79
100%
100%
5100%
5100%
5100%
5100%
90
89
82 79
8870
77
74
81
78 87
aReaction conditions: Nuc 28 (0.2 mmol), Olefin 29 (0.1 mmol), Pd(OAc)2 (0.01 mmol), 
Ligand (0.01 mmol), 2,6-DMBQ (0.15 mmol)  in benzene/dioxane (0.17 M) at 45oC for 24 h 
or at 5oC for 72 h. bIsolated yields. cDetermined by chiral HPLC. din toluene. e1 equiv. of 
Nuc 28
Table 5. Reaction Development with 2-Nitrotetralonea
Pd(OAc)2 (10 mol%)
Ligand (10 mol%)
Zn(OAc)2 (x mol%)
2,6-DMBQ (150 mol%)
Benzene/dioxane
(1:1 v/v, 0.17M)
O
NO2 +
O
NO2
PhH
28 29
 
We next move on to evaluate Pd(II)/cis-SOX catalysis in the alkylation of β-ketoesters, 
an important nucleophile class that could furnish core skeletons of complex molecules (Table 6). 
For the alkylation between allylbenzene and benzofuranone nucleophile 30, previously 
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optimized cis-SOX L17 and L19 only lead to modest enantioselectivity (79% ee and 70% ee, 
respectively). Given the compact size of 5-membered ring nucleophile, we reason that 
modulating the interactions between the cis-substituents on the oxazoline and sulfoxide might 
help to orient the steric elements towards the approaching trajectory of this nucleophile. 
Electron-rich aromatics are known to promote π-π interaction,40 which lead us to identify the 
3,4,5-trimethoxyphenyl moiety on the oxazoline (L20) to be highly beneficial for 
enantioselectivity (entry 3). Further ligand modification combines a CF3 group on the backbone, 
leading to the optimal ligand (L21) with 91% ee for the alkylated product (entry 4). In the crystal 
structure of Pd(OAc)2/L21 complex, the two aryl substituents on the oxazoline and sulfoxide are 
placed in close proximity (ca. 3 Å), suggesting a potential π-π interaction (Figure 4). This could 
place the trimethoxyaryl group in an outward orientation, possibly responsible for the enhanced 
enantioselectivity. 
Ph
+
H
O
O
Ph
O
O CO2tBu
N
O
S
O CH3
OMe
OMe
OMe
R2
L20: R2 = H
Pd(OAc)2 (10 mol%) 
SOX (10 mol%)
Zn(OAc)2 (50 mol%)
DMBQ (150 mol%)
Benzene, 5 oC
Entry Ligand ee (%)
1
2
3
4
L17
L19
L20
L21
89
Yield 
(%)
88
85 74
91 70
94 91
L21: R2 = CF3
CO2tBu
Table 6. Reaction Development with β-Ketoestersa
aReaction condition: Nuc 30 (0.2 mmol), Allylbenzene (0.1 mmol), Pd(OAc)2 (0.01 mmol), ligand (0.01 
mmol), Zn(OAc)2 2H2O (0.05 mmol), 2,6-DMBQ (0.15 mmol), Benzene (0.6 ml) at 5oC for 72 h.
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Figure 4. Crystal Structure of Pd(OAc)2/L21 Complex
~3 Å
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Pd(II)/cis-SOX catalysis is further extended to the alkylation of furanone-type β-
ketoester, which features a even more compact core structure (Table 7). Excitingly, SOX L20 
with the 3,4,5-trimethoxyphenyl substituent is capable of furnishing a good level of 
enantioselectivity (entry 1). Although a trifluoromethyl group on the ligand backbone is not 
beneficial in this case, the attachment of an expanded π-surface (9-anthracenyl) onto the 
sulfoxide (L22) improves the enantioselectivity to be 90% ee (entry 3).  
Ph
+
H Ph
O
O CO2iPr
Entry Ligand ee (%)Yield (%)
N
O
S
O
OMe
OMe
OMe L22
3 L22 66 90
O
O
O
CO2iPr
iPr
1 L20 81 87
Pd(OAc)2 (10 mol%) 
SOX (10 mol%)
Zn(OAc)2 (50 mol%)
DMBQ (150 mol%)
Dioxane, 5 oC OiPr
2 L21 81 87
Table 7. Reaction Development with β-Ketoestersa
aReaction condition: Nuc 31 (0.2 mmol), allylbenzene (0.1 mmol), Pd(OAc)2 (0.01 mmol), 
ligand (0.01 mmol), Zn(OAc)2 2H2O (0.05 mmol), 2,6-DMBQ (0.15 mmol), Dioxane (0.6 ml) 
at 5oC for 72 h.
31
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3.2.2 Reaction Scope with 2-Nitrotetralones 
Table 8. Reaction Scope with 2-Nitrotetralone
O
NO2
R1
R1 = Me (32a):    60%;    92% ee
O
NO2
O O
O
NO2
O
O
NO2
O
O
NO2
S
O
NO2
N
Boc
O
NO2
NBoc
32g, 65%;
93% ee
32h, 64%;
92% ee
32f, 65%;
90% ee
32i, 57%;
92% ee
32j, 63%;
92% ee
32k, 54%;
91% ee
Ar
+
Pd(OAc)2 (10 mol%)
ArSOX L19 (10 mol%)
Zn(OAc)2 (50 mol%)
DMBQ (150 mol%)
Dioxane/Benzene, 5oC, 72 h
H
>20:1 E/Z, >20:1 L/B
O
NO2
O
NO2
Ar
R R
O
NO2
R2
O
NO2MeO
O
NO2
OMe R2 =     Br 32p, 58%;
92% ee
32l, 67%;
90% ee
28
Br (32c):    66%;    92% ee
CO2Me (32d):    68%;    90% eeb
OMe (32b):    51%;    90% eeb
CH2OH (32e):    65%;    91% ee
 (32m); 64%; 90% ee
S
N
O
O
CH3
OtBu
L19
 (32n);  58%; 93% eeOPiv
OBn (32o); 48%; 88% ee
78%; 84% eec
isolated yields; ee
aReaction conditions: Nuc 28 (0.4 mmol), Olefin (0.2 mmol), Pd(OAc)2 (0.02 mmol), Ligand (0.02 mmol), 
Zn(OAc)2 2H2O (0.1 mmol), 2,6-DMBQ (0.3 mmol), Dioxane/Benzene (1:1, 1.2 ml) at 5oC for 72 h; Yields 
are isolated; e.e. determined by chiral HPLC analysis; Absolute stereochemistry assigned based on X-ray 
crystallography of 32p, all other compounds assigned by analogy. bSOX L17 was used. cat 25oC.  
With the optimal ligand identified for 2-nitrotetralones, the reaction scope for terminal 
olefin is examined (Table 8). A wide range of electronically varied allylarenes are well tolerated, 
including both electron-neutral/donating (32a,b) and electron-withdrawing groups (32c,d), all 
furnishing good yields and high enantioselectivities. Importantly, the bromide and ester moiety 
can serve as additional synthetic handle. It is worth pointing out that SOX L17 performs better in 
terms of enantioselectivity for substrate 32b and 32d. Additionally, a primary, benzylic alcohol-
containing substrate 32e serves as a competent alkylation partner, with no alcohol oxidation 
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observed. Furthermore, this alkylation method is found to be compatible with a variety of 
medicinally important hetereoaromatics, including coumarin (32f), chromene (32g), benzofuran 
(32h), benzothiophene (32i), 5’ and 3’-indole (32j,k), leading to alkylated product with good 
yield and high enantioselectivity in all cases. This demonstrates remarkable tolerance of sensitive 
functionalities, such as an electrophilic alkene (32f) and a strong chelating sulfur moiety (32i). 
Next, substitution on the tetralone moiety is examined to evaluate the nucleophile scope. In terms 
of 6’-substituents para to the ketone, both bromide (32m) and O-pivalate group (32n) are 
tolerated with high enantioselectivity, whereas an electron-donating O-benzyl group (32o) leads 
to diminished yield and selectivity, presumably due to the increased pKa of the nucleophile. The 
yield could be improved to 78% when the reaction is run at 25 oC. Methoxy substitution at both 
5’ and 7’-position on the tetralone proves to be competent nucleophiles (32l,p). The absolute 
stereochemistry is determined from the crystal structure of 32p.  
 
3.2.3 Reaction Scope with β-Ketoesters. 
The asymmetric alkylation with β-ketoesters is found to encompass a broad scope (Table 
9). For benzofuranone-type nucleophile 30, the catalyst loading can be lowered to 5 mol% and 
still maintain high reactivity and selectivity. With Pd(II)/SOX L21 as the catalyst, electronic 
variations on the nucleophile are well tolerated with 6-methoxy (33b) and 6-flouride group (33c). 
For the olefin partner, a wide range of allylarenes that incorporate important pharmacophores 
and heterocycles are successfully coupled with nucleophile 30, including as unprotected 
cyclopropyl amide (33d), sulfonamide (33e), safrole (33f), tetrahydroquinoline (33g), and 
benzoxazinone (33h). The absolute stereochemistry is assigned based on X-ray crystallographic 
84 
 
analysis of 33e. Furthermore, unactivated aliphatic olefins, which have not been demonstrated in 
previous asymmetric methods, are also evaluated. Encouragingly, both allylcyclohexane (33i)  
O
O CO2tBu
O
O
O
O CO2tBu
N
O
O
33f, 88%; 92% ee
O
O CO2tBu
N
Boc
O
O CO2tBu
Y
33h, 91%; 93% ee
33g, 96%; 90% ee
Ar
+
H
O
O
aReaction condition: Nuc 30 (0.4 mmol), Olefin (0.2 mmol), Pd(OAc)2 (0.01 mmol), L21 (0.01 mmol), 
Zn(OAc)2 2H2O (0.1 mmol), 2,6-DMBQ (0.3 mmol), Benzene (1.2 ml) at 5oC for 72 h.  bPd(OAc)2/L21 
(2.5 mol%) gave 72% yield. cAbsolute stereochemistry assigned based on X-ray crystallography of 
33e, all other compounds assigned by analogy. dat 25oC with 10 mol% catalyst. eee determined by 
converting the acetal group to an aldehyde.
Pd(OAc)2/L21
(5 mol%)
Zn(OAc)2 (50 mol%)
DMBQ (150 mol%)
Benzene, 5 oC
O
O CO2tBu
33i, 83%; 79% eed
CO2tBu
O
O CO2tBu
X
Y =
H
N
O
33d, 90%;
94% ee
S
N
O O
O
33e, 89%;b
92% eec
O
O CO2tBu
OEt
OEt
33j, 81%; 79% eed,e
X = yield
81%
93%
ee
92%OMe (33b)
F (33c) 90%
isolated yields; ee
Ph
O
O CO2tBu
Table 9. Reaction Scope with β-Ketoestersa
30
 
and 3-butenyl diethyl acetal (33j) show good reactivity and promising enantioselectivity towards 
alkylation.  
For furanone-type nucleophile 31, thiophene (34b) and furan (34c) can be incorporated 
into the backbone and lead to alkylated product with high enantioselectivities. Importantly, 34c 
furnishes the requisite carbon skeleton that is present in natural products such as cephalymysins 
with important biological activities.41 For the allylarene component, the incorporation of 
medicinally relevant phenylphosphate (34d), 3’-indole (34e) and safrole (34f) are well tolerated 
with good yield and high enantioselectivity.  
85 
 
O
O CO2Me
Me
34f, 90%;
91% ee
O
O CO2Me
S
Me
34b, 83%;
91% ee
O
O
O
O CO2Me
Me
34d, 74%;
93% ee
O
O CO2Me
Me
N
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34e, 58%;
95% ee
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O CO2Me
Me
34c, 67%;
93% ee
O
O
O
O
P
O
O
Et
Et Et
Et
OEtEtO
aReaction condition: Nuc 31 (0.1 mmol), Olefin (0.1 mmol), Pd(OAc)2 (0.01 mmol), L22 (0.01 mmol), 
Zn(OAc)2 2H2O (0.05 mmol), 2,6-DMBQ (0.15 mmol), Dioxane at 5oC for 72 h. b2 equiv. of nucleophile
O CO2Me
35a, 86%;
79% eeb
Br
O CO2Bn
Ph
35b, 82%;
91% eeb
O CO2Bn
Ph
35c, 71%;
93% eeb
OMe
O CO2Bn
Ph
35d, 76%;
91% eeb
CF3
Ar
X
O CO2R
Ar
+
H
Pd(OAc)2/L22
(10 mol%)
Zn(OAc)2 (50 mol%)
DMBQ (150 mol%)
Dioxane, 5 oC isolated yields; ee
X
O
O
O
R
Table 10. Reaction Scope with β-Ketoestersa
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We have also evaluated the indanone-based β-ketoester nucleophile, which could furnish 
synthetically challenging all-carbon quaternary stereocenters. Using Pd(II)/SOX L22 catalyst, 
the alkylation of this nucleophile with 4-bromoallylbenzene proceeded with a moderate level of 
enantioselectivity (35a, 79% ee). Interestingly, 4-substitution with a phenyl group at the 
indanone (35b) is found to be beneficial for enantioinduction, leading to >90% ee with both 
electron-rich and electron-deficient allylarenes (35c, d). 
 
3.2.4 Diastereoselective Allylic C–H Alkylation with β-Ketoesters. 
The ability to alkylate unactivated aliphatic olefins offers the opportunity to incorporate 
structural complexity, such as pre-existing stereogenic centers, into the alkylation partner. In the  
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N
O
MeO
Me
N
Boc
TBSO
OTMS
Ligand Yield d.r.c
L24d 35% 1:1.3
L21 91% 8:1
ent-L21 84% 1:17
PMBO
OTBS
Pd(OAc)2 (10 mol%)
L21 (10 mol%)
standard condition
25oC
HO
H H
H
OAc
O
O
O
OtBu
+
HO
H
HH
AcO O
OtBuO2C
HO
H
HH
AcO O
OtBuO2C
36
30
37b
90% yield
18:1 d.r.b
37a
89% yield
16:1 d.r.
racemic ligand
1.5:1 d.r.
S
N
O
O
CH3
F3C
OMe
OMe
OMe
ent-L21
S
N
O
O
CH3
F3C
OMe
OMe
OMe
L21
Ligand Yield d.r.
L24d 44% 1:1.2
L21 92% 3:1
ent-L21 90% 1:20
Ligand Yield d.r.
L24d 21% 1:1
L21 93% 5:1
ent-L21 89% 1:4
Ligand Yield d.r.c
L23 31% 1:1
L21 90% 4:1
ent-L21 93% 1:5
36b 36c
36e36d
aReaction condition: Olefin 36 (0.2 mmol), Nuc 30 (0.4 mmol), Pd(OAc)2 (0.02 mmol), Ligand (0.02 mmol), 
Zn(OAc)2 2H2O (0.1 mmol), 2,6-DMBQ (0.3 mmol), Benzene (1.2 ml) at 25oC for 72 h. Yields are isolated; 
d.r. are determined by 1H NMR anaylsis. bAbsolute stereochemistry assigned by X-ray crystallography of 
37b, all other compounds assigned by analogy. cd.r. determined by chiral HPLC analysis. dL24: 1,2-
Bis(phenylsulfinyl)ethane is used, when L23 gave no reaction.
N
O Me
Me
S
O Me
MeO
L23
same 
except
ent-L21 
(10 mol%)H
H
H
H
H
Table 11. Diastereoselective C–H Alkylation with β-Ketoestersa
 
context of chiral aliphatic olefins, we begin to question if the good levels of enantioselectivity 
observed with achiral substrates (33i,j, Table 9) could be translated into synthetically useful 
levels of diastereoselectivity, providing a catalyst-controlled synthesis of both stereoisomers. In 
this regard, estrone derivative 36 is examined for alkylation with β-ketoesters 30 under racemic 
Pd(II)/L23 catalysis and shows minimal inherent substrate bias (1.5:1 d.r., Table 11).  Using our 
chiral Pd(II)/SOX L21 catalyst, the reaction afforded product 37a in excellent yield (89%) and 
diastereoselectivity (16:1). Importantly, switching to the ligand enantiomer ent-L21, the sense of 
asymmetric induction is overturned to favor the other diastereomer 37b (18:1) in 90% yield. X-
ray crystallography confirms the absolute stereochemistry of 37b, which agrees with the 
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assignment of the product obtained from achiral olefin. Moreover, the good to excellent levels of 
catalyst-controlled diastereoselectivity is observed across a wide range of aliphatic substrates 
bearing nitrogen, oxygen and carbon stereogenic centers in the homoallylic positions: pyrrolidine 
(36b), Weinreb amide (36c), 1, 2-diol (36d) and androsterone derivative (36e).  
Reaction condition: (a)SnCl2 2H2O (10 equiv.), THF/H2O, 45oC, 24 h. 81% yield. (b)allyl bromide (1.1 
equiv.), K2CO3 (1.1 equiv.), MeCN, 50oC, 18 h. 72% yield. (c)Grubbs II (10 mol%), TsOH (1 equiv.), DCM, 
reflux, 24 h. 94% yield. (d)Pd/C (20 wt.%), H2 (1 atm), MeOH, 2 h, quantitative. (e)NaBH4 (1.1 equiv.), 
MeOH, 0oC. (f)vinylmagnesium bromide (3 equiv.), THF, -78oC.
90% yield
>20:1 d.r.
This route: 
43% yield, 91% ee
Previous:
6% yield, 0% ee41
65% yield
>20:1 d.r.
O
Ph
NO2
O
Ph
NH2
81% yield
78% yield, 92% ee
(a) SnCl2
Br
K2CO3
O
HN
72% yield
(b)
Ph
94% yield
(c) Grubbs II
O
N
HTsOH quantitative
(d) Pd/C, H2
O
N
H
38 39
40
O
Ph
NH2
38
(e) NaBH4
OH
Ph
NH2
42
O
Ph
NH2
38
(f)
43
MgBr
OH
Ph
NH2
Scheme 12. Synthetic Application
A. Target-oriented synthsis
B. Diastereoselective transformation
 
3.2.5 Synthetic Application 
In contrast to previous asymmetric allylic C–H alkylation methods, the chiral alkylated 
product obtained from 2-nitrotetralone and β-ketoester could be rapidly diversified and serve as 
versatile synthetic intermediates (Scheme 12). To showcase the synthetic utility of 2-
nitroketones, the nitro group is chemoselectively reduced to the amino group 38 without erosion 
in enantioselectivity. Mono-allylation of the nitrogen nucleophile, followed by ring-closing 
metathesis and olefin hydrogenation affords the spirocyclic tetralone-piperidine motif 41, an 
important pharmacophore found in potassium-competitive acid blockers.42 Importantly, the 
88 
 
synthetic route based on asymmetric alkylation provides significantly higher efficiency (43% 
overall yield and 91% ee) over a previous racemic synthesis (6% overall yield). Furthermore, the 
ketone moiety in 38 can undergo highly diastereoselective transformations, such as hydride 
reduction and Grignard addition, to afford functionalized 1, 2-amino alcohol motifs 42 and 43 as 
useful chiral building blocks. 
 
3.3 Conclusions 
We have successfully developed a new class of cis-sulfoxide-oxazoline ligands that 
enable the Pd(II)-catalyzed asymmetric allylic C–H alkylation of terminal olefins with a variety 
of synthetically versatile nucleophiles. The scope is broad with uniformly high 
enantioselectivity. Key to the catalyst development is modulating the interactions between the 
substituents in the cis-SOX ligand to orient the steric element that could impact remote 
asymmetric induction. We believe the introduction of a new class of oxidatively stable chiral 
ligands will serve as a platform to support other transition metal-catalyzed asymmetric processes 
operating under oxidative pathways. 
 
3.4 Experimental Sections 
3.4.1 General Information 
All commercially obtained reagents were used as received; Pd(OAc)2 (Johnson-Matthey 
Chemicals) was stored in a glove box, and weighed out in the air at room temperature prior to 
use. Benzene and dioxane was purified prior to use by passage through a bed of activated 
alumina (Glass Contour, Laguna Beach, California). 2,6-Dimethylbenzoquinone and zinc acetate 
dihydrdate (reagent grade) were purchased from Sigma-Aldrich and used as received. All allylic 
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C–H alkylation reactions were set up and run under ambient air with no precautions taken to 
exclude moisture. Reactions at 5oC were carried out in a cold room, where the temperature is 
monitored and maintain between 4oC–6 oC. Thin-layer chromatography (TLC) was conducted 
with E. Merck silica gel 60 F254 precoated plates (0.25 mm) and visualized with UV, Cerium-
ammonium-molybdate and potassium permanganate stain. Flash chromatography was performed 
using ZEOprep 60 ECO 43-60 micron silica gel (American International Chemical, Inc.).  
1H NMR spectra were recorded on a Varian Unity-u500nb (500 MHz), Varian Inova-500 
(500 MHz), or Varian Unity-500 (500 MHz) spectrometer and are reported in ppm using solvent 
as an internal standard (CDCl3 at 7.26 ppm). Data reported as: s = singlet, d = doublet, t = triplet, 
q = quartet, quin. = quintet, sext. = sextet, sept. = septet, o = octet, m = multiplet, b = broad, ap = 
apparent; coupling constant(s) in Hz; integration. Proton-decoupled 13C NMR spectra were 
recorded on a Carver-Bruker 500 (125MHz) or Varian Unity-500 (125MHz) spectrometer and 
are reported in ppm using solvent as an internal standard (CDCl3). 19F NMR spectra were 
recorded on a Varian Unity-500 (470 MHz) spectrometer and are reported in ppm using solvent 
as an internal standard (CDCl3). Chiral high pressure liquid chromatography (HPLC) analysis 
was performed on an Agilent 1100 Series instrument equipped with a UV detector, using a 
CHIRALPAK AD-RH, OJ-H, IA-3, IB-3, IC-3 column. Optical rotations were measured with a 
sodium lamp using a 1 mL cell with a 50 mm path length on a Jasco P-1020 polarimeter. Optical 
rotations were obtained with a sodium lamp and are reported as follows: [α]λToC (c = g/100 mL 
solvent). High-resolution mass spectra were obtained at the University of Illinois Mass 
Spectrometry Laboratory. Electrospray ionization (ESI) spectra were performed on a Waters Q-
Tof µLtima spectrometer, and electron ionization (EI) and field desorption (FD) spectra were 
performed on a Micromass 70-VSE spectrometer. 
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Preparation of SOX Ligands 
General procedure A (for ligands without CF3 group): phenyloxazoline was coupled with chiral 
sulfinate ester using previously reported procedure.37a  
 
General procedure B (for ligands with CF3 group): To a flame-dried flask under nitrogen was 
added the phenyloxazoline (1 equiv.), THF (0.1 M), and TMEDA (1.0 equiv.).  The solution was 
cooled to -94oC (acetone/liquid N2 bath) with stirring, and n-butyllithium (1.6 M in hexane, 1.0 
equiv.) was added slowly via syringe dropwise. The reaction was stirred at -94oC for 5 minutes. 
(NOTE: maintaining the temperature at -94oC was critical for this reaction. It was found to be 
effective by keeping the acetone bath frozen by liquid N2). The reaction was warmed to -78oC by 
switching to acetone/dry ice bath, upon which the chiral sulfinate ester (3.0 equiv.) was added 
slowly as a solution in THF (0.5 M) dropwise via syringe. The reaction was stirred at -78oC for 
30 minutes, then 0oC for 1 hour, and room temperature for 2 hours. The reaction was quenched 
with sat. NH4Cl (aq.) solution and diluted with EtOAc. The layers were separated and the 
aqueous layer was extracted with EtOAc two times. The combined organic layers were dried 
over anhydrous MgSO4, filtered and concentrated under reduced pressure. The crude residue was 
purified via column chromatography (acetone/hexane) to afford the desired product. 
 
 
(S)-2-(2-((S)-(4-(tert-butyl)phenyl)sulfinyl)phenyl)-4-phenyl-4,5-dihydrooxazole (L10): 
white solid. 1H NMR (500 MHz, Chloroform-d) δ 8.49 – 8.45 (m, 1H), 8.01 (dd, J = 7.7 Hz, 1H), 
7.79 (t, J = 7.5 Hz, 1H), 7.57 (t, J = 7.6 Hz, 1H), 7.45 (d, J = 8.4 Hz, 2H), 7.29 – 7.23 (m, 3H), 
91 
 
7.22 – 7.19 (m, 2H), 7.05 – 6.99 (m, 2H), 5.43 (dd, J = 10.2, 8.6 Hz, 1H), 4.73 (dd, J = 10.2, 8.4 
Hz, 1H), 4.18 (t, J = 8.5 Hz, 1H), 1.25 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 161.72, 153.78, 
146.67, 143.28, 141.52, 132.11, 130.23, 129.94, 128.59, 127.59, 126.83, 126.80, 125.79, 125.29, 
124.89, 74.40, 70.72, 34.80, 31.17. HRMS (EI) m/z calc’d for C25H25NO2S [M+H]+: 404.1684; 
found 404.1690. [α]22D = -166.7 (c = 0.57, CHCl3). 
 
 
(S)-2-(2-((S)-p-tolylsulfinyl)phenyl)-4-(4-(trifluoromethyl)phenyl)-4,5-dihydrooxazole 
(L16): white solid. 1H NMR (500 MHz, Chloroform-d) δ 8.47 (d, J = 7.9 Hz, 1H), 8.02 (d, J = 
7.8 Hz, 1H), 7.81 (t, J = 7.7 Hz, 1H), 7.59 (t, J = 7.6 Hz, 1H), 7.47 (d, J = 8.1 Hz, 2H), 7.36 (d, J 
= 8.2 Hz, 2H), 7.05 (d, J = 8.2 Hz, 2H), 6.97 (d, J = 7.9 Hz, 2H), 5.46 (dd, J = 10.2, 8.1 Hz, 1H), 
4.74 (dd, J = 10.2, 8.5 Hz, 1H), 4.16 (t, J = 8.3 Hz, 1H), 2.30 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δ 162.18, 146.49, 145.50, 145.49, 143.43, 140.95, 132.36, 130.34, 130.08, 129.83 (q, J = 
32.4 Hz), 127.08, 126.95, 125.63, 125.48 (q, J = 3.8 Hz), 124.49, 124.04 (q, J = 272.46 Hz), 
74.04, 70.24, 21.23. 19F NMR (471 MHz, CDCl3) δ -62.52. HRMS (EI) m/z calc’d for 
C23H18NO2SF3 [M+H]+: 430.1089; found 430.1080. [α]22D = -116.8 (c = 0.64, CHCl3). 
 
 
(S)-4-(4-(tert-butyl)phenyl)-2-(2-((S)-p-tolylsulfinyl)phenyl)-4,5-dihydrooxazole (L17): white 
solid. 1H NMR (500 MHz, Chloroform-d) δ 8.44 (d, J = 8.0 Hz, 1H), 8.00 (d, J = 7.7 Hz, 1H), 
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7.77 (t, J = 7.7 Hz, 1H), 7.55 (t, J = 7.6 Hz, 1H), 7.44 (d, J = 8.2 Hz, 2H), 7.29 (d, J = 8.3 Hz, 
2H), 6.97 (m, 4H), 5.39 (dd, J = 10.2, 8.4 Hz, 1H), 4.69 (dd, J = 10.1, 8.4 Hz, 1H), 4.22 (t, J = 
8.3 Hz, 1H), 2.30 (s, 3H), 1.33 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 161.52, 150.52, 146.81, 
143.50, 140.60, 138.49, 132.07, 130.21, 129.98, 129.42, 126.90, 126.57, 125.44, 125.15, 124.91, 
74.32, 70.37, 34.53, 31.38, 21.37. HRMS (EI) m/z calc’d for C26H27NO2S [M+H]+: 418.1841; 
found 418.1836. [α]22D = -171.4o (c = 1.34, CHCl3). 
 
 
(S)-4-(4-methoxyphenyl)-2-(2-((S)-p-tolylsulfinyl)phenyl)-4,5-dihydrooxazole (L18): white 
solid. 1H NMR (500 MHz, Chloroform-d) δ 8.44 (d, J = 7.9 Hz, 1H), 7.99 (d, J = 7.9 Hz, 1H), 
7.76 (t, J = 7.6 Hz, 1H), 7.55 (t, J = 7.6 Hz, 1H), 7.43 (d, J = 8.2 Hz, 2H), 6.99 (d, J = 8.0 Hz, 
2H), 6.93 (d, J = 8.6 Hz, 2H), 6.78 (d, J = 8.6 Hz, 2H), 5.35 (dd, J = 10.1, 8.3 Hz, 1H), 4.67 (dd, 
J = 10.1, 8.4 Hz, 1H), 4.15 (t, J = 8.4 Hz, 1H), 3.81 (s, 3H), 2.29 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δ 161.46, 159.04, 146.75, 143.51, 140.70, 133.70, 132.08, 130.23, 129.98, 129.42, 
127.97, 126.86, 125.19, 124.89, 113.90, 74.46, 70.20, 55.31, 21.34. HRMS (EI) m/z calc’d for 
C23H21NO3S [M+H]+: 392.1320; found 392.1324. [α]22D = -191.6 (c = 1.0, CHCl3). 
 
 
 (S)-4-(4-(tert-butoxy)phenyl)-2-(2-((S)-p-tolylsulfinyl)phenyl)-4,5-dihydrooxazole (L19): 
white solid. 1H NMR (500 MHz, Chloroform-d) δ 8.43 (d, J = 8.0 Hz, 1H), 8.00 (d, J = 7.7 Hz, 
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1H), 7.77 (t, J = 7.6 Hz, 1H), 7.55 (t, J = 7.5 Hz, 1H), 7.49 – 7.44 (m, 2H), 7.02 (d, J = 8.4 Hz, 
2H), 6.94 – 6.85 (m, 4H), 5.38 (dd, J = 10.1, 8.6 Hz, 1H), 4.70 (dd, J = 10.2, 8.4 Hz, 1H), 4.18 (t, 
J = 8.5 Hz, 1H), 2.30 (s, 3H), 1.35 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 161.63, 154.84, 
146.76, 143.51, 140.78, 136.27, 132.13, 130.24, 129.96, 129.44, 127.34, 126.84, 125.20, 124.92, 
124.15, 78.54, 74.48, 70.27, 28.86, 21.32. HRMS (ESI) m/z calc’d for C26H27NO3S [M+H]+: 
434.1790; found 434.1783. [α]23D = -219.1 (c = 1.1, CHCl3). 
 
 
 (S)-2-(2-((S)-p-tolylsulfinyl)phenyl)-4-(3,4,5-trimethoxyphenyl)-4,5-dihydrooxazole (L20): 
white solid. 1H NMR (400 MHz, Chloroform-d) δ 8.43 (d, J = 8.0 Hz, 1H), 8.00 (d, J = 7.8 Hz, 
1H), 7.78 (t, J = 7.8 Hz, 1H), 7.56 (t, J = 7.6 Hz, 1H), 7.44 (d, J = 8.2 Hz, 2H), 6.98 (d, J = 8.2 
Hz, 2H), 6.30 (s, 2H), 5.34 (dd, J = 10.1, 8.6 Hz, 1H), 4.72 (dd, J = 10.2, 8.5 Hz, 1H), 4.21 (t, J = 
8.5 Hz, 1H), 3.86 (s, 3H), 3.73 (s, 6H), 2.28 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 161.73, 
153.38, 147.24, 143.46, 140.81, 137.42, 137.12, 132.22, 130.25, 129.96, 129.31, 126.93, 125.15, 
124.75, 103.79, 74.35, 71.04, 60.86, 55.98, 21.26; HRMS (ESI) m/z calc’d for C25H25NO5S 
[M+H]+: 452.1532; found 452.1532. [α]22D = -111.9 (c = 1.1, CHCl3). 
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(S)-2-(2-((S)-p-tolylsulfinyl)-4-(trifluoromethyl)phenyl)-4-(3,4,5-trimethoxyphenyl)-4,5-
dihydrooxazole (L21): white foam. 1H NMR (500 MHz, Chloroform-d) δ 8.76 (s, 1H), 8.12 (d, 
J = 8.0 Hz, 1H), 7.81 (d, J = 7.9 Hz, 1H), 7.40 (d, J = 8.3 Hz, 2H), 6.97 (d, J = 8.0 Hz, 2H), 6.27 
(s, 2H), 5.38 (dd, J = 10.2, 8.5 Hz, 1H), 4.75 (dd, J = 10.3, 8.6 Hz, 1H), 4.26 (t, J = 8.6 Hz, 1H), 
3.87 (s, 3H), 3.72 (s, 6H), 2.28 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 160.71, 153.44, 149.18, 
142.67, 141.33, 137.58, 136.60, 134.12 (q, J = 33.5 Hz), 130.56, 129.44, 127.75, 127.10, 127.06 
(q, J = 3.7 Hz), 123.36 (q, J = 273.67 Hz), 122.42 (q, J = 3.8 Hz), 103.84, 74.56, 71.27, 60.87, 
55.97, 21.27. 19F NMR (470 MHz, CDCl3) δ -63.25. HRMS (ESI) m/z calc’d for C26H24F3NO5S 
[M+H]+: 520.1406; found 520.1414. [α]22D = -68.1 (c = 0.71, CHCl3). 
 
 
(R)-2-(2-((R)-p-tolylsulfinyl)-4-(trifluoromethyl)phenyl)-4-(3,4,5-trimethoxyphenyl)-4,5-
dihydrooxazole (ent-L21): white foam. [α]22D = 68.7 (c = 1.31, CHCl3). 
 
 
 (S)-2-(2-((S)-(4-(anthracen-9-yl)phenyl)sulfinyl)phenyl)-4-(3,4,5-trimethoxyphenyl)-4,5-
dihydrooxazole (L22): white solid. 1H NMR (500MHz, CDCl3) δ 8.55 – 8.46 (m, 2H), 8.10 (d, 
J = 7.8 Hz, 1H), 8.03 (d, J = 8.5 Hz, 2H), 7.98 (d, J = 7.5 Hz, 2H), 7.85 (t, J = 7.7 Hz, 1H), 7.63 
(t, J = 7.6 Hz, 1H), 7.50 – 7.40 (m, 4H), 7.36 (d, J = 7.7 Hz, 2H), 7.31 (d, J = 7.5 Hz, 2H), 6.51 
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(s 2H), 5.46 (t, J = 9.7 Hz, 1H), 4.84 (d, J = 9.6 Hz, 1H), 4.31 (t, J = 9.0 Hz, 1H), 3.73 (s, 6H), 
3.68 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 162.4, 153.7, 147.8, 146.0, 141.6, 137.6, 137.1, 
135.4, 132.8, 131.8, 131.4, 130.7, 130.1, 130.0, 128.6, 127.3, 126.7, 126.4, 125.8, 125.4, 125.3, 
125.2, 103.9, 74.8, 71.2, 60.9, 56.3; HRMS (ESI) m/z calc’d for C38H32NO5S [M+H]: 614.2015; 
found 614.2010. [α]21D = –229.29 (c = 0.2, CHCl3).   
 
Reaction Development with 2-Nitrotetralone (Table 5) 
Entry 1: To a ½ dram borosilicate vial with stir bar was added ligand L10 (4.1 mg, 0.01 mmol, 
0.1 equiv) and Pd(OAc)2 (2.2 mg, 0.01 mmol, 0.1 equiv). Toluene (0.2 mL) was added, and the 
vial was capped and stirred at 45˚C for 10 mins. Separately, to a ½ dram borosilicate vial with 
stir bar was added 28 (38.2 mg, 0.20 mmol, 2 equiv), 2,6-dimethylbenzoquinone (20 mg, 0.15 
mmol, 1.5 equiv). The catalyst solution was subsequently added to the reaction flask, and toluene 
(0.4 mL) was used to rinse the catalyst vial, also transferred and added to the reaction flask. 
Allylbenzene (13.0 µL, 0.10 mmol, 1 equiv) was added. The ½ dram vial was sealed with a 
Teflon cap, and allowed to stir for 24 hours at 45˚C.  Afterward, the vial was allowed to cool to 
RT, followed by the addition of saturated NaHSO3 (aq.) solution (0.2 mL). The mixture was 
stirred at RT for 15 mins, followed by the addition of anhydrous MgSO4 and filtration with 
dichloromethane. The majority of the solvent was removed under reduced pressure, and the 
remaining mixture was directly subjected to flash column chromatography (2%→5% 
EtOAc/hexanes) to provide product as a light yellow film. Run 1 (20.7 mg, 67% yield, -20% ee); 
Run 2 (19.4 mg, 63% yield, -20% ee) Average: 65% Yield, -20% ee.  
 
96 
 
Entry 2: Reaction proceeded according to procedure in Entry 1 using ligand L14 (4.1 mg, 0.01 
mmol, 0.1 equiv). Run 1 (22.7 mg, 74% yield, 64% ee); Run 2 (25.1 mg, 82% yield, 64% ee); 
Average: 78% Yield, 64% ee.  
 
Entry 3: Reaction proceeded according to procedure in Entry 1 using ligand L15 (3.7 mg, 0.01 
mmol, 0.1 equiv). Run 1 (24.8 mg, 81% yield, 66% ee); Run 2 (24.1 mg, 78% yield, 66% ee); 
Average: 80% Yield, 66% ee.  
 
Entry 4: To a ½ dram borosilicate vial with stir bar was added ligand L15 (3.7 mg, 0.01 mmol, 
0.1 equiv) and Pd(OAc)2 (2.2 mg, 0.01 mmol, 0.1 equiv). Benzene (0.2 mL) was added, and the 
vial was capped and stirred at 45˚C for 10 mins. Separately, to a ½ dram borosilicate vial with 
stir bar was added 28 (38.2 mg, 0.20 mmol, 2 equiv), 2,6-dimethylbenzoquinone (20 mg, 0.15 
mmol, 1.5 equiv) and Zn(OAc)2 dihydrate (22 mg, 0.1 mmol, 1.0 equiv). The catalyst solution 
was subsequently added to the reaction flask, and benzene (0.1 mL) and dioxane (0.3 mL) was 
used to rinse the catalyst vial, also transferred and added to the reaction flask. Allylbenzene (13.0 
µL, 0.10 mmol, 1 equiv) was added. The ½ dram vial was sealed with a Teflon cap, and allowed 
to stir for 24 hours at 45˚C.  Afterward, the reaction was quenched by the addition of saturated 
NaHSO3 (aq.) solution (0.2 mL). The mixture was stirred at RT for 15 mins, followed by the 
addition of anhydrous MgSO4 and filtration with dichloromethane. The majority of the solvent 
was removed under reduced pressure, and the remaining mixture was directly subjected to flash 
column chromatography (2%→5% EtOAc/hexanes) to provide product as a light yellow film. 
Run 1 (25.5 mg, 83% yield, 79% ee); Run 2 (24.5 mg, 80% yield, 79% ee); Average: 82% 
Yield, 79% ee.  
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Entry 5: General procedure: To a ½ dram borosilicate vial with stir bar was added ligand L15 
(3.7 mg, 0.01 mmol, 0.1 equiv) and Pd(OAc)2 (2.2 mg, 0.01 mmol, 0.1 equiv). Benzene (0.2 mL) 
was added, and the vial was capped and stirred at 45˚C for 10 mins. Separately, to a ½ dram 
borosilicate vial with stir bar was added 28 (38.2 mg, 0.20 mmol, 2 equiv), 2,6-
dimethylbenzoquinone (20 mg, 0.15 mmol, 1.5 equiv) and Zn(OAc)2 dihydrate (22 mg, 0.1 
mmol, 1.0 equiv). The catalyst solution was subsequently added to the reaction flask, and 
benzene (0.1 mL) and dioxane (0.3 mL) was used to rinse the catalyst vial, also transferred and 
added to the reaction flask. Allylbenzene (13.0 µL, 0.10 mmol, 1 equiv) was added. The ½ dram 
vial was sealed with a Teflon cap, and allowed to stir for 72 hours at 5˚C.  Afterward, the 
reaction was quenched by the addition of saturated NaHSO3 (aq.) solution (0.2 mL). The mixture 
was stirred at RT for 15 mins, followed by the addition of anhydrous MgSO4 and filtration with 
dichloromethane. The majority of the solvent was removed under reduced pressure, and the 
remaining mixture was directly subjected to flash column chromatography (2%→5% 
EtOAc/hexanes) to provide product as a light yellow film. Run 1 (21.8 mg, 71% yield, 88% ee); 
Run 2 (20.8 mg, 68% yield, 88% ee); Average: 70% Yield, 88% ee. 
 
Entry 6: Reaction proceeded according to the General procedure in Entry 5 using ligand L16 (4.3 
mg, 0.01 mmol, 0.1 equiv). Run 1 (23.3 mg, 76% yield, 87% ee); Run 2 (24.5 mg, 80% yield, 
87% ee); Average: 78% Yield, 87% ee.  
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Entry 7: Reaction proceeded according to the General procedure in Entry 5 using ligand L17 (4.2 
mg, 0.01 mmol, 0.1 equiv). Run 1 (22.7 mg, 74% yield, 90% ee); Run 2 (24.3 mg, 79% yield, 
90% ee); Average: 77% Yield, 90% ee.  
 
Entry 8: Reaction proceeded according to the General procedure in Entry 5 using ligand L18 (3.9 
mg, 0.01 mmol, 0.1 equiv). Run 1 (23.8 mg, 77% yield, 89% ee); Run 2 (21.5 mg, 70% yield, 
89% ee); Average: 74% Yield, 89% ee.  
 
Entry 9: Reaction proceeded according to the General procedure in Entry 5 using ligand L19 (4.4 
mg, 0.01 mmol, 0.1 equiv). Run 1 (24.0 mg, 78% yield, 92% ee); Run 2 (25.5 mg, 83% yield, 
92% ee); Average: 81% Yield, 92% ee.  
 
Entry 10: Reaction proceeded according to the General procedure in Entry 5 using ligand L19 
(4.4 mg, 0.01 mmol, 0.1 equiv) and Zn(OAc)2 dihydrate (11 mg, 0.05 mmol, 0.5 equiv). Run 1 
(26.2 mg, 85% yield, 92% ee); Run 2 (25.0 mg, 81% yield, 92% ee); Average: 83% Yield, 92% 
ee.  
 
Entry 11: Reaction proceeded according to the General procedure in Entry 5 using ligand L19 
(4.4 mg, 0.01 mmol, 0.1 equiv) and Zn(OAc)2 dihydrate (5.5 mg, 0.025 mmol, 0.25 equiv). Run 
1 (25.2 mg, 82% yield, 92% ee); Run 2 (22.9 mg, 75% yield, 92% ee); Average: 79% Yield, 
92% ee.  
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Entry 12: Reaction proceeded according to the General procedure in Entry 5 using ligand L19 
(4.4 mg, 0.01 mmol, 0.1 equiv), nucleophile 28 (19.0 mg, 0.10 mmol, 1 equiv) and Zn(OAc)2 
dihydrate (5.5 mg, 0.025 mmol, 0.25 equiv). Run 1 (17.1 mg, 56% yield, 91% ee); Run 2 (19.5 
mg, 64% yield, 91% ee); Average: 60% Yield, 91% ee.  
 
Reaction Development with β-Ketoester 30 (Table 6) 
Entry 1: General procedure: To a ½ dram borosilicate vial with stir bar was added ligand L17 
(4.2 mg, 0.01 mmol, 0.1 equiv) and Pd(OAc)2 (2.2 mg, 0.01 mmol, 0.1 equiv). Benzene (0.2 mL) 
was added, and the vial was capped and stirred at 45˚C for 10 mins. Separately, to a ½ dram 
borosilicate vial with stir bar was added Zn(OAc)2 dihydrate (11 mg, 0.05 mmol, 0.5 equiv), 2,6-
dimethylbenzoquinone (20 mg, 0.15 mmol, 1.5 equiv) and 30 (47 mg, 0.20 mmol, 2 equiv). The 
catalyst solution was subsequently added to the reaction flask, and benzene (0.4 mL) was used to 
rinse the catalyst vial, also transferred and added to the reaction flask. Allylbenzene (13.0 µL, 
0.10 mmol, 1 equiv) was added. The ½ dram vial was sealed with a Teflon cap, and allowed to 
stir for 72 hours at 5˚C.  Afterward, the reaction mixture was directly subjected to flash column 
chromatography (1%→2% EtOAc/hexanes) to provide product as a white film. Run 1 (29.8 mg, 
85% yield, 74% ee); Run 2 (29.4 mg, 84% yield, 74% ee) Average: 85% Yield, 74% ee.  
 
Entry 2: Reaction proceeded according to the General procedure for Entry 1 using ligand L19 
(4.4 mg, 0.01 mmol, 0.1 equiv). Run 1 (31.3 mg, 89% yield, 70% ee); Run 2 (32.2 mg, 92% 
yield, 70% ee); Average: 91% Yield, 70% ee.  
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Entry 3: Reaction proceeded according to the General procedure for Entry 1 using ligand L20 
(4.5 mg, 0.01 mmol, 0.1 equiv). Run 1 (31.6 mg, 90% yield, 89% ee); Run 2 (30.1 mg, 86% 
yield, 89% ee); Average: 88% Yield, 89% ee.  
 
Entry 4: Reaction proceeded according to the General procedure for Entry 1 using ligand L21 
(5.2 mg, 0.01 mmol, 0.1 equiv). Run 1 (33.2 mg, 95% yield, 92% ee); Run 2 (32.6 mg, 93% 
yield, 92% ee); Average: 94% Yield, 91% ee.  
 
Reaction Development with β-Ketoester 31 (Table 7) 
Entry 1: General procedure: To a ½ dram borosilicate vial with stir bar was added ligand L20 
(5.2 mg, 0.01 mmol, 0.1 equiv) and Pd(OAc)2 (2.2 mg, 0.01 mmol, 0.1 equiv). Dioxane (0.3 mL) 
was added, and the vial was capped and stirred at 45˚C for 10 mins. Separately, to a ½ dram 
borosilicate vial with stir bar was added Zn(OAc)2 dihydrate (11 mg, 0.05 mmol, 0.5 equiv), 2,6-
dimethylbenzoquinone (20 mg, 0.15 mmol, 1.5 equiv) and 31 (45 mg, 0.20 mmol, 2 equiv). The 
catalyst solution was subsequently added to the reaction flask, and dioxane (0.3 mL) was used to 
rinse the catalyst vial, also transferred and added to the reaction flask. The vial was sealed with a 
Teflon cap, cooled to 5˚C in a cold room for 10 min. Allylbenzene (13 µL, 0.1 mmol) was added 
via syringe, and the reaction vial was again capped and stirred for 72 hours at 5˚C.  
Subsequently, the reaction mixture was directly subjected to flash column chromatography 
(10%→20%→30%→50% EtOAc/hexanes) to provide the alkylated product as a clear oil: 27.9 
mg, 81% yield, 87% ee. 
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Entry 2: Reaction proceeded according to the General procedure for Entry 1 using ligand L21: 
30.7 mg, 89% yield, 86% ee. 
 
Entry 3: Reaction proceeded according to the General procedure for Entry 5 using ligand L10 
(6.1 mg, 0.01 mmol, 0.1 equiv). Run 1 (19.9 mg, 58% yield, 90% ee); Run 2 (24.4 mg, 71% 
yield, 90% ee); Run 3 (23.8 mg, 69% yield, 90% ee). Average: 66% yield, 90% ee. 
 
Reaction Scope with 2-Nitrotetralone (Table 8) 
General procedure: To a ½ dram borosilicate vial with stir bar was added ligand L17 (8.4 mg, 
0.02 mmol, 0.1 equiv) or L19 (8.7 mg, 0.02 mmol, 0.1 equiv) and Pd(OAc)2 (4.5 mg, 0.02 mmol, 
0.1 equiv). Benzene (0.4 mL) was added, and the vial was capped and stirred at 45˚C for 10 
mins. Separately, to a 1 dram borosilicate vial with stir bar was added 28 (76.5 mg, 0.40 mmol, 2 
equiv), 2,6-dimethylbenzoquinone (40 mg, 0.3 mmol, 1.5 equiv) and Zn(OAc)2 dihydrate (22 
mg, 0.1 mmol, 0.5 equiv). The catalyst solution was subsequently added to the reaction flask, 
and benzene (0.2 mL) and dioxane (0.6 mL) was used to rinse the catalyst vial, also transferred 
and added to the reaction flask. Allylarene (0.20 mmol, 1 equiv) was added. The 1 dram vial was 
sealed with a Teflon cap, and allowed to stir for 72 hours at 5˚C.  Afterward, the reaction was 
diluted with 20 mL EtOAc, which was washed by saturated NaHSO3 (aq.) solution (10 mL) or 
5% K2CO3 (aq.) solution (10 mL) (NOTE: The purpose of aqueous wash is for the ease of 
purification. NaHSO3 was used to remove remaining DMBQ oxidant, whereas K2CO3 was used 
to remove remaining nitroketone nucleophile). The organic layer was separated, dried over 
anhydrous MgSO4 and filtered. The solvent was removed under reduced pressure, and the 
remaining mixture was purified by flash column chromatography to provide product.  
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(R,E)-2-nitro-2-(3-(p-tolyl)allyl)-3,4-dihydronaphthalen-1(2H)-one (32a): 4-allyltoluene 
(26.4 mg, 0.20 mmol, 1 equiv) was reacted according to the general procedure using L19 with 
NaHSO3 work up. Purification by flash column chromatography (2%→5% EtOAc/hexanes) 
provided the product as a yellow oil. Run 1 (38.6 mg, 60% yield, 92% ee); Run 2 (36.0 mg, 56% 
yield, 92% ee); Run 3 (41.4 mg, 64% yield, 92% ee). Average: 60% (±4.2%) yield, 92% ee. 
The enantiomeric excess was determined by chiral HPLC analysis (CHIRALPAK AD-RH 
column, 0.5 mL/min, 55% MeCN in H2O, λ = 254 nm): tR(major) = 43.343 min, tR(minor) = 
46.711 min. 1H NMR (500 MHz, Chloroform-d) δ 8.15 (d, J = 8.0 Hz, 1H), 7.58 (t, J = 7.6 Hz, 
1H), 7.41 (t, J = 7.6 Hz, 1H), 7.30 – 7.27 (m, 3H), 7.14 (d, J = 7.7 Hz, 2H), 6.57 (d, J = 15.8 Hz, 
1H), 6.12 (dt, J = 15.3, 7.4 Hz, 1H), 3.25 (ddd, J = 14.5, 7.3, 1.4 Hz, 1H), 3.17 – 3.10 (m, 2H), 
3.08 – 2.96 (m, 2H), 2.53 (ddd, J = 14.1, 8.9, 4.8 Hz, 1H), 2.36 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δ 187.97, 142.35, 137.84, 135.89, 134.54, 133.64, 130.72, 129.29, 128.91, 128.83, 
127.45, 126.30, 120.50, 93.93, 38.06, 31.66, 25.25, 21.20. HRMS (ESI) m/z calc’d for 
C20H19NO3 [M+Na]+: 344.1263; found 344.1269. [α]23D = +6.4 (c = 1.1, CHCl3). 
 
 
(R,E)-2-(3-(4-methoxyphenyl)allyl)-2-nitro-3,4-dihydronaphthalen-1(2H)-one (32b): 4-
allylanisole (30.0 mg, 0.20 mmol, 1 equiv) was reacted according to the general procedure using 
L17 with K2CO3 work up. Purification by flash column chromatography (20%→30%→50% 
DCM/hexanes) provided the product as a colorless oil. Run 1 (35.4 mg, 53% yield, 90% ee); Run 
103 
 
2 (36.4 mg, 54% yield, 90% ee); Run 3 (31.7 mg, 47% yield, 90% ee). Average: 51% (±3.7%) 
yield, 90% ee. The enantiomeric excess was determined by chiral HPLC analysis (CHIRALPAK 
AD-RH column, 0.5 mL/min, 55% MeCN in H2O, λ = 254 nm): tR(major) = 36.912 min, 
tR(minor) = 40.779 min. 1H NMR (500 MHz, Chloroform-d) δ 8.11 (d, J = 7.7 Hz, 1H), 7.54 (t, J 
= 7.5 Hz 1H), 7.38 (t, J = 7.6 Hz, 1H), 7.29 – 7.23 (m, 3H), 6.83 (d, J = 8.6 Hz, 2H), 6.51 (d, J = 
15.7 Hz, 1H), 6.00 (dt, J = 15.3, 7.4 Hz, 1H), 3.80 (s, 3H), 3.20 (ddd, J = 14.4, 7.2, 1.3 Hz, 1H), 
3.14 – 3.06 (m, 2H), 3.05 – 2.92 (m, 2H), 2.50 (ddd, J = 14.1, 8.8, 4.8 Hz, 1H). 13C NMR (126 
MHz, CDCl3) δ 188.00, 159.45, 142.35, 135.42, 134.53, 130.73, 129.24, 128.91, 128.82, 127.60, 
127.45, 119.24, 114.00, 93.98, 55.30, 38.09, 31.64, 25.26. HRMS (ESI) m/z calc’d for 
C20H19NO4 [M+Na]+: 360.1212; found 360.1218. [α]22D = +7.1 (c = 1, CHCl3). 
 
 
 (R,E)-2-(3-(4-bromophenyl)allyl)-2-nitro-3,4-dihydronaphthalen-1(2H)-one (32c): 4-
bromoallylbenzene (39.4 mg, 0.20 mmol, 1 equiv) was reacted according to the general 
procedure using L19 with NaHSO3 work up. Purification by flash column chromatography 
(5%→8% EtOAc/hexanes) provided the product as a white solid. Run 1 (49.5 mg, 64% yield, 
92% ee); Run 2 (51.3 mg, 66% yield, 92% ee); Run 3 (52.5 mg, 68% yield, 92% ee). Average: 
66% (±2.0%) yield, 92% ee. The enantiomeric excess was determined by chiral HPLC analysis 
(CHIRALPAK AD-RH column, 0.5 mL/min, 60% MeCN in H2O, λ = 280 nm): tR(major) = 
37.178 min, tR(minor) = 43.913 min. 1H NMR (500 MHz, Chloroform-d) δ 8.11 (d, J = 7.9 Hz, 
1H), 7.55 (t, J = 7.5 Hz, 1H), 7.41 (d, J = 8.5 Hz, 2H), 7.38 (t, J = 8.2 Hz, 1H), 7.26 (d, J = 7.7 
Hz, 1H), 7.20 (d, J = 8.5 Hz, 2H), 6.50 (d, J = 15.8 Hz, 1H), 6.17 (dt, J = 15.7, 7.4 Hz, 1H), 3.20 
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(ddd, J = 14.4, 7.2, 1.4 Hz, 1H), 3.15 – 3.06 (m, 2H), 3.05 – 2.91 (m, 2H), 2.47 (ddd, J = 14.2, 
9.1, 4.7 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 187.82, 142.25, 135.34, 134.79, 134.61, 131.70, 
130.71, 128.93, 128.83, 127.93, 127.51, 122.56, 121.74, 93.72, 38.12, 31.91, 25.24; HRMS 
(ESI) m/z calc’d for C19H16BrNO3 [M+Na]+: 408.0211; found 408.0222. [α]23D = +20.8 (c = 
1.43, CHCl3). 
 
 
Methyl (R,E)-4-(3-(2-nitro-1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)prop-1-en-1-
yl)benzoate (32d): Methyl 4-allylbenzoate (35.2 mg, 0.20 mmol, 1 equiv) was reacted according 
to the general procedure using L17 with K2CO3 work up. Purification by flash column 
chromatography (8%→10%→15% EtOAc/hexanes) provided the product as a colorless oil. Run 
1 (49.2 mg, 67% yield, 90% ee); Run 2 (47.5 mg, 65% yield, 90% ee); Run 3 (52.5 mg, 72% 
yield, 90% ee). Average: 68% (±3.5%) yield, 90% ee. The enantiomeric excess was 
determined by chiral HPLC analysis (CHIRALCEL OJ-H column, 1 mL/min, 40% isopropanol 
in hexane, λ = 280 nm): tR(major) = 22.985 min, tR(minor) = 34.484 min. 1H NMR (500 MHz, 
Chloroform-d) δ 8.11 (d, J = 7.4 Hz, 1H), 7.96 (d, J = 8.3 Hz, 2H), 7.55 (t, J = 7.5 Hz, 1H), 7.42 
– 7.35 (m, 3H), 7.26 (d, J = 7.5 Hz, 1H), 6.60 (d, J = 15.6 Hz, 1H), 6.30 (dt, J = 15.4, 7.4 Hz, 
1H), 3.90 (s, 3H), 3.24 (dd, J = 14.1, 7.1 Hz, 1H), 3.16 – 3.07 (m, 2H), 3.05 – 2.93 (m, 2H), 2.48 
(ddd, J = 14.3, 9.1, 4.5 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 187.76, 166.75, 142.24, 140.77, 
135.07, 134.64, 130.68, 129.94, 129.34, 128.94, 128.83, 127.52, 126.30, 124.56, 93.70, 52.11, 
38.18, 31.97, 25.24. HRMS (ESI) m/z calc’d for C21H19NO5 [M+H]+: 366.1341; found 
366.1331. [α]23D = +24.8 (c = 0.72, CHCl3). 
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(R,E)-2-(3-(4-(hydroxymethyl)phenyl)allyl)-2-nitro-3,4-dihydronaphthalen-1(2H)-one 
(32e): (4-allylphenyl)methanol (30.0 mg, 0.20 mmol, 1 equiv) was reacted according to the 
general procedure using L19 with K2CO3 work up. Purification by flash column 
chromatography (15%→20%→30% Acetone/hexanes) provided the product as a colorless oil. 
Run 1 (41.9 mg, 62% yield, 91% ee); Run 2 (44.3 mg, 66% yield, 91% ee); Run 3 (45.0 mg, 67% 
yield, 91% ee). Average: 65% (±2.4%) yield, 91% ee. The enantiomeric excess was 
determined by chiral HPLC analysis (CHIRALCEL OJ-H column, 1 mL/min, 40% isopropanol 
in hexane, λ = 260 nm): tR(major) = 11.964 min, tR(minor) = 18.490 min. 1H NMR (500 MHz, 
Chloroform-d) δ 8.11 (d, J = 7.2 Hz, 1H), 7.55 (t, J = 7.5 Hz, 1H), 7.38 (t, J = 7.6 Hz, 1H), 7.33 
(d, J = 8.2 Hz, 2H), 7.29 (d, J = 8.1 Hz, 2H), 7.26 (d, J = 7.7 Hz, 1H), 6.56 (d, J = 15.7 Hz, 1H), 
6.16 (dt, J = 15.4, 7.4 Hz, 1H), 4.66 (s, 2H), 3.22 (ddd, J = 14.5, 7.2, 1.4 Hz, 1H), 3.15 – 3.07 
(m, 2H), 3.06 – 2.93 (m, 2H), 2.49 (ddd, J = 14.1, 8.9, 4.7 Hz, 1H), 1.74 (br, 1H). 13C NMR (126 
MHz, CDCl3) δ 187.94, 142.32, 140.62, 135.85, 135.61, 134.59, 130.70, 128.93, 128.83, 127.48, 
127.22, 126.59, 121.70, 93.88, 65.02, 38.09, 31.77, 25.25. HRMS (ESI) m/z calc’d for 
C20H19NO4 [M+Na]+: 360.1212; found 360.1213. [α]23D = +14.7 (c = 1.6, CHCl3). 
 
 
(R,E)-6-(3-(2-nitro-1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)prop-1-en-1-yl)-2H-chromen-
2-one (32f): 6-allyl-2H-chromen-2-one (37.2 mg, 0.20 mmol, 1 equiv) was reacted according to 
the general procedure using L19 with K2CO3 work up. Purification by flash column 
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chromatography (15%→35% EtOAc/hexanes) provided the product as a white solid. Run 1 (47.8 
mg, 64% yield, 90% ee); Run 2 (50.5 mg, 67% yield, 90% ee); Run 3 (47.2 mg, 63% yield, 90% 
ee). Average: 65% (±2.3%) yield, 90% ee. The enantiomeric excess was determined by chiral 
HPLC analysis (CHIRALPAK OJ-H column, 1 mL/min, 50% isopropanol in hexanes, λ = 254 
nm): tR(major) = 21.454 min, tR(minor) = 32.135 min. 1H NMR (500 MHz, Chloroform-d) δ 8.12 
(d, J = 7.9 Hz, 1H), 7.67 (d, J = 9.6 Hz, 1H), 7.55 (t, J = 7.5 Hz, 1H), 7.50 (dd, J = 8.6, 2.1 Hz, 
1H), 7.42 (d, J = 2.1 Hz, 1H), 7.39 (t, J = 7.7 Hz, 1H), 7.29 – 7.23 (m, 2H), 6.61 – 6.53 (d, J = 
15.8 Hz, 1H), 6.42 (d, J = 9.5 Hz, 1H), 6.21 (dt, J = 15.8, 7.4 Hz, 1H), 3.23 (ddd, J = 14.3, 7.2, 
1.4 Hz, 1H), 3.17 – 3.08 (m, 2H), 3.07 – 2.95 (m, 2H), 2.48 (ddd, J = 14.3, 9.3, 4.5 Hz, 1H); 13C 
NMR (126 MHz, CDCl3) δ 187.80, 160.52, 153.55, 143.21, 142.20, 134.66, 134.01, 133.07, 
130.73, 129.76, 128.94, 128.82, 127.54, 125.40, 122.95, 118.87, 117.14, 117.11, 93.73, 38.20, 
32.12, 25.25; HRMS (ESI) m/z calculated for C22H17NO5 [M+H]+: 376.1185, found 376.1176. 
[α]22D = +30.6 (c = 0.81, CHCl3). 
 
 
(R,E)-2-(3-(2,2-dimethyl-2H-chromen-6-yl)allyl)-2-nitro-3,4-dihydronaphthalen-1(2H)-one 
(32g): 6-allyl-2,2-dimethyl-2H-chromene (40.0 mg, 0.20 mmol, 1 equiv) was reacted according 
to the general procedure using L19 with K2CO3 work up. Purification by flash column 
chromatography (2%→5% EtOAc/hexanes) provided the product as a yellow oil. Run 1 (49.8 
mg, 64% yield, 93% ee); Run 2 (52.7 mg, 68% yield, 93% ee); Run 3 (49.1 mg, 63% yield, 93% 
ee). Average: 65% (±2.5%) yield, 93% ee. The enantiomeric excess was determined by chiral 
HPLC analysis (CHIRALPAK AD-RH column, 0.5 mL/min, 65% MeCN in H2O, λ = 254 nm): 
107 
 
tR(major) = 23.538 min, tR(minor) = 29.110 min. 1H NMR (500 MHz, Chloroform-d) δ 8.11 (d, J 
= 7.9 Hz, 1H), 7.54 (t, J = 7.5 Hz, 1H), 7.38 (t, J = 7.7 Hz, 1H), 7.25 (d, J = 6.9 Hz, 1H), 7.08 
(dd, J = 8.3, 2.2 Hz, 1H), 6.97 (d, J = 2.2 Hz, 1H), 6.70 (d, J = 8.3 Hz, 1H), 6.46 (d, J = 15.8 Hz, 
1H), 6.29 (d, J = 9.9 Hz, 1H), 5.97 (dt, J = 15.7, 7.5 Hz, 1H), 5.62 (d, J = 9.8 Hz, 1H), 3.19 (ddd, 
J = 14.3, 7.3, 1.3 Hz, 1H), 3.15 – 2.92 (m, 4H), 2.49 (ddd, J = 14.1, 8.9, 4.8 Hz, 1H), 1.41 (s, 
6H); 13C NMR (126 MHz, CDCl3) δ 188.00, 152.94, 142.35, 135.47, 134.52, 131.19, 130.73, 
129.26, 128.90, 128.82, 127.44, 127.35, 124.07, 122.05, 121.23, 119.06, 116.40, 93.98, 76.50, 
38.08, 31.65, 28.01, 25.26 ; HRMS (EI) m/z calculated for C24H23NO4 [M]+: 389.16271, found 
389.16269. [α]22D = +2.8 (c = 1.26, CHCl3). 
 
 
 (R,E)-2-(3-(benzofuran-5-yl)allyl)-2-nitro-3,4-dihydronaphthalen-1(2H)-one (32h): 5-
allylbenzofuran (32.0 mg, 0.20 mmol, 1 equiv) was reacted according to the general procedure 
using L19 with K2CO3 work up. Purification by flash column chromatography (2%→8% 
EtOAc/hexanes) provided the product as a yellow oil. Run 1 (38.2 mg, 55% yield, 92% ee); Run 
2 (48.8 mg, 70% yield, 92% ee); Run 3 (46.1 mg, 66% yield, 92% ee). Average: 64% (±7.9%) 
yield, 92% ee. The enantiomeric excess was determined by chiral HPLC analysis (CHIRALPAK 
OJ-H column, 1 mL/min, 40% isopropanol in hexanes, λ = 254 nm): tR(major) = 17.595 min, 
tR(minor) = 28.628 min. 1H NMR (500 MHz, Chloroform-d) δ 8.13 (d, J = 7.9 Hz, 1H), 7.60 (d, 
J = 2.2 Hz, 1H), 7.57 – 7.52 (m, 2H), 7.42 (d, J = 8.5 Hz, 1H), 7.38 (t, J = 7.7 Hz, 1H), 7.31 (d, J 
= 8.6 Hz, 1H), 7.26 (d, J = 7.5 Hz, 1H), 6.73 (d, J = 2.2 Hz, 1H), 6.66 (d, J = 15.8 Hz, 1H), 6.13 
(dt, J = 15.8, 7.4 Hz, 1H), 3.24 (ddd, J = 14.3, 7.2, 1.4 Hz, 1H), 3.16 – 3.07 (m, 2H), 3.06 – 2.95 
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(m, 2H), 2.55 – 2.47 (m, 1H); 13C NMR (126 MHz, CDCl3) δ 188.00, 154.75, 145.61, 142.35, 
136.13, 134.56, 131.58, 130.73, 128.93, 128.82, 127.78, 127.46, 122.89, 120.43, 119.16, 111.44, 
106.64, 93.98, 38.11, 31.73, 25.27; HRMS (ESI) m/z calculated for C21H17NO4 [M+Na]+: 
370.1055, found 370.1065. [α]22D = +26.8 (c = 1.33, CHCl3). 
 
 
(R,E)-2-(3-(benzo[b]thiophen-5-yl)allyl)-2-nitro-3,4-dihydronaphthalen-1(2H)-one (32i): 5-
allylbenzothiophene (35.0 mg, 0.20 mmol, 1 equiv) was reacted according to the general 
procedure using L19 with K2CO3 work up. Purification by flash column chromatography 
(2%→8% EtOAc/hexanes) provided the product as a white solid. Run 1 (41.3 mg, 57% yield, 
92% ee); Run 2 (42.8 mg, 59% yield, 92% ee); Run 3 (41.2 mg, 57% yield, 92% ee). Average: 
57% yield, 92% ee. The enantiomeric excess was determined by chiral HPLC analysis 
(CHIRALPAK AD-RH column, 0.5 mL/min, 65% MeCN in H2O, λ = 254 nm): tR(major) = 
31.236 min, tR(minor) = 38.111 min. 1H NMR (500 MHz, Chloroform-d) δ 8.13 (d, J = 8.0 Hz, 
1H), 7.79 (d, J = 8.4 Hz, 1H), 7.75 (s, 1H), 7.55 (t, J = 7.5 Hz, 1H), 7.43 (d, J = 5.5 Hz, 1H), 
7.41 – 7.35 (m, 2H), 7.30 (d, J = 5.5 Hz, 1H), 7.26 (d, J = 7.6 Hz, 1H), 6.68 (d, J = 15.7 Hz, 1H), 
6.22 (dt, J = 15.7, 7.4 Hz, 1H), 3.26 (ddd, J = 14.2, 7.2, 1.3 Hz, 1H), 3.15 (ddd, J = 14.3, 7.6, 1.3 
Hz, 1H), 3.12 – 3.08 (m, 1H), 3.05 – 2.96 (m, 2H), 2.57 – 2.47 (m, 1H); 13C NMR (126 MHz, 
CDCl3) δ 187.95, 142.32, 139.96, 139.23, 136.07, 134.56, 132.85, 130.74, 128.92, 128.85, 
127.48, 127.09, 123.87, 122.54, 122.43, 121.73, 121.24, 93.91, 38.18, 31.79, 25.27; HRMS 
(ESI) m/z calculated for C21H17NO3S [M+H]+: 364.0983, found 364.0997. [α]22D: +9.4 (c = 1.04, 
CHCl3). 
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Tert-butyl (R,E)-5-(3-(2-nitro-1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)prop-1-en-1-yl)-1H-
indole-1-carboxylate (32j): Tert-butyl 5-allyl-1H-indole-1-carboxylate 5-allylbenzofuran (51.4 
mg, 0.20 mmol, 1 equiv) was reacted according to the general procedure using L19 with K2CO3 
work up. Purification by flash column chromatography (2%→5% EtOAc/hexanes) provided the 
product as a yellow oil. Run 1 (56.2 mg, 63% yield, 92% ee); Run 2 (56.2 mg, 63% yield, 92% 
ee); Run 3 (56.3 mg, 63% yield, 92% ee). Average: 63% (±0.1%) yield, 92% ee. The 
enantiomeric excess was determined by chiral HPLC analysis (CHIRALPAK OJ-H column, 1 
mL/min, 20% isopropanol in hexanes, λ = 254 nm): tR(major) = 16.544 min, tR(minor) = 25.050 
min. 1H NMR (500 MHz, Chloroform-d) δ 8.13 (d, J = 8.0 Hz, 1H), 8.05 (d, J = 8.6 Hz, 1H), 
7.60 – 7.52 (m, 2H), 7.51 (d, J = 1.7 Hz, 1H), 7.38 (t, J = 7.6 Hz, 1H), 7.32 (dd, J = 8.7, 1.8 Hz, 
1H), 7.26 (d, J = 7.5 Hz, 1H), 6.66 (d, J = 15.8 Hz, 1H), 6.52 (d, J = 3.7 Hz, 1H), 6.14 (dt, J = 
15.7, 7.4 Hz, 1H), 3.24 (ddd, J = 14.4, 7.3, 1.3 Hz, 1H), 3.17 – 3.08 (m, 2H), 3.07 – 2.94 (m, 
2H), 2.53 (ddd, J = 14.1, 8.8, 4.5 Hz, 1H), 1.66 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 188.00, 
149.59, 142.36, 136.33, 134.88, 134.53, 131.20, 130.84, 130.74, 128.91, 128.84, 127.45, 126.53, 
122.69, 120.20, 118.96, 115.19, 107.31, 93.99, 83.82, 38.14, 31.69, 28.20, 25.28; HRMS (ESI): 
m/z calculated for C26H26N2O5 [M+H]+: 447.1920, found 447.1923. [α]22D = +2.5 (c = 1.57, 
CHCl3). 
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Tert-butyl (R,E)-3-(3-(2-nitro-1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)prop-1-en-1-yl)-1H-
indole-1-carboxylate (32k): Tert-butyl 3-allyl-1H-indole-1-carboxylate (51.4 mg, 0.2 mmol, 1 
equiv) was reacted according to the general procedure using L19 with K2CO3 work up. 
Purification by flash column chromatography (2%→5% EtOAc/hexanes) provided the product as 
a clear oil. Run 1 (49.2 mg, 55% yield, 91% ee); Run 2 (48.7 mg, 55% yield, 91% ee); Run 3 
(47.7 mg, 53% yield, 91% ee). Average: 54% (±0.9%) yield, 91% ee. The enantiomeric excess 
was determined by chiral HPLC analysis (CHIRALPAK AD-RH column, 0.5 mL/min, 65% 
MeCN in H2O, λ = 254 nm): tR(major) = 23.775 min, tR(minor) = 29.914 min. 1H NMR (500 
MHz, Chloroform-d) δ 8.16 (d, J = 8.2 Hz, 1H), 8.13 (d, J = 8.0 Hz, 1H), 7.69 (d, J = 7.8 Hz, 
1H), 7.59 (s, 1H), 7.55 (t, J = 7.5 Hz, 1H), 7.38 (t, J = 7.6 Hz, 1H), 7.33 (dd, J = 8.4, 7.2 Hz, 
1H), 7.29 – 7.24 (m, 2H), 6.67 (d, J = 15.9 Hz, 1H), 6.23 (dt, J = 15.9, 7.4 Hz, 1H), 3.27 (ddd, J 
= 14.3, 7.2, 1.3 Hz, 1H), 3.17 – 3.08 (m, 2H), 3.08 – 2.96 (m, 2H), 2.57 – 2.48 (m, 1H), 1.67 (s, 
9H); 13C NMR (126 MHz, CDCl3) δ 188.00, 149.48, 142.32, 135.87, 134.57, 130.75, 128.93, 
128.84, 128.42, 127.47, 127.28, 124.77, 124.07, 123.02, 121.85, 119.82, 117.99, 115.39, 93.98, 
83.99, 38.72, 31.78, 28.20, 25.28; HRMS (ESI) m/z calculated for C26H26N2O5 [M+H]+: 
447.1920, found 447.1916. [α]22D = +13.2 (c = 1.59, CHCl3). 
 
 
(R)-2-cinnamyl-5-methoxy-2-nitro-3,4-dihydronaphthalen-1(2H)-one (32l): 5-methoxy-2-
nitro-3,4-dihydronaphthalen-1(2H)-one (88.5 mg, 0.4 mmol, 2 equiv) was reacted with 
allylbenzene (26.0 µL, 0.20 mmol, 1 equiv) according to the general procedure using L19 with 
NaHSO3 work up. Purification by flash column chromatography (2%→5%→10% 
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EtOAc/hexanes) provided the product as a clear oil. Run 1 (43.7 mg, 65% yield, 89% ee); Run 2 
(44.8 mg, 66% yield, 90% ee); Run 3 (46.9 mg, 70% yield, 90% ee). Average: 67% (±2.4%) 
yield, 90% ee. The enantiomeric excess was determined by chiral HPLC analysis (CHIRALPAK 
AD-RH column, 0.5 mL/min, 55% MeCN in H2O, λ = 254 nm): tR(major) = 37.080 min, 
tR(minor) = 57.154 min. 1H NMR (500 MHz, Chloroform-d) δ 7.71 (d, J = 7.9 Hz, 1H), 7.35 (m, 
3H), 7.30 (t, J = 7.6 Hz, 2H), 7.24 (t, J = 7.1 Hz, 1H), 7.07 (d, J = 8.1 Hz, 1H), 6.57 (d, J = 15.6 
Hz, 1H), 6.17 (dt, J = 15.4, 7.4 Hz, 1H), 3.87 (s, 3H), 3.22 (ddd, J = 14.6, 7.3, 1.4 Hz, 1H), 3.05 
(ddd, J = 14.6, 7.8, 1.3 Hz, 1H), 3.01 – 2.90 (m, 3H), 2.49 – 2.39 (m, 1H). 13C NMR (126 MHz, 
CDCl3) δ 188.32, 156.68, 136.46, 135.92, 131.54, 131.35, 128.59, 127.89, 127.83, 126.41, 
121.69, 120.12, 115.14, 93.86, 55.75, 37.77, 30.79, 19.42. HRMS (ESI) m/z calculated for 
C20H19NO4 [M+Na]+: 360.1212, found 360.1216. [α]22D = +19.3 (c = 1, CHCl3). 
 
 
 (R)-6-bromo-2-cinnamyl-2-nitro-3,4-dihydronaphthalen-1(2H)-one (32m): 6-bromo-2-nitro-
3,4-dihydronaphthalen-1(2H)-one (108 mg, 0.4 mmol, 2 equiv) was reacted with allylbenzene 
(26.0 µL, 0.20 mmol, 1 equiv) according to the general procedure in benzene (0.8 mL)/dioxane 
(0.8 mL)* using L19 with NaHSO3 work up. Purification by flash column chromatography 
(0%→20%→30% DCM/hexanes) provided the product as a clear oil. Run 1 (49.2 mg, 64% 
yield, 90% ee); Run 2 (47.8 mg, 62% yield, 90% ee); Run 3 (51.3 mg, 66% yield, 90% ee). 
Average: 64% (±2.3%) yield, 90% ee. The enantiomeric excess was determined by chiral 
HPLC analysis (CHIRALPAK AD-RH column, 0.5 mL/min, 70% MeCN in H2O, λ = 280 nm): 
tR(major) = 18.295 min, tR(minor) = 21.638 min. 1H NMR (500 MHz, Chloroform-d) δ 7.97 (d, J 
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= 8.5 Hz, 1H), 7.52 (d, J = 8.5 Hz, 1H), 7.45 (s, 1H), 7.36 – 7.28 (m, 4H), 7.24 (t, J = 7.1 Hz, 
1H), 6.57 (d, J = 15.7 Hz, 1H), 6.13 (dt, J = 15.4, 7.4 Hz, 1H), 3.20 (ddd, J = 14.3, 7.3, 1.4 Hz, 
1H), 3.11 (ddd, J = 14.3, 7.6, 1.3 Hz, 1H), 3.06 (m, 1H), 3.02 – 2.89 (m, 2H), 2.47 (ddd, J = 
14.3, 9.4, 5.8 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 187.08, 143.87, 136.31, 136.23, 131.86, 
131.05, 130.37, 130.08, 129.61, 128.62, 128.01, 126.41, 121.30, 93.50, 38.14, 31.61, 24.99. 
HRMS (ESI) m/z calculated for C19H16BrNO3 [M+H]+: 386.0392, found 386.0381. [α]22D = 
+43.6 (c = 0.52, CHCl3); *NOTE: while running at standard molarity (0.17 M) gave inconsistent 
enantioselectivities (88%-90%), running at slightly diluted molarity (0.12 M) resolved the issue, 
possibly due to improved homogeneity. 
 
 
(R)-6-cinnamyl-6-nitro-5-oxo-5,6,7,8-tetrahydronaphthalen-2-yl pivalate (32n): 6-nitro-5-
oxo-5,6,7,8-tetrahydronaphthalen-2-yl pivalate (116.5 mg, 0.4 mmol, 2 equiv) was reacted with 
allylbenzene (26.0 µL, 0.20 mmol, 1 equiv) according to the general procedure using L19 with 
NaHSO3 work up. Purification by flash column chromatography (2%→5%→10%  
EtOAc/hexanes) provided the product as a clear oil. Run 1 (47.2 mg, 58% yield, 93% ee); Run 2 
(45.2 mg, 55% yield, 93% ee); Run 3 (49.7 mg, 61% yield, 92% ee). Average: 58% (±2.8%) 
yield, 93% ee. The enantiomeric excess was determined by chiral HPLC analysis (CHIRALPAK 
AD-RH column, 0.5 mL/min, 60% MeCN in H2O, λ = 260 nm): tR(major) = 33.431 min, 
tR(minor) = 44.185 min. 1H NMR (500 MHz, Chloroform-d) δ 8.15 (d, J = 8.6 Hz, 1H), 7.33 (d, 
J = 7.2 Hz, 2H), 7.29 (t, J = 7.4 Hz, 2H), 7.24 (t, J = 7.1 Hz, 1H), 7.08 (dd, J = 8.6, 2.3 Hz, 1H), 
7.01 (d, J = 2.2 Hz, 1H), 6.57 (d, J = 15.8 Hz, 1H), 6.14 (dt, J = 15.5, 7.4 Hz, 1H), 3.23 (dd, J = 
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14.5, 7.0 Hz, 1H), 3.14 – 3.06 (m, 2H), 3.03 - 2.92 (m, 2H), 2.50 (m, 1H), 1.37 (s, 9H). 13C NMR 
(126 MHz, CDCl3) δ 186.86, 176.37, 155.89, 144.21, 136.36, 136.11, 130.81, 128.61, 128.20, 
127.95, 126.42, 121.56, 121.48, 121.14, 93.72, 39.29, 38.04, 31.64, 27.05, 25.33. HRMS (ESI) 
m/z calculated for C24H25NO5 [M+H]+: 408.1811, found 408.1805. [α]23D = +16.1 (c = 0.64, 
CHCl3). 
 
 
(R)-6-(benzyloxy)-2-cinnamyl-2-nitro-3,4-dihydronaphthalen-1(2H)-one (32o): 6-
(benzyloxy)-2-nitro-3,4-dihydronaphthalen-1(2H)-one (60 mg, 0.2 mmol, 2 equiv) was reacted 
with allylbenzene (13.0 µL, 0.10 mmol, 1 equiv) according to the general procedure using L19 
without work up (directly dry-loaded onto column). Purification by flash column 
chromatography (5%→10% EtOAc/hexanes) provided the product as a clear oil. Run 1 (19.5 
mg, 47% yield, 88% ee); Run 2 (20.2 mg, 49% yield, 88% ee); Run 3 (20.0 mg, 48% yield, 88% 
ee). Average: 48% (±0.9%) yield, 88% ee. Reaction at 25oC: Run 4 (32.4 mg, 78% yield, 
84% ee). The enantiomeric excess was determined by chiral HPLC analysis (CHIRALPAK AD-
RH column, 0.5 mL/min, 70% MeCN in H2O, λ = 254 nm): tR(major) = 28.220 min, tR(minor) = 
33.725 min. 1H NMR (500 MHz, Chloroform-d) δ 8.09 (d, J = 8.8 Hz, 1H), 7.44 – 7.28 (m, 9H), 
7.24 (t, J = 7.3 Hz, 1H), 6.97 (dd, J = 8.8, 2.4 Hz, 1H), 6.77 (d, J = 2.5 Hz, 1H), 6.57 (d, J = 15.6 
Hz, 1H), 6.15 (dt, J = 15.3, 7.4 Hz, 1H), 5.13 (s, 2H), 3.22 (dd, J = 14.4, 7.2 Hz, 1H), 3.10 (dd, J 
= 14.5, 7.4 Hz, 1H), 3.05 (dt, J = 11.0, 5.0 Hz, 1H), 3.00 – 2.90 (m, 2H), 2.51 – 2.43 (m, 1H). 
13C NMR (126 MHz, CDCl3) δ 186.48, 163.69, 144.98, 136.46, 135.87, 135.81, 131.47, 128.76, 
128.59, 128.38, 127.88, 127.45, 126.39, 124.26, 121.89, 114.90, 113.61, 93.78, 70.28, 38.17, 
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31.72, 25.60. HRMS (ESI) m/z calculated for C26H23NO4 [M+H]+: 414.1705, found 414.1720. 
[α]22D = +65.7 (c = 1, CHCl3). 
 
 
(R)-2-cinnamyl-7-methoxy-2-nitro-3,4-dihydronaphthalen-1(2H)-one (32p): 7-methoxy-2-
nitro-3,4-dihydronaphthalen-1(2H)-one (88.5 mg, 0.4 mmol, 2 equiv) was reacted with 
allylbenzene (26.0 µL, 0.20 mmol, 1 equiv) according to the general procedure using L7 without 
work up (directly dry-loaded onto column). Purification by flash column chromatography 
(2%→8%  EtOAc/hexanes) provided the product as a white powder. Run 1 (38.0 mg, 56% yield, 
92% ee); Run 2 (38.7 mg, 57% yield, 92% ee); Run 3 (41.1 mg, 61% yield, 92% ee). Average: 
58% (±2.4%) yield, 92% ee. The enantiomeric excess was determined by chiral HPLC analysis 
(CHIRALPAK OJ-H column, 1 mL/min, 30% isopropanol in hexanes, λ = 254 nm): tR(major) = 
12.481 min, tR(minor) = 19.875 min. 1H NMR (500 MHz, Chloroform-d) δ 7.56 (d, J = 2.7 Hz, 
1H), 7.36 – 7.32 (m, 2H), 7.32 – 7.27 (m, 2H), 7.26 – 7.21 (m, 1H), 7.17 (d, J = 8.5 Hz, 1H), 
7.12 (dd, J = 8.5, 2.7 Hz, 1H), 6.57 (d, J = 15.9 Hz, 1H), 6.16 (dt, J = 15.8, 7.4 Hz, 1H), 3.86 (s, 
3H), 3.21 (ddd, J = 14.4, 7.2, 1.4 Hz, 1H), 3.12 (ddd, J = 14.3, 7.6, 1.3 Hz, 1H), 3.07 – 2.91 (m, 
3H), 2.51 – 2.44 (m, 1H); 13C NMR (126 MHz, CDCl3) δ 187.94, 158.84, 136.42, 136.00, 
134.95, 131.48, 130.15, 128.60, 127.92, 126.40, 123.30, 121.67, 110.28, 93.81, 55.59, 38.11, 
32.05, 24.52; HRMS (ESI) m/z calculated for C20H19NO4 [M+H]+: 338.1392, found 338.1381. 
[α]23D: +2.9 (c = 0.59, CHCl3). Single crystals were grown by recrystallization from warm 
diethyl ether. The absolute stereochemistry is determined by X-ray crystallography.  
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Scheme 13. Crystal Structure of 32p 
 
 
Crystal data and structure refinement for dd48fsa (32p). 
Identification code  dd48fsa 
Empirical formula  C20 H19 N O4 
Formula weight  337.36 
Temperature  110(2) K 
Wavelength  1.54178 ≈ 
Crystal system  Orthorhombic 
Space group  P212121 
Unit cell dimensions a = 7.2794(2) ≈ a= 90∞. 
 b = 7.9760(2) ≈ b= 90∞. 
 c = 28.9295(8) ≈ g = 90∞. 
Volume 1679.66(8) ≈3 
Z 4 
116 
 
Scheme 13. (cont.) 
Density (calculated) 1.334 Mg/m3 
Absorption coefficient 0.762 mm-1 
F(000) 712 
Crystal size 0.574 x 0.185 x 0.157 mm3 
Theta range for data collection 3.055 to 68.249∞. 
Index ranges -8<=h<=8, -8<=k<=9, -32<=l<=34 
Reflections collected 15671 
Independent reflections 3063 [R(int) = 0.0410] 
Completeness to theta = 67.679∞ 99.9 %  
Absorption correction Integration 
Max. and min. transmission 1.0000 and 0.7163 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3063 / 0 / 227 
Goodness-of-fit on F2 1.071 
Final R indices [I>2sigma(I)] R1 = 0.0293, wR2 = 0.0695 
R indices (all data) R1 = 0.0316, wR2 = 0.0709 
Absolute structure parameter -0.01(9) 
Extinction coefficient 0.0060(5) 
Largest diff. peak and hole 0.221 and -0.171 e.≈-3 
 
General procedure: To a ½ dram borosilicate vial with stir bar was added ligand L21 (5.2 mg, 
0.01 mmol, 0.05 equiv) and Pd(OAc)2 (2.2 mg, 0.01 mmol, 0.05 equiv). Benzene (0.2 mL) was 
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added, and the vial was capped and stirred at 45˚C until all solids had dissolved. Separately, to a 
second 1 dram borosilicate vial with stir bar was added nucleophile 30 (94 mg, 0.4 mmol, 2.0 
equiv), 2,6-dimethylbenzoquinone (40 mg, 0.3 mmol, 1.5 equiv) and Zn(OAc)2 dihydrate (22 
mg, 0.1 mmol, 0.5 equiv). The catalyst solution was subsequently added to the reaction flask, 
and Benzene (1.0 mL) was used to rinse the catalyst vial, also transferred and added to the 
reaction flask (total volume: 1.2 mL). The reaction vial was sealed with a Teflon cap and cooled 
at 5˚C for 10 min. Allylarene (0.20 mmol, 1.0 equiv) was then added and the reaction was 
allowed to stir for 72 hours at 5˚C. Afterward, the reaction mixture was directly subjected to 
flash column chromatography to provide product.  
 
 
Tert-butyl (R)-2-cinnamyl-6-methoxy-3-oxo-2,3-dihydrobenzofuran-2-carboxylate (33b): 
Allylbenzene (13.0 µL, 0.10 mmol, 1 equiv) reacted with nucleophile 30 according to the 
general procedure. Purification by flash column chromatography (5%→10% EtOAc/hexanes) 
provided the product as a clear oil: Run 1 (30.7 mg, 81% yield, 92% ee); Run 2 (32.5 mg, 85% 
yield, 92% ee); Run 3 (29.6 mg, 78% yield, 92% ee). Average: 81% (±3.8%) yield, 92% ee. 
The enantiomeric excess was determined by chiral HPLC analysis (CHIRALPAK OJ-H column, 
1 mL/min, 2% isopropanol in hexanes, λ = 280 nm): tR(minor) = 21.130 min, tR(major) = 23.398 
min. 1H NMR (500 MHz, Chloroform-d) δ 7.54 (d, J = 9.1 Hz, 1H), 7.29 – 7.25 (m, 4H), 7.22 – 
7.17 (m, 1H), 6.67 – 6.62 (m, 2H), 6.56 (d, J = 15.8 Hz, 1H), 6.09 (dt, J = 15.8, 7.2 Hz, 1H), 3.88 
(s, 3H), 3.17 (dd, J = 14.6, 7.7 Hz, 1H), 2.88 (dd, J = 14.6, 6.8, 1H), 1.45 (s, 9H). 13C NMR (126 
MHz, CDCl3) δ 193.43, 174.84, 168.65, 164.54, 136.94, 134.98, 128.44, 127.45, 126.27, 125.91, 
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121.62, 112.64, 112.30, 96.16, 92.28, 83.65, 55.92, 37.52, 27.85. HRMS (ESI) m/z calc’d for 
C23H24O5 [M+H]+: 381.1702; found 381.1690. [α]22D = -33.0 (c = 1.2, CHCl3). 
 
 
Tert-butyl (R)-2-cinnamyl-6-fluoro-3-oxo-2,3-dihydrobenzofuran-2-carboxylate (33c): 
Allylbenzene (13.0 µL, 0.10 mmol, 1 equiv) reacted with nucleophile 30 according to the 
general procedure. Purification by flash column chromatography (1%→2% EtOAc/hexanes) 
provided the product as a clear oil: Run 1 (34.7 mg, 94% yield, 90% ee); Run 2 (34.3 mg, 93% 
yield, 90% ee); Run 3 (33.8 mg, 92% yield, 90% ee). Average: 93% (±1.2%) yield, 90% ee. 
The enantiomeric excess was determined by chiral HPLC analysis (CHIRALPAK OJ-H column, 
1 mL/min, 2% isopropanol in hexanes, λ = 280 nm): tR(minor) = 6.422 min, tR(major) = 11.157 
min. 1H NMR (500 MHz, Chloroform-d) δ 7.66 (dd, J = 8.5, 5.7 Hz, 1H), 7.29 – 7.24 (m, 5H), 
7.24 – 7.17 (m, 1H), 6.90 (dd, J = 9.0, 2.1 Hz, 1H), 6.82 (td, J = 8.7, 2.1 Hz, 1H), 6.57 (d, J = 
15.9 Hz, 1H), 6.07 (dt, J = 15.6, 7.3 Hz, 1H), 3.18 (dd, J = 14.5, 7.1 Hz, 1H), 2.92 (dd, J = 14.5, 
7.1 Hz, 1H), 1.46 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 193.97, 173.73 (d, J = 15.0 Hz), 
169.52 (d, J = 259.2 Hz), 163.88, 136.75, 135.42, 128.49, 127.61, 126.79 (d, J = 12.2 Hz), 
126.28, 120.94, 116.34, 111.40 (d, J = 24.4 Hz), 100.93 (d, J = 26.1 Hz). 92.64, 84.04, 37.37, 
27.81. 19F NMR (471 MHz, Chloroform-d) δ -95.86. HRMS (ESI) m/z calc’d for C22H21FO4 
[M+Na]+: 391.1322; found 391.1321. [α]23D = +46.7 (c = 1.44, CHCl3). 
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Tert-butyl (R,E)-2-(3-(4-(cyclopropylcarbamoyl)phenyl)allyl)-3-oxo-2,3-
dihydrobenzofuran-2-carboxylate (33d): 4-allyl-N-cyclopropylbenzamide (40.2 mg, 0.2 mmol, 
1.0 equiv) reacted with nucleophile 30 according to the general procedure. Purification by flash 
column chromatography (20%→30% Acetone/hexanes) provided the product as a colorless gel. 
Run 1 (78.9 mg, 91% yield, 94% ee); Run 2 (77.1 mg, 89% yield, 94% ee); Run 3 (79.0 mg, 91% 
yield, 94% ee). Average: 90% (±1.2%) yield, 94% ee. The enantiomeric excess was 
determined by chiral HPLC analysis (CHIRALPAK IA-3 column, 1 mL/min, 5% isopropanol in 
hexanes, λ = 254 nm): tR(minor) = 53.437 min, tR(major) = 57.398 min.  1H NMR (500 MHz, 
Chloroform-d) δ 7.67 – 7.59 (m, 4H), 7.26 (d, J = 8.3 Hz, 2H), 7.21 (dd, J = 9.0, 0.8 Hz, 1H), 
7.09 (td, J = 7.5, 0.8 Hz, 1H), 6.56 (d, J = 16.1 Hz, 1H), 6.32 (br, 1H), 6.16 (ddd, J = 15.8, 7.7, 
7.0 Hz, 1H), 3.18 (ddd, J = 14.6, 7.7, 1.3 Hz, 1H), 2.91 – 2.83 (m, 2H), 1.42 (s, 9H), 0.82 (m, 
2H), 0.58 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 195.84, 172.23, 168.40, 164.11, 139.87, 
138.56, 134.22, 133.20, 127.13, 126.27, 124.88, 123.67, 122.59, 119.55, 113.45, 91.26, 83.94, 
37.50, 27.81, 23.12, 6.76. HRMS (ESI) m/z calc’d for C26H27NO5 [M+H]+: 434.1967; found 
434.1961. [α]22D = +84.1o (c = 1.1, CHCl3). 
 
 
Tert-butyl (R,E)-2-(3-(4-(morpholinosulfonyl)phenyl)allyl)-3-oxo-2,3-dihydrobenzofuran-2-
carboxylate (33e): 4-((4-allylphenyl)sulfonyl)morpholine (54 mg, 0.2 mmol, 1.0 equiv) reacted 
with nucleophile 30 according to the general procedure. Purification by flash column 
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chromatography (20%→30% EtOAc/hexanes) provided the product as a white solid: Run 1 (89.2 
mg, 89% yield, 92% ee).  
Using 2.5 mol% catalyst: L21 (5.2 mg, 0.01 mmol, 0.05 equiv) and Pd(OAc)2 (2.2 mg, 0.01 
mmol, 0.05 equiv), nucleophile 30 (235 mg, 1 mmol, 2.0 equiv), 2,6-dimethylbenzoquinone (102 
mg, 0.75 mmol, 1.5 equiv) and Zn(OAc)2 dihydrate (55 mg, 0.25 mmol, 0.5 equiv). 4-((4-
allylphenyl)sulfonyl)morpholine (135 mg, 0.5 mmol, 1.0 equiv) in Benzene (total reaction 
volume: 3 mL): Run 2 (184.6 mg, 74% yield, 92% ee); Run 3 (175 mg, 70% yield, 92% ee). 
Average: 72% yield, 92% ee. The enantiomeric excess was determined by chiral HPLC 
analysis (CHIRALPAK IB-3 column, 1 mL/min, 5% isopropanol in hexanes, λ = 280 nm): 
tR(major) = 19.003 min, tR(minor) = 21.562 min. 1H NMR (500 MHz, Chloroform-d) δ 7.66 (m,, 
2H), 7.63 (dd, J = 8.1 Hz, 2H), 7.39 (d, J = 8.4 Hz, 2H), 7.21 (d, J = 8.5 Hz, 1H), 7.12 (t, J = 7.4 
Hz, 1H), 6.60 (d, J = 15.9 Hz, 1H), 6.25 (dt, J = 15.8, 7.3 Hz, 1H), 3.75 – 3.67 (m, 4H), 3.21 (dd, 
J = 14.6, 7.5 Hz, 1H), 2.99 – 2.95 (m, 4H), 2.92 (dd, J = 14.7, 7.1 Hz, 1H), 1.44 (s, 9H). 13C 
NMR (126 MHz, CDCl3) δ 195.74, 172.24, 164.05, 141.54, 138.62, 133.61, 133.43, 128.16, 
126.73, 125.73, 124.95, 122.68, 119.54, 113.46, 91.05, 84.03, 66.09, 45.96, 37.33, 27.82. HRMS 
(ESI) m/z calc’d for C26H29NO7S [M+H]+: 500.1732; found 500.1736. [α]22D = +83.6 (c = 1.0, 
CHCl3). Single crystals suitable for X-ray crystallography were grown by slow diffusion from 
Et2O/Hexane. The absolute stereochemistry is determined by X-ray crystallography. 
 
 
Tert-butyl (R,E)-2-(3-(benzo[d][1,3]dioxol-5-yl)allyl)-3-oxo-2,3-dihydrobenzofuran-2-
carboxylate (33f): Safrole (33 mg, 0.2 mmol, 1.0 equiv) reacted with nucleophile 30 according 
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to the general procedure. Purification by flash column chromatography (5%→8% 
EtOAc/hexanes) provided the product as a clear oil: Run 1 (69.3 mg, 88% yield, 92% ee); Run 2 
(68.8 mg, 87% yield, 92% ee); Run 3 (69.4 mg, 88% yield, 92% ee). Average: 88% (±0.4%) 
yield, 92% ee. The enantiomeric excess was determined by chiral HPLC analysis (CHIRALPAK 
AD-RH column, 0.75 mL/min, 45% MeCN in H2O, λ = 280 nm): tR(minor) = 34.062 min, 
tR(major) = 36.926 min. 1H NMR (500 MHz, Chloroform-d) δ 7.68 – 7.59 (m, 2H), 7.22 (d, J = 
8.3 Hz, 1H), 7.09 (t, J = 7.4 Hz, 1H), 6.77 (s, 1H), 6.69 (d, J = 1.1 Hz, 2H), 6.46 (dd, J = 15.7, 
1.2 Hz, 1H), 5.96 – 5.86 (m, 3H), 3.14 (dd, J = 14.6, 7.6 Hz, 1H), 2.85 (dd, J = 14.6, 7.0 Hz, 
1H), 1.44 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 195.97, 172.27, 164.21, 147.89, 147.14, 
138.44, 134.71, 131.35, 124.85, 122.46, 120.92, 119.67, 119.49, 113.45, 108.16, 105.57, 101.00, 
91.53, 83.77, 37.48, 27.83. HRMS (ESI) m/z calc’d for C23H22O6 [M+Na]+: 417.1314; found 
417.1320. [α]23D = +107.2 (c = 0.87, CHCl3). 
 
 
Tert-butyl (R,E)-6-(3-(2-(tert-butoxycarbonyl)-3-oxo-2,3-dihydrobenzofuran-2-yl)prop-1-
en-1-yl)-3,4-dihydroquinoline-1(2H)-carboxylate (33g): Tert-butyl 6-allyl-3,4-
dihydroquinoline-1(2H)-carboxylate (55 mg, 0.2 mmol, 1.0 equiv) reacted with nucleophile 30 
according to the general procedure. Purification by flash column chromatography 
(5%→10%→15% EtOAc/hexanes) provided the product as a clear oil: Run 1 (94.5 mg, 93% 
yield, 90% ee); Run 2 (98.3 mg, 97% yield, 90% ee); Run 3 (97.8 mg, 97% yield, 90% ee). 
Average: 96% (±2.0%) yield, 90% ee. The enantiomeric excess was determined by chiral 
HPLC analysis (CHIRALPAK IB-3 column, 1 mL/min, 1% isopropanol in hexanes, λ = 280 
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nm): tR(major) = 6.752 min, tR(minor) = 9.283 min. 1H NMR (500 MHz, Chloroform-d) δ 7.66 – 
7.60 (m, 2H), 7.55 (d, J = 8.6 Hz, 1H), 7.21 (d, J = 8.5 Hz, 1H), 7.09 (t, J = 7.4 Hz, 1H), 7.02 
(dd, J = 8.6, 2.1 Hz, 1H), 6.95 (d, J = 2.1 Hz, 1H), 6.47 (d, J = 15.6 Hz, 1H), 5.98 (dt, J = 15.7, 
7.3 Hz, 1H), 3.69 – 3.64 (m, 2H), 3.15 (dd, J = 14.6, 7.8 Hz, 1H), 2.87 (dd, J = 14.7, 6.9 Hz, 
1H), 2.69 (t, J = 6.6 Hz, 2H), 1.88 (p, J = 6.4 Hz, 2H), 1.50 (s, 9H), 1.44 (s, 9H). 13C NMR (126 
MHz, CDCl3) δ 196.02, 172.29, 164.24, 153.83, 138.42, 138.00, 134.68, 131.81, 129.69, 126.42, 
124.84, 123.93, 123.70, 122.44, 120.01, 119.69, 113.46, 91.57, 83.75, 80.81, 44.75, 37.60, 28.38, 
27.84, 27.54, 23.44. HRMS (ESI) m/z calc’d for C30H35NO6 [M+H]+: 506.2543; found 
506.2551. [α]23D = +83.4 (c = 1.1, CHCl3). 
 
 
Tert-butyl (R,E)-2-(3-(1-methyl-2-oxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)allyl)-3-oxo-
2,3-dihydrobenzofuran-2-carboxylate (33h): 6-allyl-1-methyl-1,4-dihydro-2H-
benzo[d][1,3]oxazin-2-one (41 mg, 0.2 mmol, 1.0 equiv) reacted with nucleophile 30 according 
to the general procedure. Purification by flash column chromatography 
(10%→20%→30%→40% EtOAc/hexanes) provided the product as a clear oil: Run 1 (78.5 mg, 
90% yield, 93% ee); Run 2 (78.3 mg, 90% yield, 93% ee); Run 3 (81.3 mg, 93% yield, 93% ee). 
Average: 91% (±1.9%) yield, 93% ee. The enantiomeric excess was determined by chiral 
HPLC analysis (CHIRALPAK OJ-H column, 1 mL/min, 30% isopropanol in hexanes, λ = 280 
nm): tR(minor) = 21.957 min, tR(major) = 27.179 min. 1H NMR (500 MHz, Chloroform-d) δ 7.63 
(m, 2H), 7.23 – 7.18 (m, 2H), 7.09 (t, J = 7.4 Hz, 1H), 7.01 (d, J = 1.9 Hz, 1H), 6.80 (d, J = 8.4 
Hz, 1H), 6.49 (d, J = 16.1 Hz, 1H), 6.02 (dt, J = 15.6, 7.3 Hz, 1H), 5.12 (s, 2H), 3.32 (s, 3H), 
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3.15 (dd, J = 14.6, 7.7 Hz, 1H), 2.87 (dd, J = 14.5, 6.9 Hz, 1H), 1.42 (s, 9H). 13C NMR (126 
MHz, CDCl3) δ 195.86, 172.23, 164.15, 153.12, 138.51, 137.62, 133.74, 132.04, 127.17, 124.87, 
122.55, 121.86, 121.18, 120.68, 119.62, 113.44, 112.92, 91.37, 83.86, 67.28, 37.43, 31.55, 27.82. 
HRMS (ESI) m/z calc’d for C25H25NO6 [M+H]+: 436.1760; found 436.1767. [α]23D = +90.3 (c = 
0.8, CHCl3). 
 
 
Tert-butyl (R,E)-2-(3-cyclohexylallyl)-3-oxo-2,3-dihydrobenzofuran-2-carboxylate (33i): To 
a ½ dram borosilicate vial with stir bar was added ligand L21 (5.2 mg, 0.01 mmol, 0.1 equiv) 
and Pd(OAc)2 (2.2 mg, 0.01 mmol, 0.1 equiv). Benzene (0.2 mL) was added, and the vial was 
capped and stirred at 45˚C for 10 mins. Separately, to a ½ dram borosilicate vial with stir bar was 
added Zn(OAc)2 dihydrate (11 mg, 0.05 mmol, 0.5 equiv), 2,6-dimethylbenzoquinone (20 mg, 
0.15 mmol, 1.5 equiv) and 30 (47 mg, 0.20 mmol, 2 equiv). The catalyst solution was 
subsequently added to the reaction flask, and benzene (0.4 mL) was used to rinse the catalyst 
vial, also transferred and added to the reaction flask. Allylcyclohexane (12.4 mg, 0.1 mmol, 1.0 
equiv) was added. The vial was sealed with a Teflon cap, and allowed to stir for 72 hours at 
room temperature. Afterward, the reaction mixture was directly subjected to flash column 
chromatography (1%→2% EtOAc/hexanes) to provide product as a colorless oil. Run 1 (29.6 
mg, 83% yield, 79% ee); Run 2 (30.4 mg, 85% yield, 79% ee); Run 3 (28.7 mg, 81% yield, 79% 
ee); Average: 83% (±2.4%) yield, 79% ee. The enantiomeric excess was determined to be 79% 
by chiral HPLC analysis (CHIRALPAK AD-RH column, 0.5 mL/min, 55% MeCN in H2O, λ = 
254 nm): tR(minor) = 30.213 min, tR(major) = 33.981 min. 1H NMR (500 MHz, Chloroform-d) δ 
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7.65 – 7.58 (m, 2H), 7.19 (d, J = 8.9 Hz, 1H), 7.08 (t, J = 7.4 Hz, 1H), 5.55 (dd, J = 15.5, 6.9 Hz, 
1H), 5.23 (ddd, J = 15.6, 7.9, 6.7 Hz, 1H), 2.92 (dd, J = 14.4, 7.8 Hz, 1H), 2.69 (dd, J = 14.4, 6.7 
Hz, 1H), 1.87 – 1.75 (m, 1H), 1.67 – 1.48 (m, 5H), 1.44 (s, 9H), 1.20 – 1.01 (m, 3H), 0.92 (m, 
2H). 13C NMR (126 MHz, CDCl3) δ 196.25, 172.32, 164.38, 142.60, 138.23, 124.64, 122.23, 
119.96, 118.43, 113.36, 91.73, 83.49, 40.55, 37.19, 32.62, 27.82, 26.08, 25.82. HRMS (ESI) m/z 
calc’d for C22H28O4 [M+H]+: 357.2066; found 357.2062. [α]23D = +75.5 (c = 0.67, CHCl3). 
 
 
Tert-butyl (R,E)-2-(4,4-diethoxybut-2-en-1-yl)-3-oxo-2,3-dihydrobenzofuran-2-carboxylate 
(33j): To a ½ dram borosilicate vial with stir bar was added ligand L21 (5.2 mg, 0.01 mmol, 0.1 
equiv) and Pd(OAc)2 (2.2 mg, 0.01 mmol, 0.1 equiv). Benzene (0.2 mL) was added, and the vial 
was capped and stirred at 45˚C for 10 mins. Separately, to a ½ dram borosilicate vial with stir bar 
was added Zn(OAc)2 dihydrate (11 mg, 0.05 mmol, 0.5 equiv), 2,6-dimethylbenzoquinone (20 
mg, 0.15 mmol, 1.5 equiv) and 30 (47 mg, 0.20 mmol, 2 equiv). The catalyst solution was 
subsequently added to the reaction flask, and benzene (0.4 mL) was used to rinse the catalyst 
vial, also transferred and added to the reaction flask. 3-Butenal diethyl acetal (14.4 mg, 0.1 
mmol, 1.0 equiv) was added. The vial was sealed with a Teflon cap, and allowed to stir for 48 
hours at room temperature. Afterward, the reaction mixture was directly subjected to flash 
column chromatography (silica neutralized with 1% Et3N in 5% EtOAc/hexanes, flushed with 
5%→8%→10%  EtOAc/hexanes) to provide product as a colorless oil. Run 1 (31.6 mg, 84% 
yield, 79% ee); Run 2 (29.7 mg, 79% yield, 79% ee); Run 3 (30.3 mg, 80% yield, 79% ee); 
Average: 81% (±2.6%) yield, 79% ee. The product is converted into the aldehyde (see below) 
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for chiral HPLC analysis. The enantiomeric excess was determined to be 79% by chiral HPLC 
analysis (CHIRALPAK OJ-H column, 1 mL/min, 10% isopropanol in hexanes, λ = 254 nm): 
tR(minor) = 5.381 min, tR(major) = 8.786 min. 1H NMR (500 MHz, Chloroform-d) δ 7.68 – 7.62 
(m, 2H), 7.22 (d, J = 9.0 Hz, 1H), 7.12 (t, J = 7.5 Hz, 1H), 5.75 – 5.65 (m, 2H), 4.75 – 4.72 (m, 
1H), 3.55 – 3.43 (m, 2H), 3.39 – 3.26 (m, 2H), 3.04 (dd, J = 14.4, 5.3 Hz, 1H), 2.80 (dd, J = 
14.4, 5.3 Hz, 1H), 1.46 (s, 9H), 1.13 (dt, J = 11.1, 7.0 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 
195.95, 172.33, 164.14, 138.36, 133.32, 125.62, 124.77, 122.40, 119.72, 113.45, 100.98, 91.11, 
83.85, 60.98, 60.91, 36.40, 27.76, 15.12, 15.10. HRMS (ESI) m/z calc’d for C21H28O6 [M+Na]+: 
399.1784; found 399.1783. [α]23D = +37.2 (c = 1.6, CHCl3). 
 
 
Tert-butyl (R,E)-3-oxo-2-(4-oxobut-2-en-1-yl)-2,3-dihydrobenzofuran-2-carboxylate: 1H 
NMR (500 MHz, Chloroform-d) δ 9.44 (d, J = 7.8 Hz, 1H), 7.71 – 7.65 (m, 2H), 7.22 (d, J = 8.7 
Hz, 1H), 7.15 (t, J = 7.5 Hz, 1H), 6.78 – 6.68 (m, 1H), 6.25 (dd, J = 15.8, 7.8 Hz, 1H), 3.29 (dd, 
J = 15.1, 7.4 Hz, 1H), 2.96 (dd, J = 15.2, 7.0 Hz, 1H), 1.43 (s, J = 1.0 Hz, 9H). 13C NMR (126 
MHz, CDCl3) δ 195.27, 193.13, 172.22, 163.66, 148.59, 138.85, 136.75, 125.08, 122.95, 119.24, 
113.52, 89.92, 84.50, 36.37, 27.75. HRMS (ESI) m/z calc’d for C17H18O5 [M+Na]+: 325.1052; 
found 325.1055. 
Scheme 14. Crystal Structure of 33e 
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Scheme 14. (cont.) 
 
Crystal data and structure refinement for dd95is (33e). 
Identification code  dd95is 
Empirical formula  C26 H29 N O7 S 
Formula weight  499.56 
Temperature  100(2) K 
Wavelength  0.71073 ≈ 
Crystal system  Triclinic 
Space group  P1 
Unit cell dimensions a = 8.1073(3) ≈ a= 74.9956(16)∞. 
 b = 12.6392(5) ≈ b= 81.3175(16)∞. 
 c = 13.2065(6) ≈ g = 71.4936(14)∞. 
Volume 1236.04(9) ≈3 
127 
 
Scheme 14. (cont.) 
Z 2 
Density (calculated) 1.342 Mg/m3 
Absorption coefficient 0.177 mm-1 
F(000) 528 
Crystal size 0.388 x 0.275 x 0.152 mm3 
Theta range for data collection 2.620 to 28.350∞. 
Index ranges -10<=h<=10, -16<=k<=16, -17<=l<=17 
Reflections collected 102095 
Independent reflections 12247 [R(int) = 0.0717] 
Completeness to theta = 25.242∞ 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7457 and 0.6562 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 12247 / 145 / 675 
Goodness-of-fit on F2 1.038 
Final R indices [I>2sigma(I)] R1 = 0.0376, wR2 = 0.0824 
R indices (all data) R1 = 0.0479, wR2 = 0.0874 
Absolute structure parameter -0.01(3) 
Extinction coefficient 0.0170(14) 
Largest diff. peak and hole 0.383 and -0.304 e.≈-3 
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General procedure: To a ½ dram borosilicate vial with stir bar was added ligand L22 (6.1 mg, 
0.01 mmol, 0.1 equiv) and Pd(OAc)2 (2.2 mg, 0.01 mmol, 0.1 equiv). Dioxane (0.3 mL) was 
added, and the vial was capped and stirred at 45˚C until all solids had dissolved. Separately, to a 
second ½ dram borosilicate vial with stir bar was added nucleophile, 2,6-dimethylbenzoquinone 
(20.8 mg, 0.15 mmol, 1.5 equiv) and Zn(OAc)2 dihydrate (11 mg, 0.05 mmol, 0.5 equiv). The 
catalyst solution was subsequently added to the reaction flask, and dioxane (volume specified 
below) was used to rinse the catalyst vial, also transferred and added to the reaction flask. The 
reaction vial was sealed with a Teflon cap and cooled at 5˚C for 10 min. Allylarene (0.10 mmol, 
1 equiv) was then added and the reaction was allowed to stir for 72 hours at 5˚C.  Afterward, the 
reaction mixture was directly subjected to flash column chromatography to provide product.  
 
 
Methyl (R)-2-cinnamyl-4-methyl-3-oxo-5-(thiophen-2-yl)-2,3-dihydrofuran-2-carboxylate 
(34b): Allylbenzene (13.0 µL, 0.10 mmol, 1 equiv) was reacted with nucleophile (24 mg, 0.10 
mmol, 1 equiv) in Dioxane (1.5 mL total volume) using 1 dram vial according to the general 
procedure. Purification by flash column chromatography (10%→20%→30%→50% 
EtOAc/hexanes) provided the product as a clear oil. Run 1 (29.1 mg, 82% yield, 91% ee); Run 2 
(28.6 mg, 81% yield, 91% ee); Run 3 (30.1 mg, 85% yield, 91% ee). Average: 83% (±2.2%) 
yield, 91% ee. The enantiomeric excess was determined to be 91% by chiral HPLC analysis 
(CHIRALPAK IB-3 column, 0.5 mL/min, 10% isopropanol in hexane, λ = 254 nm, tR(minor) = 
9.52 min, tR(major) = 10.04 min.). 1H NMR (500MHz, CDCl3) δ 7.80 (dd, J = 3.9, 1.2 Hz, 1H), 
7.71 (dd, J = 5.1, 1.2 Hz, 1H), 7.35 – 7.16 (m, 6H), 6.56 (d, J = 15.8 Hz, 1H), 6.07 (dt, J = 15.2, 
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7.3 Hz, 1H), 3.78 (s, 3H), 3.20 (dd, J = 15.4, 7.4 Hz, 1H), 2.95 (dd, J = 14.6, 7.2 Hz, 1H), 2.00 
(s, 3H); 13C NMR (125 MHz, CDCl3) δ 198.0, 174.9, 166.1, 137.1, 135.4, 132.1, 132.0, 131.1, 
128.6, 128.5, 127.7, 126.5, 121.3, 107.9, 89.8, 53.5, 37.9, 7.2; HRMS (ESI) m/z calc’d for 
C20H18O4S [M+H]: 355.1004; found 355.0998. [α]22D = +93.19 (c = 0.13, CHCl3).   
 
 
Methyl (R)-5-cinnamyl-5'-ethyl-3-methyl-4-oxo-4,5-dihydro-[2,2'-bifuran]-5-carboxylate 
(34c): Allylbenzene (13.0 µL, 0.10 mmol, 1 equiv) was reacted with nucleophile (25 mg, 0.10 
mmol, 1 equiv) in Dioxane (0.6 mL total volume) according to the general procedure. 
Purification by flash column chromatography (10%→20%→30%→50% EtOAc/hexanes) 
provided the product as a clear oil. Run 1 (23.2 mg, 63% yield, 93% ee); Run 2 (24.5 mg, 67% 
yield, 93% ee); Run 3 (25.6 mg, 70% yield, 93% ee). Average: 67% (±3.3%) yield, 93% ee. 
The enantiomeric excess was determined to be 93% by chiral HPLC analysis (CHIRALPAK OJ-
H column, 0.5 mL/min, 20% isopropanol in hexane, λ = 230 nm, tR(minor) = 10.82 min, 
tR(major) = 12.83 min.) 1H NMR (500MHz, CDCl3) δ 7.33 – 7.24 (m, 4H), 7.24 – 7.16 (m, 1H), 
7.11 (d, J = 3.5 Hz, 1H), 6.54 (d, J = 15.8 Hz, 1H), 6.25 (d, J = 3.4 Hz, 1H), 6.06 (dt, J = 15.2, 
7.3 Hz, 1H), 3.77 (s, 3H), 3.17 (dd, J = 14.7, 7.5 Hz, 1H), 2.94 (dd, J = 14.4, 7.2 Hz, 1H), 2.77 
(q, J = 7.6 Hz, 2H), 1.99 (s, 3H), 1.30 (t, J = 7.6 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 197.8, 
170.8, 166.2, 163.6, 143.9, 137.1, 135.2, 128.6, 127.6, 126.5, 121.4, 117.7, 107.7, 107.2, 89.6, 
53.4, 37.9, 21.9, 11.9, 6.4; HRMS (ESI) m/z calc’d for C22H22O5 [M+H]: 367.1545; found 
367.1541. [α]22D = +135.15 (c = 0.11, CHCl3). 
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Methyl (R,E)-5-(3-(3-((diethoxyphosphoryl)oxy)phenyl)allyl)-5'-ethyl-3-methyl-4-oxo-4,5-
dihydro-[2,2'-bifuran]-5-carboxylate (34d): 3-allylphenyl diethyl phosphate (27 mg, 0.10 
mmol, 1 equiv) was reacted with nucleophile (25 mg, 0.10 mmol, 1 equiv) in Dioxane (0.6 mL 
total volume) according to the general procedure. Purification by flash column chromatography 
(10%→20%→30%→50% EtOAc/hexanes) provided the product as a clear oil. Run 1 (39.1 mg, 
75% yield, 93% ee); Run 2 (37.2 mg, 72% yield, 93% ee); Run 3 (38.8 mg, 75% yield, 93% ee). 
Average: 74% (±2.0%) yield, 93% ee. The enantiomeric excess was determined to be 93% by 
chiral HPLC analysis (CHIRALPAK IB-3 column, 0.5 mL/min, 5% isopropanol in hexane, λ = 
254 nm, tR(minor) = 36.87 min, tR(major) = 38.83 min). 1H NMR (500MHz, CDCl3) δ 7.22 (t, J 
= 7.9 Hz, 1H), 7.13 – 7.05 (m, 4H), 6.50 (d, J = 15.7 Hz, 1H), 6.25 (d, J = 3.4 Hz, 1H), 6.06 (dt, 
J = 15.2, 7.3 Hz, 1H), 4.27 – 4.14 (m, 4H), 3.76 (s, 3H), 3.15 (dd, J = 14.6, 7.5 Hz, 1H), 2.92 
(dd, J = 14.7, 7.2 Hz, 1H), 2.77 (q, J = 7.6 Hz, 2H), 1.99 (s, 3H), 1.33 (t, J = 7.3 Hz, 6H), 1.29 (t, 
J = 9.0 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 197.6, 170.8, 166.2, 163.7, 151.0 (d, JP = 6.3 
Hz), 143.8, 139.0, 134.3, 129.7, 123.2, 122.7, 119.0 (d, JP = 5.0 Hz), 117.8 (d, JP = 5.0 Hz), 
117.8, 107.7, 107.1, 89.4, 64.7 (d, JP = 6.3 Hz), 53.4, 37.8, 21.9, 16.2 (d, JP = 5.0 Hz), 11.9, 6.4; 
31P NMR (202MHz, CDCl3) δ –5.2; HRMS (ESI) m/z calc’d for C26H31O9P [M+H]: 519.1784; 
found 519.1786. [α]23D = +121.00 (c = 0.10, CHCl3).   
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Tert-butyl (R,E)-3-(3-(5'-ethyl-5-(methoxycarbonyl)-3-methyl-4-oxo-4,5-dihydro-[2,2'-
bifuran]-5-yl)prop-1-en-1-yl)-1H-indole-1-carboxylate (34e): Tert-butyl 3-allyl-1H-indole-1-
carboxylate (25.7 mg, 0.10 mmol, 1 equiv) was reacted with nucleophile (25 mg, 0.10 mmol, 1 
equiv) in Dioxane (0.6 mL total volume) according to the general procedure. Purification by 
flash column chromatography (10%→20%→30%→50% EtOAc/hexanes) provided the product 
as a clear oil. Run 1 (29.0 mg, 57% yield, 95% ee); Run 2 (28.3 mg, 56% yield, 95% ee); Run 3 
(30.8 mg, 61% yield, 95% ee). Average: 58% (±2.6%) yield, 95% ee. The enantiomeric excess 
was determined to be 95% by chiral HPLC analysis (CHIRALPAK IA-3 column, 0.5 mL/min, 
10% isopropanol in hexane, λ = 330 nm, tR(major) = 3.76 min, tR(minor) = 4.48 min). 1H NMR 
(500MHz, CDCl3) δ 8.12 (d, J = 8.3 Hz, 1H), 7.59 (d, J = 7.9 Hz, 1H), 7.51 (s, 1H), 7.30 (t, J = 
8.4 Hz, 1H), 7.19 (t, J = 8.9 Hz, 1H), 7.12 (d, J = 3.5 Hz, 1H), 6.63 (d, J = 16.0 Hz, 1H), 6.25 (d, 
J = 3.5 Hz, 1H), 6.10 (dt, J = 15.3, 7.3 Hz, 1H), 3.78 (s, 3H), 3.19 (dd, J = 14.7, 7.5 Hz, 1H), 
3.02 (dd, J = 14.3, 6.9 Hz, 1H), 2.77 (q, J = 7.6 Hz, 2H), 1.99 (s, 3H), 1.65 (s, 9H), 1.29 (t, J = 
7.6 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 197.9, 170.8, 166.3, 163.6, 149.7, 143.9, 135.9, 
128.8, 126.4, 124.7, 123.7, 122.9, 121.9, 119.9, 118.6, 117.7, 115.4, 107.7, 107.3, 89.6, 84.0, 
53.4, 38.4, 28.3, 21.9, 11.9, 6.4; HRMS (ESI) m/z calc’d for C29H31NO7 [M+H]: 506.2179; 
found 506.2178. [α]23D = +109.85 (c = 0.31, CHCl3).  
 
132 
 
 
Methyl (R,E)-5-(3-(benzo[d][1,3]dioxol-5-yl)allyl)-5'-ethyl-3-methyl-4-oxo-4,5-dihydro-
[2,2'-bifuran]-5-carboxylate (34f): Safrole (14.8 mg, 0.10 mmol, 1 equiv) was reacted with 
nucleophile (25 mg, 0.10 mmol, 1 equiv) in Dioxane (0.6 mL total volume) according to the 
general procedure. Purification by flash column chromatography (10%→20%→30%→50% 
EtOAc/hexanes) provided the product as a clear oil. Run 1 (37.8 mg, 92% yield, 91% ee); Run 2 
(35.7 mg, 87% yield, 91% ee); Run 3 (37.3 mg, 91% yield, 91% ee). Average: 90% (±2.7%) 
yield, 91% ee. The enantiomeric excess was determined to be 91% by chiral HPLC analysis 
(CHIRALPAK OJ-H column, 0.5 mL/min, 40% isopropanol in hexane, λ = 260 nm, tR(major) = 
12.82 min, tR(minor) = 16.11 min). 1H NMR (500MHz, CDCl3) δ 7.10 (d, J = 3.5 Hz, 1H), 6.82 
(s, 1H), 6.76 – 6.67 (m, 2H), 6.44 (d, J = 15.6 Hz, 1H), 6.25 (d, J = 3.2 Hz, 1H), 5.92 (s, 2H), 
5.87 (dt, J = 15.9, 7.3 Hz, 1H), 3.76 (s, 3H), 3.13 (dd, J = 14.7, 7.5 Hz, 1H), 2.91 (dd, J = 14.6, 
7.2 Hz, 1H), 2.77 (q, J = 7.6 Hz, 2H), 1.98 (s, 3H), 1.30 (t, J = 7.6 Hz, 3H); 13C NMR (125 MHz, 
CDCl3) δ 197.8, 170.8, 166.2, 163.6, 148.0, 147.2, 143.9, 134.8, 131.6, 121.1, 119.5, 117.7, 
108.3, 107.7, 107.2, 105.8, 101.1, 89.6, 53.4, 37.8, 21.9, 11.9, 6.4; HRMS (ESI) m/z calc’d for 
C23H22O7 [M+H]: 411.1444; found 411.1443. [α]23D = +113.49 (c = 0.23, CHCl3).   
 
 
Methyl (E)-2-(3-(4-bromophenyl)allyl)-1-oxo-2,3-dihydro-1H-indene-2-carboxylate (35a): 
4-Bromoallylbenzene (19.7 mg, 0.1 mmol, 1.0 equiv) reacted with nucleophile (38 mg, 0.20 
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mmol, 2 equiv.) in Dioxane (0.6 mL total volume) according to the general procedure. 
Purification by flash column chromatography (5%→8%→10% EtOAc/hexanes) provided the 
product as a clear oil: Run 1 (32.6 mg, 85% yield, 79% ee); Run 2 (31.9mg, 83% yield, 79% ee); 
Run 3 (34.7 mg, 90% yield, 79% ee). Average: 86% (±3.8%) yield, 79% ee. The enantiomeric 
excess was determined by chiral HPLC analysis (CHIRALPAK OJ-H column, 1 mL/min, 10% 
isopropanol in hexanes, λ = 260 nm): tR(minor) = 23.800 min, tR(major) = 31.201 min. 1H NMR 
(500 MHz, Chloroform-d) δ 7.79 (d, J = 7.6 Hz, 1H), 7.62 (t, J = 7.5 Hz, 1H), 7.47 (d, J = 7.6 
Hz, 1H), 7.40 (t, J = 7.5 Hz, 1H), 7.36 (d, J = 8.5 Hz, 2H), 7.08 (d, J = 8.4 Hz, 2H), 6.41 (d, J = 
15.6 Hz, 1H), 6.04 (dt, J = 15.6, 7.4 Hz, 1H), 3.72 (s, 3H), 3.67 (d, J = 17.3 Hz, 1H), 3.18 (d, J = 
17.3 Hz, 1H), 3.03 (dd, J = 14.1, 7.3 Hz, 1H), 2.73 (dd, J = 14.1, 7.5 Hz, 1H). 13C NMR (126 
MHz, CDCl3) δ 201.92, 171.20, 152.92, 135.82, 135.55, 135.01, 133.12, 131.56, 127.89, 127.73, 
126.45, 125.27, 124.87, 121.19, 60.25, 52.88, 38.29, 36.14. HRMS (ESI) m/z calc’d for 
C20H17BrO3 [M+H]+: 385.0439; found 385.0433. [α]23D = +103.1 (c = 0.385, CHCl3). 
 
 
Benzyl (R)-2-cinnamyl-1-oxo-4-phenyl-2,3-dihydro-1H-indene-2-carboxylate (35b): 
Allylbenzene (13.0 µL, 0.10 mmol, 1 equiv) reacted with nucleophile (68 mg, 0.20 mmol, 2 
equiv.) in Dioxane (0.6 mL total volume) according to the general procedure. Purification by 
flash column chromatography (5%→8%→10% EtOAc/hexanes) provided the product as a clear 
oil: Run 1 (36.4 mg, 79% yield, 91% ee); Run 2 (37.7 mg, 82% yield, 91% ee); Run 3 (38.9 mg, 
85% yield, 91% ee). Average: 82% (±2.7%) yield, 91% ee. The enantiomeric excess was 
determined by chiral HPLC analysis (CHIRALPAK OJ-H column, 1 mL/min, 5% isopropanol in 
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hexanes, λ = 254 nm): tR(major) = 5.261 min, tR(minor) = 7.151 min. 1H NMR (500 MHz, 
Chloroform-d) δ 7.73 (d, J = 7.7 Hz, 1H), 7.53 (d, J = 7.4 Hz, 1H), 7.42 (t, J = 7.5 Hz, 1H), 7.39 
– 7.35 (m, 2H), 7.33 – 7.29 (m, 3H), 7.25 – 7.20 (m, 5H), 7.18 – 7.05 (m, 5H), 6.34 (d, J = 15.7 
Hz, 1H), 5.90 (dt, J = 15.8, 7.4 Hz, 1H), 5.10 (s, 2H), 3.66 (d, J = 17.4 Hz, 1H), 3.06 (d, J = 17.4 
Hz, 1H), 2.99 (dd, J = 14.1, 7.6 Hz, 1H), 2.69 (dd, J = 14.1, 7.3 Hz, 1H). 13C NMR (126 MHz, 
CDCl3) δ 201.92, 170.38, 150.53, 140.33, 138.72, 136.83, 135.71, 135.56, 135.54, 134.22, 
128.72, 128.56, 128.47, 128.43, 128.21, 127.91, 127.83, 127.43, 126.21, 124.18, 123.80, 67.27, 
60.98, 38.33, 35.88. (missing one carbon in the aromatic region, possibly due to overlapping). 
HRMS (ESI) m/z calc’d for C32H36O3 [M+H]+: 459.1960; found 459.1945. [α]23D = +16.0 (c = 
0.68, CHCl3). 
 
 
Benzyl (R,E)-2-(3-(3-methoxyphenyl)allyl)-1-oxo-4-phenyl-2,3-dihydro-1H-indene-2-
carboxylate (35c): 3-allylanisole (14.8 mg, 0.10 mmol, 1 equiv) reacted with nucleophile (68 
mg, 0.20 mmol, 2 equiv.) in Dioxane (0.6 mL total volume) according to the general procedure. 
Purification by flash column chromatography (5%→8%→10% EtOAc/hexanes) provided the 
product as a clear oil: Run 1 (36.8 mg, 75% yield, 92% ee); Run 2 (33.4 mg, 68% yield, 93% ee); 
Run 3 (33.5 mg, 69% yield, 93% ee). Average: 71% (±3.9%) yield, 93% ee. The enantiomeric 
excess was determined by chiral HPLC analysis (CHIRALPAK OJ-H column, 1 mL/min, 30% 
isopropanol in hexanes, λ = 254 nm): tR(major) = 18.424 min, tR(minor) = 23.131 min. 1H NMR 
(500 MHz, Chloroform-d) δ 7.80 (d, J = 7.6 Hz, 1H), 7.61 (d, J = 7.3 Hz, 1H), 7.52 – 7.36 (m, 
7H), 7.34 – 7.27 (m, 4H), 7.15 (t, J = 7.9 Hz, 1H), 6.77 – 6.72 (m, 2H), 6.69 (s, 1H), 6.39 (d, J = 
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15.7 Hz, 1H), 5.97 (dt, J = 15.3, 7.4 Hz, 1H), 5.17 (s, 2H), 3.76 (s, 3H), 3.73 (d, J = 17.8 Hz, 
1H), 3.14 (d, J = 17.4 Hz, 1H), 3.06 (dd, J = 14.2, 7.7 Hz, 1H), 2.78 (dd, J = 13.9, 7.2 Hz, 1H). 
13C NMR (126 MHz, CDCl3) δ 201.95, 170.40, 159.65, 150.55, 140.34, 138.72, 138.30, 135.73, 
135.56, 134.16, 129.42, 128.73, 128.56, 128.51, 128.48, 128.44, 128.22, 127.87, 127.84, 124.53, 
123.80, 118.88, 113.06, 111.49, 67.27, 60.94, 55.22, 38.27, 35.87. HRMS (ESI) m/z calc’d for 
C33H28O4 [M+H]+: 489.2066; found 489.2057. [α]23D = +14.3 (c = 0.7, CHCl3). 
 
 
Benzyl (R,E)-1-oxo-4-phenyl-2-(3-(4-(trifluoromethyl)phenyl)allyl)-2,3-dihydro-1H-indene-
2-carboxylate (35d): 4-trifluoromethylallylbenzene (18.6 mg, 0.10 mmol, 1 equiv) reacted with 
nucleophile (68 mg, 0.20 mmol, 2 equiv.) in Dioxane (0.6 mL total volume) according to the 
general procedure. Purification by flash column chromatography (5%→8% EtOAc/hexanes) 
provided the product as a clear oil: Run 1 (40.5 mg, 77% yield, 91% ee); Run 2 (39.6 mg, 75% 
yield, 91% ee); Run 3 (39.3 mg, 75% yield, 91% ee). Average: 76% (±1.2%) yield, 91% ee. 
The enantiomeric excess was determined by chiral HPLC analysis (CHIRALPAK OJ-H column, 
1 mL/min, 10% isopropanol in hexanes, λ = 254 nm): tR(major) = 10.815 min, tR(minor) = 
15.988 min. 1H NMR (500 MHz, Chloroform-d) δ 7.83 (d, J = 7.6 Hz, 1H), 7.64 (d, J = 7.4 Hz, 
1H), 7.55 – 7.39 (m, 9H), 7.35 – 7.29 (m, 4H), 7.24 (d, J = 8.1 Hz, 2H), 6.45 (d, J = 15.7 Hz, 
1H), 6.10 (dt, J = 15.4, 7.4 Hz, 1H), 5.24 – 5.16 (m, 2H), 3.79 (d, J = 17.4 Hz, 1H), 3.13 (d, J = 
17.4 Hz, 1H), 3.10 (dd, J = 14.1, 7.3 Hz, 1H), 2.80 (ddd, J = 14.1, 7.3 Hz, 1H). 13C NMR (126 
MHz, CDCl3) δ 201.71, 170.27, 150.34, 140.34, 140.22, 138.65, 135.81, 135.49, 135.47, 132.90, 
129.18 (q, J = 32.4 Hz), 128.76, 128.58, 128.56, 128.45, 128.29, 127.99, 127.90, 127.10, 126.35, 
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125.38 (q, J = 3.8 Hz), 124.15 (q, J = 271.9 Hz), 123.86, 67.35, 60.78, 38.30, 36.07. 19F NMR 
(471 MHz, Chloroform-d) δ -62.46. HRMS (ESI) m/z calc’d for C33H25O3F3 [M+H]+: 527.1834; 
found 527.1820. [α]23D = +10.4 (c = 1.51, CHCl3). 
 
Diastereoselective C-H Alkylation with β-Ketoester (Table 11) 
General procedure: To a ½ dram borosilicate vial with stir bar was added ligand L21 or ent-
L21 (10.4 mg, 0.02 mmol, 0.1 equiv) and Pd(OAc)2 (4.5 mg, 0.02 mmol, 0.1 equiv). Benzene 
(0.4 mL) was added, and the vial was capped and stirred at 45˚C until all solids had dissolved. 
Separately, to a second 1 dram borosilicate vial with stir bar was added nucleophile 30 (94 mg, 
0.4 mmol, 2.0 equiv), 2,6-dimethylbenzoquinone (40 mg, 0.3 mmol, 1.5 equiv) and Zn(OAc)2 
dihydrate (22 mg, 0.1 mmol, 0.5 equiv). The catalyst solution was subsequently added to the 
reaction flask, and Benzene (0.8 mL) was used to rinse the catalyst vial, also transferred and 
added to the reaction flask (total volume: 1.2 mL). Terminal olefin substrate 36 (0.20 mmol, 1.0 
equiv) was then added and the reaction was allowed to stir for 72 hours at room temperature 
(25˚C).  Afterward, the reaction mixture was directly subjected to flash column chromatography 
to provide the product.  
 
Racemic reaction condition A: A ½ dram oven dried borosilicate vial equipped with a Teflon 
magnetic stir bar was charged with nucleophile 30 (47 mg, 0.2 mmol, 2.0 equiv), 2,6-
dimethylbenzoquinone (DMBQ) (20.4 mg, 0.15 mmol, 1.5 equiv) and Pd(OAc)2/bis-sulfoxide 
catalyst (5.0 mg, 0.010 mmol, 0.1 equiv.). To the reaction vial was sequentially added DMSO 
(0.24 mL) and Dioxane (0.06 mL). Terminal olefin substrate 36 (0.10 mmol, 1.0 equiv) was then 
added and the reaction was allowed to stir for 24 hours at 45˚C. The reaction mixture was 
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quenched with saturated aqueous NH4Cl solution (10 mL) and extracted with ethyl acetate 
(EtOAc) (3 x 10 mL). The combined organic extracts were dried over anhydrous MgSO4, filtered 
and concentrated in vacuo. The crude reaction mixture was purified by flash column 
chromatography to provide the racemic standard.  
 
Racemic reaction condition B: To a 1 dram borosilicate vial with stir bar was added racemic 
SOX ligand L23 (6.8 mg, 0.02 mmol, 0.1 equiv), Pd(OAc)2 (4.5 mg, 0.02 mmol, 0.1 equiv), 2,6-
dimethylbenzoquinone (40 mg, 0.3 mmol, 1.5 equiv), Zn(OAc)2 dihydrate (22 mg, 0.1 mmol, 0.5 
equiv), nucleophile 30 (94 mg, 0.4 mmol, 2.0 equiv) and benzene (1.2 mL). Terminal olefin 
substrate 36 (0.20 mmol, 1.0 equiv) was then added and the reaction was allowed to stir for 24 
hours at 45˚C.  Afterward, the reaction mixture was directly subjected to flash column 
chromatography to provide the product.  
 
 
Tert-butyl (R)-2-((E)-3-((8R,9S,13S,14S,16S,17S)-17-acetoxy-3-hydroxy-13-methyl-
7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-16-yl)allyl)-3-oxo-2,3-
dihydrobenzofuran-2-carboxylate (37a) 
Tert-butyl (S)-2-((E)-3-((8R,9S,13S,14S,16S,17S)-17-acetoxy-3-hydroxy-13-methyl-
7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-16-yl)allyl)-3-oxo-2,3-
dihydrobenzofuran-2-carboxylate (37b) 
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Estrone derivative 36 (71 mg, 0.2 mmol, 1.0 equiv) was reacted with nucleophile 30 according to 
the general procedure. Purification by flash column chromatography (10%→20%→30% 
EtOAc/hexanes) provided the diastereomeric product 37a and 37b as a white solid.  
With L21: Run 1 (103.8 mg, 88% yield); Run 2 (105.2 mg, 90% yield). Average: 89% yield, 
16:1 d.r. The diastereomeric ratio was determined by 1H NMR, after purification of an 
inseparable mixture of diastereomers. 
With ent-L21: Run 1 (104.7 mg, 89% yield); Run 2 (105.2 mg, 90% yield). Average: 90% 
yield, 1:18 d.r. The diastereomeric ratio was determined by 1H NMR, after purification of an 
inseparable mixture of diastereomers. 
With racemic condition B: Run 1 (102.0 mg, 87% yield); Run 2 (96.1 mg, 82% yield). 
Average: 85% yield, 1.5:1 d.r. The diastereomeric ratio was determined by 1H NMR, after 
purification of an inseparable mixture of diastereomers. 
37a: 1H NMR (500 MHz, Chloroform-d) δ 7.68 – 7.58 (m, 2H), 7.20 (d, J = 8.3 Hz, 1H), 7.12 – 
7.05 (m, 2H), 6.63 (dd, J = 8.5, 2.7 Hz, 1H), 6.57 (d, J = 2.8 Hz, 1H), 5.67 (dd, J = 15.3, 8.0 Hz, 
1H), 5.59 (br, 1H), 5.26 (dt, J = 14.3, 6.8 Hz, 1H), 4.59 (d, J = 8.0 Hz, 1H), 2.94 (dd, J = 14.6, 
7.3 Hz, 1H), 2.83 – 2.77 (m, 3H), 2.58 – 2.48 (m, 1H), 2.25 – 2.18 (m, 1H), 2.16 – 2.08 (m, 1H), 
1.93 (s, 3H), 1.77 – 1.69 (m, 2H), 1.61 (m, 1H), 1.49 – 1.22 (m, 15H), 0.74 (s, 3H). 13C NMR 
(126 MHz, CDCl3) δ 196.46, 172.42, 170.96, 164.44, 153.71, 139.09, 138.45, 137.97, 132.09, 
126.45, 124.71, 122.34, 120.54, 119.93, 115.30, 113.49, 112.80, 91.57, 86.35, 83.78, 77.27, 
48.53, 44.19, 43.69, 38.42, 36.95, 36.82, 30.62, 29.57, 27.80, 27.03, 26.10, 21.04, 12.53. HRMS 
(ESI) m/z calc’d for C36H42O7 [M+Na]+: 609.2821; found 609.2826. [α]23D = +30.1 (c = 0.81, 
CHCl3). 
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37b: 1H NMR (500 MHz, Chloroform-d) δ 7.66 – 7.60 (m, 2H), 7.22 (d, J = 8.3 Hz, 1H), 7.14 – 
7.05 (m, 2H), 6.64 (dd, J = 8.4, 2.7 Hz, 1H), 6.57 (d, J = 2.7 Hz, 1H), 5.66 (dd, J = 15.2, 8.1 Hz, 
1H), 5.60 (br, 1H), 5.27 (dt, J = 14.4, 7.0 Hz, 1H), 4.56 (d, J = 8.0 Hz, 1H), 2.95 (dd, J = 14.6, 
7.3 Hz, 1H), 2.81 – 2.71 (m, 3H), 2.58 – 2.50 (m, 1H), 2.25 – 2.18 (m, 1H), 2.14 – 2.08 (m, 1H), 
1.97 (s, 3H), 1.77 – 1.69 (m, 2H), 1.64 – 1.54 (m, 1H), 1.49 – 1.14 (m, 15H), 0.75 (s, 3H). 13C 
NMR (126 MHz, CDCl3) δ 196.36, 172.42, 171.02, 164.41, 153.73, 139.18, 138.41, 137.95, 
132.05, 126.45, 124.78, 122.38, 120.55, 119.88, 115.31, 113.48, 112.82, 91.51, 86.32, 83.76, 
77.26, 48.55, 44.02, 43.72, 38.37, 36.91, 36.87, 30.25, 29.55, 27.83, 27.04, 26.07, 21.05, 12.53. 
[α]23D = -43.8 (c = 1.05, CHCl3). Single crystals of 37b suitable for X-ray crystallography were 
grown by slow diffusion from Et2O/Hexane. The absolute stereochemistry is determined by X-
ray crystallography.  
 
 
Tert-butyl (S)-2-((E)-3-((R)-2-(tert-butoxycarbonyl)-3-oxo-2,3-dihydrobenzofuran-2-
yl)prop-1-en-1-yl)pyrrolidine-1-carboxylate (38a) 
Tert-butyl (S)-2-((E)-3-((S)-2-(tert-butoxycarbonyl)-3-oxo-2,3-dihydrobenzofuran-2-
yl)prop-1-en-1-yl)pyrrolidine-1-carboxylate (38b) 
Tert-butyl (S)-2-allylpyrrolidine-1-carboxylate 36b (42 mg, 0.2 mmol, 1.0 equiv) was reacted 
with nucleophile 30 according to the general procedure. Purification by flash column 
chromatography (5%→10% Acetone/hexanes) provided the diastereomeric product 38a and 38b 
as a colorless oil, which solidifies upon refrigeration.  
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With L21: Run 1 (82.5 mg, 93% yield); Run 2 (78.2 mg, 88% yield). Average: 91% yield, 8:1 
d.r. The diastereomeric ratio was determined by chiral HPLC analysis (CHIRALPAK IA-3 
column, 1 mL/min, 2% isopropanol in Hexanes, λ = 325 nm): tR(major) = 8.984 min, tR(minor) = 
11.421 min.  
With ent-L21: Run 1 (75.4 mg, 85% yield); Run 2 (73.6 mg, 83% yield). Average: 84% yield, 
1:17 d.r. The diastereomeric ratio was determined by chiral HPLC analysis (CHIRALPAK IA-3 
column, 1 mL/min, 2% isopropanol in Hexanes, λ = 325 nm): tR(minor) = 8.946 min, tR(major) = 
11.194 min. 
With racemic condition A: Run 1 (33.6 mg, 38% yield); Run 2 (28.7 mg, 32% yield). Average: 
35% yield, 1:1.3 d.r. The diastereomeric ratio was determined by chiral HPLC analysis 
(CHIRALPAK IA-3 column, 1 mL/min, 2% isopropanol in Hexanes, λ = 325 nm): tR(minor) = 
9.096 min, tR(major) = 11.528 min. 
 
38a and 38b gave identical 1H and 13C NMR, therefore the spectral data of 38b (1:17 d.r.) was 
reported below: 
 
38a: 8:1 diastereomeric mixture, [α]22D = +10.6 (c = 0.75, CHCl3). 
 
38b: 1:17 diastereomeric mixture, 1H NMR (500 MHz, Chloroform-d) δ 7.60 – 7.53 (m, 2H), 
7.12 (d, J = 8.6 Hz, 1H), 7.02 (t, J = 7.4 Hz, 1H), 5.46 (d, J = 14.5 Hz, 1H), 5.24 (dt, J = 14.5 Hz, 
7.3 Hz, 1H), 4.22 – 4.00 (br, 1H), 3.26 – 3.02 (m, 2H), 2.90 (dd, J = 14.4, 7.2 Hz, 1H), 2.78 – 
2.64 (br, 1H), 1.85 – 1.48 (m, 4H), 1.37 (s, 9H), 1.32 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 
196.17, 172.38, 164.28, 154.50, 138.33, 136.76 (br), 124.67, 122.33, 120.65 (br), 119.88, 113.37, 
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91.42, 83.62, 79.04, 58.11 (br), 45.88 (br), 36.36, 31.92, 29.70, 28.45, 27.79. HRMS (ESI) m/z 
calc’d for C25H33NO6 [M+Na]+: 466.2206; found 466.2202. [α]22D = -103.5 (c = 0.85, CHCl3). 
 
 
Tert-butyl (R)-2-((S,E)-5-(methoxy(methyl)amino)-4-methyl-5-oxopent-2-en-1-yl)-3-oxo-2,3-
dihydrobenzofuran-2-carboxylate (39a) 
Tert-butyl (S)-2-((S,E)-5-(methoxy(methyl)amino)-4-methyl-5-oxopent-2-en-1-yl)-3-oxo-2,3-
dihydrobenzofuran-2-carboxylate (39b) 
Weinreb amide substrate 36c (31.4 mg, 0.2 mmol, 1.0 equiv) was reacted with nucleophile 30 
according to the general procedure. Purification by flash column chromatography (10%→20% 
EtOAc/hexanes) provided the diastereomeric product 39a and 39b as a colorless oil.  
With L21: Run 1 (70.1 mg, 90% yield); Run 2 (74.3 mg, 95% yield). Average: 93% yield, 5:1 
d.r. The diastereomeric ratio was determined by 1H NMR, after purification of an inseparable 
mixture of diastereomers. 
With ent-L21: Run 1 (68.5 mg, 88% yield); Run 2 (69.9 mg, 90% yield). Average: 89% yield, 
1:4 d.r. The diastereomeric ratio was determined by 1H NMR, after purification of an 
inseparable mixture of diastereomers. 
With racemic condition A: Run 1 (16.8 mg, 22% yield); Run 2 (14.6 mg, 19% yield). Average: 
21% yield, 1:1 d.r. The diastereomeric ratio was determined by 1H NMR, after purification of 
an inseparable mixture of diastereomers. 
39a: 1H NMR (500 MHz, Chloroform-d) δ 7.65 – 7.59 (m, 2H), 7.18 (d, J = 8.7 Hz, 1H), 7.08 (t, 
J = 7.5 Hz, 1H), 5.72 (dd, J = 15.4, 8.2 Hz, 1H), 5.41 (dt, J = 15.0, 7.3 Hz, 1H), 3.55 (s, 3H), 
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3.09 (s, 3H), 2.94 (dd, J = 14.3, 8.2 Hz, 1H), 2.72 (dd, J = 14.5, 6.5 Hz, 1H), 1.42 (s, 9H), 1.02 
(d, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 196.01, 175.13, 172.29, 164.18, 138.34, 
136.10, 124.70, 122.67, 122.34, 119.80, 113.42, 91.29, 83.70, 61.37, 38.95, 36.79, 32.18, 27.79, 
17.66. HRMS (ESI) m/z calc’d for C21H27NO6 [M+H]+: 390.1917; found 390.1911. [α]22D = 
+33.4 (c = 1.45, CHCl3). 
 
39b: 1H NMR (500 MHz, Chloroform-d) δ 7.65 – 7.59 (m, 2H), 7.17 (d, J = 8.6 Hz, 1H), 7.08 (t, 
J = 7.4 Hz, 1H), 5.72 (dd, J = 15.5, 8.1 Hz, 1H), 5.38 (ddd, J = 15.4, 7.7 Hz, 6.8 Hz, 1H), 3.51 (s, 
3H), 3.05 (s, 3H), 2.94 (dd, J = 14.6, 7.5 Hz, 1H), 2.73 (dd, J = 14.5, 6.7 Hz, 1H), 1.41 (s, 9H), 
1.06 (d, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 196.06, 175.10, 172.32, 164.21, 
138.26, 136.16, 124.68, 122.51, 122.30, 119.85, 113.44, 91.35, 83.70, 61.33, 38.81, 36.79, 32.13, 
27.75, 17.70. [α]22D = -66.2 (c = 1.48, CHCl3). 
 
 
Tert-butyl (R)-2-((R,E)-4-((tert-butyldimethylsilyl)oxy)-5-((4-methoxybenzyl)oxy)pent-2-en-
1-yl)-3-oxo-2,3-dihydrobenzofuran-2-carboxylate (40a) 
Tert-butyl (S)-2-((R,E)-4-((tert-butyldimethylsilyl)oxy)-5-((4-methoxybenzyl)oxy)pent-2-en-
1-yl)-3-oxo-2,3-dihydrobenzofuran-2-carboxylate (40b) 
Chiral diol substrate 36d (67.3 mg, 0.2 mmol, 1.0 equiv) was reacted with nucleophile 30 
according to the general procedure. Purification by flash column chromatography 
(2%→5%→10% EtOAc/hexanes) provided the diastereomeric product 40a and 40b as a 
colorless oil.  
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With L21: Run 1 (102.3 mg, 90% yield); Run 2 (106.8 mg, 94% yield). Average: 92% yield, 
3:1 d.r. The diastereomeric ratio was determined by 1H NMR, after purification of an 
inseparable mixture of diastereomers. 
With ent-L21: Run 1 (100.2 mg, 88% yield); Run 2 (104.5 mg, 92% yield). Average: 90% 
yield, 1:20 d.r. The diastereomeric ratio was determined by 1H NMR, after purification of an 
inseparable mixture of diastereomers. 
With racemic condition A: Run 1 (51.4 mg, 45% yield); Run 2 (48.8 mg, 43% yield). Average: 
44% yield, 1:1.2 d.r. The diastereomeric ratio was determined by 1H NMR, after purification of 
an inseparable mixture of diastereomers. 
40a: 1H NMR (500 MHz, Chloroform-d) δ 7.63 – 7.54 (m, 2H), 7.21 (d, J = 8.7 Hz, 2H), 7.16 (d, 
J = 8.9 Hz, 1H), 7.07 (t, J = 7.5 Hz, 1H), 6.86 (d, J = 8.5 Hz, 2H), 5.67 (dd, J = 8.9 Hz, 1H), 5.57 
– 5.48 (m, 1H), 4.42 – 4.35 (m, 2H), 4.17 – 4.12 (m, 1H), 3.80 (s, 3H), 3.27 – 3.15 (m, 2H), 2.98 
(dd, J = 14.7, 6.4 Hz, 1H), 2.87 (dd, J = 14.7, 7.8 Hz, 1H), 1.42 (s, 9H), 0.78 (s, 9H), -0.10 (s, 
3H), -0.18 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 196.28, 172.47, 164.43, 159.06, 138.26, 
136.22, 130.50, 129.10, 124.71, 122.33, 121.73, 119.99, 113.68, 113.46, 91.41, 83.62, 74.67, 
72.89, 71.73, 55.27, 36.33, 27.78, 25.78, 18.18, -4.96, -4.98. HRMS (ESI) m/z calc’d for 
C32H44O7Si [M+Na]+: 591.2754; found 591.2759. [α]24D = +18.5 (c = 1.12, CHCl3). 
 
40b: 1H NMR (500 MHz, Chloroform-d) δ 7.63 – 7.57 (m, 2H), 7.21 (d, J = 8.6 Hz, 2H), 7.16 (d, 
J = 8.1 Hz, 1H), 7.07 (t, J = 7.4, 1H), 6.86 (d, J = 8.6 Hz, 2H), 5.67 (dd, J = 15.4, 5.4 Hz, 1H), 
5.58 – 5.48 (m, 1H), 4.39 (d, J = 2.9 Hz, 2H), 4.15 (q, J = 5.1 Hz, 1H), 3.80 (s, 3H), 3.27 – 3.16 
(m, 2H), 2.98 (dd, J = 14.5, 7.5 Hz, 1H), 2.81 (dd, J = 14.5, 6.8 Hz, 1H), 1.42 (s, 9H), 0.80 (s, 
9H), -0.08 (s, 3H), -0.12 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 196.15, 172.44, 164.33, 159.06, 
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138.30, 136.29, 130.52, 129.11, 124.76, 122.30, 122.09, 119.87, 113.68, 113.40, 91.27, 83.59, 
74.74, 72.92, 71.98, 55.26, 36.54, 27.77, 25.79, 18.19, -4.87, -4.93. [α]24D = -36.0 (c = 1.23, 
CHCl3). 
 
 
Tert-butyl (2R)-2-((E)-3-((3R,10S,13S,17S)-17-((tert-butyldimethylsilyl)oxy)-10,13-dimethyl-
3-((trimethylsilyl)oxy)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)allyl)-3-oxo-2,3-
dihydrobenzofuran-2-carboxylate (41a) 
Tert-butyl (2S)-2-((E)-3-((3R,10S,13S,17S)-17-((tert-butyldimethylsilyl)oxy)-10,13-dimethyl-
3-((trimethylsilyl)oxy)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)allyl)-3-oxo-2,3-
dihydrobenzofuran-2-carboxylate (41b) 
Androsterone derivative 36e (103 mg, 0.2 mmol, 1.0 equiv) was reacted with nucleophile 30 
according to the general procedure. Purification by flash column chromatography (2% 
EtOAc/hexanes) provided the diastereomeric product 41a and 41b as a colorless oil.  
With L21: Run 1 (132.2 mg, 88% yield); Run 2 (138.5 mg, 92% yield). Average: 90% yield, 
4.3:1 d.r. The diastereomeric ratio was determined by chiral HPLC analysis (CHIRALPAK IC-3 
column, 0.8 mL/min, 0.3% isopropanol in Hexanes, λ = 254 nm): tR(minor) = 4.252 min, 
tR(major) = 4.524 min.  
With ent-L21: Run 1 (136.7 mg, 91% yield); Run 2 (144.1 mg, 96% yield). Average: 93% 
yield, 1:5 d.r. The diastereomeric ratio was determined by chiral HPLC analysis (CHIRALPAK 
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IC-3 column, 0.8 mL/min, 0.3% isopropanol in Hexanes, λ = 254 nm): tR(major) = 4.373 min, 
tR(minor) = 4.686 min. 
With racemic condition B: Run 1 (47.0 mg, 31% yield); Run 2 (45.0 mg, 30% yield). Average: 
31% yield, 1:1 d.r. The diastereomeric ratio was determined by chiral HPLC analysis 
(CHIRALPAK IC-3 column, 0.8 mL/min, 0.3% isopropanol in Hexanes, λ = 254 nm): tR(major) 
= 4.374 min, tR(minor) = 4.676 min. 
41a: 1H NMR (500 MHz, Chloroform-d) δ 7.64 – 7.59 (m, 2H), 7.17 (d, J = 8.3 Hz, 1H), 7.08 (t, 
J = 7.4 Hz, 1H), 5.70 (d, J = 15.7 Hz, 1H), 5.30 (dt, J = 15.8, 7.2 Hz, 1H), 3.52 (t, J = 8.3 Hz, 
1H), 2.95 (dd, J = 14.4, 7.4 Hz, 1H), 2.80 (dd, J = 14.5, 7.1 Hz, 1H), 1.89 – 1.79 (m, 1H), 1.69 
(m, 1H), 1.65 – 1.60 (m, 1H), 1.51 (m, 2H), 1.44 (s, 9H), 1.42 – 1.27 (m, 5H), 1.26 – 1.15 (m, 
4H), 1.12 – 0.94 (m, 5H), 0.92 – 0.80 (m, 2H), 0.86 (s, 9H), 0.67 (s, 3H), 0.62 (m, 1H), 0.57 (s, 
3H), -0.01 (s, 9H), -0.01 (s, 6H). 13C NMR (126 MHz, CDCl3) δ 196.30, 172.38, 164.37, 144.82, 
138.27, 124.65, 122.31, 119.98, 118.05, 113.39, 91.37, 83.62, 81.86, 74.20, 54.66, 50.68, 43.30, 
40.66, 40.49, 37.18, 36.84, 35.59, 35.57, 33.78, 33.16, 31.69, 30.91, 28.19, 27.79, 25.86, 23.50, 
20.60, 18.11, 11.48, 11.37, 2.42, -4.51, -4.82. HRMS (ESI) m/z calc’d for C44H70O6Si2 
[M+Na]+: 773.4609; found 773.4595. [α]24D = +10.8 (c = 1.2, CHCl3). 
 
41b: 1H NMR (500 MHz, Chloroform-d) δ 7.64 – 7.59 (m, 2H), 7.18 (d, J = 8.2 Hz, 1H), 7.08 (t, 
J = 7.4 Hz, 1H), 5.70 (d, J = 15.7 Hz, 1H), 5.31 (dt, J = 15.5, 7.5 Hz, 1H), 3.52 (t, J = 8.3 Hz, 
1H), 2.95 (dd, J = 14.7, 7.4 Hz, 1H), 2.79 (dd, J = 14.3, 7.1 Hz, 1H), 1.84 (m, 1H), 1.69 (m, 1H), 
1.62 (m, 1H), 1.55 – 1.47 (m, 2H), 1.44 (s, 9H), 1.42 – 1.28 (m, 5H), 1.26 – 1.15 (m, 4H), 1.14 – 
0.95 (m, 5H), 0.92 – 0.80 (m, 2H), 0.86 (s, 9H), 0.67 (s, 3H), 0.66 – 0.59 (m, 1H), 0.57 (s, 3H), -
0.01 (s, 9H), -0.01 (s, 6H). 13C NMR (126 MHz, CDCl3) δ 196.29, 172.37, 164.35, 144.82, 
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138.29, 124.66, 122.31, 119.96, 118.07, 113.39, 91.37, 83.62, 81.86, 74.18, 54.66, 50.69, 43.30, 
40.52, 40.02, 37.19, 36.89, 35.60, 35.58, 33.80, 33.77, 31.72, 30.91, 28.22, 27.79, 25.86, 23.50, 
20.60, 18.11, 11.47, 11.37, 2.41, -4.51, -4.82. [α]24D = -14.0 (c = 1.0, CHCl3). 
 
Scheme 15. Crystal Structure of 37b 
 
 
Crystal data and structure refinement for dd27esa (13b). 
Identification code  dd27esa 
Empirical formula  C36 H42 O7 
Formula weight  586.69 
Temperature  100(2) K 
Wavelength  1.54178 ≈ 
Crystal system  Orthorhombic 
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Scheme 15. (cont.) 
Space group  P212121 
Unit cell dimensions a = 12.9410(3) ≈ a= 90∞. 
 b = 13.1806(3) ≈ b= 90∞. 
 c = 18.8817(4) ≈ g = 90∞. 
Volume 3220.65(12) ≈3 
Z 4 
Density (calculated) 1.210 Mg/m3 
Absorption coefficient 0.670 mm-1 
F(000) 1256 
Crystal size 0.354 x 0.163 x 0.116 mm3 
Theta range for data collection 4.090 to 68.447∞. 
Index ranges -15<=h<=15, -15<=k<=15, -22<=l<=22 
Reflections collected 26546 
Independent reflections 5895 [R(int) = 0.0365] 
Completeness to theta = 67.679∞ 100.0 %  
Absorption correction Integration 
Max. and min. transmission 0.9388 and 0.8218 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5895 / 31 / 397 
Goodness-of-fit on F2 1.165 
Final R indices [I>2sigma(I)] R1 = 0.0391, wR2 = 0.0943 
R indices (all data) R1 = 0.0427, wR2 = 0.0971 
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Scheme 15. (cont.) 
Absolute structure parameter 0.08(8) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.293 and -0.328 e.≈-3 
 
 
(R)-2-amino-2-cinnamyl-3,4-dihydronaphthalen-1(2H)-one (38) 
To a 20 mL vial fitted with a magnetic stir bar was added alkylated product (277 mg, 0.9 mmol, 
1 equiv, 92% ee), THF (4 mL), and H2O (0.5 mL), followed by the addition of SnCl2 dihydrate 
(2 g, 9 mmol, 10 equiv). The reaction was capped and stirred at 45oC for 24 h. After cooled 
down to room temperature, the reaction was quenched with 50 mL saturated NaHCO3 (aq.) 
(CAUTION: gas evolved). The aqueous layer was extracted with EtOAc (4 x 40 mL). The 
organic layers were combined and dried over anhydrous Na2SO4. The solid was filtered off and 
the solvent was removed under reduced pressure. The crude was purified by silica column 
chromatography (0%→1%→2%→5% MeOH/DCM) to afford pure product 38 as a yellowish 
thick oil (202 mg, 0.73 mmol, 81% yield). 1H NMR (500 MHz, Chloroform-d) δ 8.08 (d, J = 7.9 
Hz, 1H), 7.50 (td, J = 7.5 Hz, 1H), 7.38 – 7.33 (m, 3H), 7.30 (t, J = 7.6 Hz, 2H), 7.27 – 7.25 (m, 
1H), 7.22 (t, J = 7.3 Hz, 1H), 6.48 (d, J = 16.0 Hz, 1H), 6.24 (ddd, J = 15.7, 8.3, 6.5 Hz, 1H), 
3.15 (ddd, J = 16.8, 11.3, 5.0 Hz, 1H), 2.99 (dt, J = 17.6, 4.5 Hz, 1H), 2.55 (ddd, J = 14.1, 8.4, 
1.1 Hz, 1H), 2.48 (ddd, J = 14.1, 6.6, 1.5 Hz, 1H), 2.25 (ddd, J = 13.6, 5.0, 3.8 Hz, 1H), 2.08 
(ddd, J = 13.6, 11.3, 5.2 Hz, 1H), 1.99 (br, 2H). 13C NMR (126 MHz, CDCl3) δ 201.29, 143.19, 
137.09, 134.23, 133.55, 130.87, 128.86, 128.52, 128.18, 127.38, 126.88, 126.25, 124.15, 59.22, 
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40.05, 34.43, 25.81. HRMS (ESI) m/z calc’d for C19H19NO [M+H]+: 278.1545; found 278.1545. 
[α]22D = -6.7 (c = 1.06, CHCl3). 
 
 
 (R)-2-(allylamino)-2-cinnamyl-3,4-dihydronaphthalen-1(2H)-one (39) 
To an oven-dried 1 dram vial was added 2-aminotetralone 38 (111 mg, 0.4 mmol, 1 equiv), 
anhydrous K2CO3 (61 mg, 0.44 mmol, 1.1 equiv) and acetonitrile (1 mL, 0.4 M) under N2. Allyl 
bromide (0.04 mL, 0.44 mmol, 1.1 equiv) was then added. The reaction was stirred under N2 at 
50oC for 24 h. After cooled down to room temperature, the volatiles were removed under 
reduced pressure. The crude was purified by silica column chromatography 
(5%→8%→10%→15% EtOAc/Hexanes) to afford pure product 39 as a colorless oil (92 mg, 
0.29 mmol, 72% yield). 1H NMR (500 MHz, Chloroform-d) δ 8.10 (d, J = 7.9 Hz, 1H), 7.50 (t, 
J = 7.5 Hz, 1H), 7.35 (m, 3H), 7.30 (t, J = 7.5 Hz, 2H), 7.22 (m, 2H), 6.47 (d, J = 15.8 Hz, 1H), 
6.21 (dt, J = 15.4, 7.4 Hz, 1H), 5.91 (ddt, J = 16.4, 11.1, 6.0 Hz, 1H), 5.20 (d, J = 17.2 Hz, 1H), 
5.06 (d, J = 10.1 Hz, 1H), 3.24 – 3.15 (m, 2H), 3.15 – 2.98 (m, 2H), 2.60 (d, J = 7.4 Hz, 2H), 
2.35 (ddd, J = 14.6, 9.7, 5.4 Hz, 1H), 2.16 (dt, J = 13.7, 5.1 Hz, 1H), 2.02 (br, 1H). 13C NMR 
(126 MHz, CDCl3) δ 199.39, 143.13, 137.26, 137.08, 133.78, 133.43, 131.62, 128.77, 128.49, 
128.08, 127.27, 126.81, 126.24, 124.61, 115.81, 62.83, 45.82, 38.37, 31.49, 25.57. HRMS (ESI) 
m/z calc’d for C22H23NO [M+H]+: 318.1858; found 318.1867. [α]22D = +35.0 (c = 1.34, CHCl3). 
*The major side product was found to be the double allylation product of the amino group, 
accounting for ~20% yield. 
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 (R)-3,3',4,6'-tetrahydro-1H,1'H-spiro[naphthalene-2,2'-pyridin]-1-one (40) 
(NOTE: commercial p-Toluenesulfonic acid monohydrate was azeotroped with benzene 5 times 
to afford anhydrous TsOH) To a 100 mL flamed-dried RBF fitted with a magnetic stir bar was 
added 39 (85 mg, 0.27 mmol, 1 equiv), anhydrous TsOH (46 mg, 0.27 mmol, 1 equiv) and dry 
DCM (27 mL, 0.01M) under N2. The solution was stirred at room temperature for 30 mins. 
Grubbs catalyst (2nd generation) (23 mg, 0.027 mmol, 0.1 equiv) was then added. The reaction 
was fitted with an oven-dried condenser and refluxed at 55  under N2 for 24 h. After cooled 
down to room temperature, the reaction was quenched with 40 mL saturated NaHCO3 (aq.). The 
layers were separated and the aqueous layer was extracted with DCM (4 x 30 mL). The organic 
layers were combined and dried over anhydrous Na2SO4. The solid was filtered off and the 
solvent was removed under reduced pressure. The crude was purified by silica column 
chromatography (0%→1%→2%→5% MeOH/DCM) to afford pure product 40 as a yellowish oil 
(54.3 mg, 0.25 mmol, 94% yield). 1H NMR (500 MHz, Chloroform-d) δ 8.04 (d, J = 7.9 Hz, 
1H), 7.47 (t, J = 7.5 Hz, 1H), 7.31 (t, J = 7.8 Hz, 1H), 7.23 (d, J = 7.7 Hz, 1H), 5.85 – 5.80 (m, 
1H), 5.79 – 5.73 (m, 1H), 3.50 – 3.42 (m, 1H), 3.42 – 3.36 (m, 1H), 3.10 (ddd, J = 17.5, 6.6, 5.1 
Hz, 1H), 2.94 (ddd, J = 17.5, 8.5, 5.1 Hz, 1H), 2.35 (ap. dp, J = 17.6, 2.9 Hz, 1H), 2.26 (ddd, J = 
13.7, 6.7, 5.1 Hz, 1H), 2.19 – 2.11 (m, 1H), 2.06 (ddd, J = 17.7, 4.8, 3.2, 1H), 2.02 – 1.99 (br, 
1H). 13C NMR (126 MHz, CDCl3) δ 199.24, 142.99, 133.33, 131.18, 128.68, 128.20, 126.73, 
126.08, 123.18, 56.94, 41.53, 31.08, 29.63, 25.28. HRMS (ESI) m/z calc’d for C14H15NO 
[M+H]+: 214.1232; found 214.1238. [α]22D = +23.9 (c = 0.71, CHCl3). 
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(S)-3,4-dihydro-1H-spiro[naphthalene-2,2'-piperidin]-1-one (41) 
To a 10 mL RBF was added 40 (42.5 mg, 0.2 mmol, 1 equiv) and methanol (2 mL, 0.1M). The 
flask was flushed with nitrogen. Palladium on carbon (5 wt. % loading) (11 mg) was added and 
the flask was then flushed with hydrogen for 5 mins. The reaction was stirred under H2 at room 
temperature for 2 hours. (IMPORTANT: prolonged reaction time could lead to over-reduction 
of the ketone). The reaction was filtered through a Celite plug to remove Pd/C. The solvent was 
removed under reduced pressure to afford the product 41 as a colorless oil (43.2 mg, 
quantitative, 91% ee). Proton NMR matches with the previously reported data.42 1H NMR (500 
MHz, Chloroform-d) δ 8.01 (d, J = 7.9 Hz, 1H), 7.45 (t, J = 7.5 Hz, 1H), 7.30 (t, J = 7.6 Hz, 1H), 
7.21 (d, J = 7.7 Hz, 1H), 3.10 – 3.02 (m, 1H), 3.02 – 2.92 (m, 2H), 2.85 (ddd, J = 13.1, 9.1, 3.7 
Hz, 1H), 2.41 (dt, J = 13.8, 5.0 Hz, 1H), 2.11 (br, 1H), 2.03 (ddd, J = 13.7, 9.8, 5.8 Hz, 1H), 1.81 
– 1.61 (m, 3H), 1.58 – 1.51 (m, 2H), 1.49 – 1.40 (m, 1H). 13C NMR (126 MHz, CDCl3) δ 199.91, 
142.40, 133.34, 131.17, 128.66, 128.11, 126.74, 59.20, 41.32, 31.37, 30.37, 26.01, 25.34, 20.23; 
HRMS (ESI) m/z calc’d for C14H17NO [M+H]+: 216.1388; found 216.1385. [α]22D = +36.7 (c = 
0.5, CHCl3). Product 41 was converted to N-acetylated product for the determination of 
enantiomeric excess. The enantiomeric excess was determined to be 91% by chiral HPLC 
analysis (CHIRALPAK OJ-H column, 1 mL/min, 5% isopropanol in hexanes, λ = 254 nm): 
tR(major) = 14.549 min, tR(major) = 30.668 min. 
 
 
 (1S,2R)-2-amino-2-cinnamyl-1,2,3,4-tetrahydronaphthalen-1-ol (42) 
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To a 20 mL vial was added 38 (57 mg, 0.2 mmol, 1 equiv) and methanol (4 mL, 0.05 M). The 
vial was cooled to 0oC in an ice bath. NaBH4 (8.5 mg, 0.22 mmol, 1.1 equiv.) was added at 0oC 
(CAUTION: gas evolved). Then the reaction was stirred at 0oC for 10 min, before removal of all 
the volatiles under reduced pressure. The crude was purified via silica column chromatography 
(1%→2%→5%→10% MeOH/DCM) to afford pure product 42 as a white paste (51.7 mg, 90% 
yield). 1H NMR (500 MHz, Chloroform-d) δ 7.47 (dd, J = 5.5, 3.5 Hz, 1H), 7.40 (d, J = 7.1 Hz, 
2H), 7.31 (t, J = 7.6 Hz, 2H), 7.24 – 7.20 (m, 3H), 7.14 (dd, J = 5.4, 3.4 Hz, 1H), 6.53 (d, J = 
15.8 Hz, 1H), 6.40 (dt, J = 15.5, 7.5 Hz, 1H), 4.48 (s, 1H), 2.90 (t, J = 6.8 Hz, 2H), 2.55 (dd, J = 
14.0, 7.5 Hz, 1H), 2.30 (dd, J = 14.0, 7.6 Hz, 1H), 2.15 (br, 3H), 2.05 (dt, J = 13.4, 6.6 Hz, 1H), 
1.72 (dt, J = 13.7, 6.9 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 137.28, 137.16, 135.32, 134.16, 
128.72, 128.56, 128.54, 127.60, 127.30, 126.47, 126.19, 125.10, 75.78, 54.66, 38.19, 31.06, 
25.87. HRMS (ESI) m/z calc’d for C19H21NO [M+H]+: 280.1701; found 280.1708. [α]23D = -
34.4 (c = 0.89, CHCl3). The amino alcohol was derivatized into oxazolidinone for the 
determination of relative stereochemistry via NOESY analysis. 
 
 
 (1S,2R)-2-amino-2-cinnamyl-1-vinyl-1,2,3,4-tetrahydronaphthalen-1-ol (43) 
To a flamed-dried 25 mL RBF was added 38 (55.5 mg, 0.18 mmol, 1 equiv) and THF (2 mL, 0.1 
M) under N2. The solution was cooled to -78oC, followed by the addition of vinylmagnesium 
bromide solution (1 M in THF) (0.6 mL, 0.6 mmol, 3 equiv.). The reaction was stirred at -78oC 
for 2 h and then quenched with sat. NH4Cl solution. The aqueous layer was extracted with DCM 
(10 mL x 3). The organic layers were combined and dried over anhydrous NaSO4. After 
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filtration, all the volatiles were removed under reduced pressure. The crude was purified via 
silica column chromatography (1%→2%→5%→10% MeOH/DCM) to afford pure product 21 as 
a white paste (36.0 mg, 65% yield). 1H NMR (500 MHz, Chloroform-d) δ 7.53 – 7.44 (m, 1H), 
7.39 – 7.36 (m, 2H), 7.30 (dd, J = 8.5, 6.9 Hz, 2H), 7.24 – 7.19 (m, 3H), 7.15 – 7.08 (m, 1H), 
6.47 (d, J = 15.8 Hz, 1H), 6.35 (dt, J = 15.4, 7.4 Hz, 1H), 6.20 (dd, J = 17.1, 10.7 Hz, 1H), 5.30 – 
5.20 (m, 2H), 3.04 – 2.86 (m, 2H), 2.49 (dd, J = 14.2, 7.7 Hz, 1H), 2.37 (dd, J = 14.2, 7.2 Hz, 
1H), 1.98 (ddd, J = 13.8, 6.7, 4.2 Hz, 1H), 1.89 (ddd, J = 13.9, 9.1, 7.3 Hz, 1H), 2.08 – 1.45 (br, 
3H). 13C NMR (126 MHz, CDCl3) δ 141.90, 139.59, 137.37, 134.91, 133.76, 128.55, 128.53, 
127.23, 127.16, 127.13, 126.37, 126.12, 126.06, 115.41, 78.75, 56.57, 37.46, 31.14, 26.15. 
HRMS (ESI) m/z calc’d for C21H23NO [M+H]+: 306.1858; found 306.1862. [α]24D = -89.93 (c = 
1.54, CHCl3). The relative stereochemistry was determined via NOESY analysis.  
 
Determination of Relative Stereochemistry 
Oxazolidinone formation: To an oven-dried 1-dram vial was added 42 (50 mg, 0.18 mmol, 1 
equiv), dry DCM (0.9 mL) and triethylamine (0.05 mL, 0.36 mmol, 2 equiv) under N2. Phenyl 
chloroformate (28 mg, 0.18 mmol, 1 equiv.) was added at room temperature. The reaction was 
stirred for 90 mins. Then, the volatiles were removed under reduced pressure. The crude was 
purified via silica column chromatography (10%→20%→30% EtOAc/Hexanes) to afford pure 
product as a thick paste (15.9 mg, 30% yield). The un-cyclized carbamate was also isolated as 
the major side product (30.5 mg, 42% yield). 
 
154 
 
Compound 43 was also exposed to the same condition. However, only un-cyclized carbamate 
was isolated without the formation of oxazolidinone, presumably due to the congested tertiary 
alcohol in 43.  
 
NH
O
O
Ph
Ha
He
Hb
Hc
Hd
Hf
Hg
a
b,c
d,e
f
g
NOE correlation:
 
The 1H signals were unambiguously assigned by 1H, 13C, COSY and HSQC NMR analysis. 
NOESY NMR revealed the following NOE correlation: Ha (δ 5.33) → Hb (δ 3.11), Ha (δ 5.33) → 
Hd (δ 2.02), Hc (δ 2.98) → Hf (δ 1.90), He (δ 2.25) → Hf (δ 1.90), He (δ 2.25) → Hg (δ 6.08). 
These NOE strongly agree with the conformation shown above, which establishes the trans- 
relationship3 between the hydroxyl and the amino group. 
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The 1H signals of compound  were unambiguously assigned by 1H, 13C, COSY and HSQC NMR 
analysis. NOESY NMR revealed the NOE correlation between Ha (δ 6.20) → Hb (δ 1.89), which 
dictates the vinyl group at the (pseudo)axial position;  Hd (δ 2.94) → He (δ 2.37), which dictates 
the phenylpropenyl group also at the (pseudo)axial position. These two results establish the 
trans- relationship between the hydroxyl and the amino group. Additional NOE signals also 
agree with the conformation shown above: Hc (δ 1.98) → He (δ 2.37), Hc (δ 1.98) → Hf (δ 6.35).  
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